Ischemic Stroke

On this page

Quick Reference

RxDrug of choiceAlteplase 0.9 mg/kg IV (max 90 mg) within 4.5 hours; tenecteplase 0.25 mg/kg IV bolus is an alternative, especially for LVO.

AltAlternativesTenecteplase 0.25 mg/kg IV bolus; tirofiban 0.4 μg/kg/min for 30 min then 0.1 μg/kg/min for 24 h after thrombolysis; clopidogrel + aspirin for DAPT; DOACs (rivaroxaban, apixaban, edoxaban) for AF.

⊘AvoidThrombolysis if symptom onset >4.5 h (unless favorable imaging), INR >1.7, platelets <100,000, recent major surgery, active bleeding. EVT contraindicated if large core with no penumbra or poor collateral status.

DxTest of choiceNoncontrast CT head (first test to exclude hemorrhage) followed by CTA + CTP (or MRI DWI + PWI) to identify LVO and salvageable tissue.

ScKey scoreNIHSS (severity), ASPECTS (early ischemic changes on CT), modified Rankin Scale (functional outcome), CHA₂DS₂-VASc (AF stroke risk).

→When to referFor EVT: LVO within 24 h with favorable imaging. For carotid revascularization: symptomatic stenosis ≥50% or asymptomatic ≥70%. For PFO closure: cryptogenic stroke with high-risk PFO. For rehabilitation: all patients with residual deficits.

Time is brain: golden-hour thrombolysis (NNT 2.6) and EVT for LVO (NNT 3-10) are the most powerful interventions. Etiology-guided secondary prevention with DAPT, DOACs, and statins reduces recurrence by 50-70%.

Ischemic stroke, central nervous system infarction due to focal ischemia, accounts for 87% of all strokes and is a leading cause of long-term disability worldwide. The cornerstone of acute management is rapid reperfusion: intravenous thrombolysis within 4.5 hours (alteplase 0.9 mg/kg or tenecteplase 0.25 mg/kg) and endovascular thrombectomy for large-vessel occlusion up to 24 hours in selected patients. Etiologic classification (TOAST) guides secondary prevention: dual antiplatelet therapy for noncardioembolic minor stroke, direct oral anticoagulants for atrial fibrillation, and high-intensity statins for all. Every 30-minute reduction in door-to-needle time improves the odds of functional independence by 1.8%.

Overview and Recommendations

Background

•Ischemic stroke is defined as brain, spinal cord, or retinal cell death attributable to ischemia, confirmed by neuropathology, neuroimaging, or clinical evidence of permanent injury. It accounts for approximately 87% of the 13.7 million new strokes worldwide each year and is the second-leading cause of death globally, with 3.29 million deaths in 2019 projected to rise to 4.90 million by 2030.
•The etiologic classification, large-artery atherosclerosis, cardioembolism, small-vessel occlusion, other determined cause, and cryptogenic (TOAST), is essential because it dictates acute treatment and secondary prevention. Cardioembolic strokes carry the highest 30-day case fatality (28%) and 6-month dependency or death (62%).
•The ischemic cascade begins within seconds of flow cessation: cerebral blood flow below 10-15 mL/100 g/min triggers ATP depletion, cytotoxic edema, glutamate excitotoxicity, and calcium-mediated cell death. The penumbra, tissue at risk but still viable, expands at an average rate of 5.4 mL/h in large-vessel occlusion, creating a time-dependent window for reperfusion.
•Immunothrombosis amplifies injury: neutrophil extracellular traps (NETs) stabilize thrombi and cause no-reflow after reperfusion. Interleukin-6 levels predict recurrence in large-artery and small-vessel subtypes, and viral transcripts (CMV, EBV) are elevated in stroke blood, suggesting a role for chronic infection in pathogenesis.
•The tissue-based definition of transient ischemic attack (TIA), transient neurologic dysfunction without infarction, replaced the time-based definition. After TIA, the pooled risk of subsequent ischemic stroke is 2.4% within 2 days and 4.7% within 90 days, making urgent evaluation and prevention critical.
•Key prognostic tools include the (NIHSS) for severity grading and the (mRS) for functional outcome. The dynamic continuum from benign oligemia to leaky core underpins reperfusion decision-making and explains why some patients with large cores still benefit from thrombectomy.

Evaluation

•Suspect ischemic stroke in any patient with acute onset of focal neurologic deficits, unilateral weakness, sensory loss, aphasia, hemianopia, ataxia, or vertigo, especially when onset is witnessed and maximal at onset. Nonfocal symptoms (headache, altered consciousness) are more common in women and increase the risk of misdiagnosis.
•Ask about the exact time of symptom onset or last known well, which determines eligibility for thrombolysis. In wake-up stroke (15-25% of cases), the median time from last seen well to arrival is 288 minutes, and advanced imaging is required to select candidates for reperfusion.
•Examine using the NIHSS to quantify severity: mild (0-4), moderate (5-14), severe (≥15). Perform a focused neurologic exam including cranial nerves, motor/sensory function, coordination, and language. Assess for stroke mimics: postictal Todd paresis, migraine aura, hypoglycemia, functional disorder.
•Order a noncontrast CT head immediately to exclude intracerebral hemorrhage. CT angiography (CTA) identifies large-vessel occlusion (LVO), the trigger for endovascular thrombectomy. CT perfusion (CTP) or MRI perfusion quantifies ischemic core and penumbra; the Target Mismatch profile (core <70 mL, mismatch >10 mL, ratio >1.2) selects patients for late-window treatment.
•MRI with diffusion-weighted imaging (DWI) is the gold standard for diagnosis, with ~93% sensitivity within 12 hours. A negative DWI does not rule out stroke, posterior circulation ischemia has 5-fold higher odds of being DWI-negative. The DWI-FLAIR mismatch (DWI hyperintense, FLAIR negative) identifies patients with unknown onset who benefit from thrombolysis.
•Obtain routine labs: CBC, creatinine, glucose, coagulation profile, troponin. Point-of-care glucose excludes hypoglycemic mimic. Consider GFAP testing (portable device) to distinguish hemorrhage from ischemia when CT is equivocal, GFAP <30 pg/mL with NIHSS >6 has 100% NPV for intracerebral hemorrhage.
•Diagnostic criteria are clinical: acute focal deficit with imaging evidence of infarction or, if imaging is negative, a clinical syndrome consistent with stroke. The tissue-based definition means any clinical syndrome with infarction on imaging is stroke, regardless of symptom duration.
•Also consider alternative diagnoses: seizure (EEG, hyperperfusion on rTmax), migraine with aura (gradual spread, headache, normal DWI), CNS tumor (subacute onset, mass effect), CNS infection (fever, CSF pleocytosis). In young adults, screen for Fabry disease, CADASIL, and patent foramen ovale.
•Perform cardiac monitoring (telemetry for ≥24 hours) to detect atrial fibrillation. In cryptogenic stroke, implantable loop recorder detects paroxysmal AF in 21% vs 7.5% with conventional monitoring and reduces recurrence (HR 0.32).
•Assess dysphagia before any oral intake using a bedside swallow screen. The Predictive Swallowing Score (age, NIHSS, lesion location, aspiration risk, oral impairment) stratifies risk; score ≥8 predicts persistent dysphagia at 7 days with 96% probability.

Management

•Initiate intravenous thrombolysis within 4.5 hours of symptom onset: alteplase 0.9 mg/kg (max 90 mg), 10% as bolus, remainder over 60 minutes. Alternatively, tenecteplase 0.25 mg/kg IV bolus (max 25 mg) is noninferior and preferred in patients with LVO. Golden-hour thrombolysis doubles the odds of excellent recovery (NNT 2.6).
•For patients presenting 4.5-24 hours after onset with favorable penumbral imaging (core <70 mL, mismatch ratio >1.2), thrombolysis remains beneficial: alteplase improved functional independence in posterior circulation stroke (89.6% vs 72.6%; aRR 1.16). Tenecteplase 0.25 mg/kg also improves reperfusion without excess sICH.
•Perform endovascular thrombectomy (EVT) for anterior circulation LVO (ICA, M1-MCA) with ASPECTS ≥6 within 6 hours (NNT 3-10). For ASPECTS 3-5, EVT still improves independent ambulation (RR 1.9) and survival (RR 0.9). EVT is also effective up to 24 hours in patients selected by DAWN/DEFUSE-3 criteria.
•For medium-vessel occlusion (M2-MCA, PCA), EVT is not routinely recommended, the ESCAPE-MeVO trial showed no benefit and possible harm (sICH 5.4% vs 2.2%). Individualize for severe deficits and favorable anatomy.
•Maintain systolic BP >140 mm Hg during EVT to support collateral flow; after successful reperfusion, target SBP <160 mm Hg. Intensive BP lowering (<120 mm Hg) worsens functional outcomes and quality of life.
•After thrombolysis, start antiplatelet therapy at 24 hours if no hemorrhagic transformation. For noncardioembolic minor stroke/TIA, initiate dual antiplatelet therapy (DAPT) within 24-72 hours: clopidogrel 300 mg load + aspirin 100-300 mg, continue for 21-90 days. In CYP2C19 loss-of-function carriers, use ticagrelor 180 mg load + aspirin instead.
•Tirofiban infusion (0.4 μg/kg/min for 30 min, then 0.1 μg/kg/min for 24 h) after thrombolysis improves excellent functional outcome (65.9% vs 54.9%; RR 1.20) without increasing sICH. Consider in patients with high-risk noncardioembolic stroke.
•For cardioembolic stroke due to atrial fibrillation, start a DOAC (e.g., rivaroxaban 20 mg daily, apixaban 5 mg BID, edoxaban 60 mg daily) within 48 hours to 14 days depending on infarct size. Use the 1-2-3-4-day rule: day 1 after TIA, day 2 after mild stroke (NIHSS 0-7), day 3 after moderate (8-15), day 4 after severe (≥16).
•Initiate high-intensity statin (atorvastatin 40-80 mg daily) within 24 hours. Immediate intensive statin (80 mg for 21 days then 40 mg) does not reduce 90-day stroke but improves functional outcome (OR 0.83). Add ezetimibe or PCSK9 inhibitor if LDL ≥70 mg/dL on maximally tolerated statin.
•Target blood pressure <130/80 mm Hg for long-term secondary prevention. In the first 72 hours after successful reperfusion, permit mild hypertension (SBP 140-180 mm Hg) to maintain penumbral perfusion.
•Avoid non-dihydropyridine CCBs (diltiazem, verapamil) in acute phase. Avoid adding antiplatelet to anticoagulation in AF patients without compelling indication (increases major bleeding without net benefit). Avoid switching a failing DOAC to warfarin, prefer DOAC-to-DOAC or dose adjustment.
•Refer for carotid revascularization (CEA or stenting) in symptomatic stenosis ≥50% or asymptomatic ≥70% with favorable anatomy. CREST-2 showed stenting plus medical management reduced 4-year stroke/death (2.8% vs 6.0%; NNT 31).
•Refer for PFO closure in selected young patients with cryptogenic stroke and high-risk PFO (RoPE score ≥7, large shunt). Closure reduces recurrent stroke (RR 0.42) but increases new-onset AF (RR 4.59); Amplatzer device preferred.
•Monitor for complications: hemorrhagic transformation (sICH 2-8%), malignant cerebral edema (midline shift >11 mm within 20 hours), post-stroke seizures (3% acute, 10-15% late). Use levetiracetam 500-1500 mg/day for seizures; do not use primary prophylaxis.
•Discharge criteria: stable neurologic status, no active bleeding, controlled blood pressure, ability to swallow safely (or feeding tube in place), and follow-up plan for rehabilitation and secondary prevention. Arrange early rehabilitation (within 30 days) including physical, occupational, and speech therapy.

Board Review — High Yield

•Time is brain, Every 30-minute reduction in door-to-needle time increases odds of mRS 0-1 by 1.8%; golden-hour thrombolysis NNT = 2.6.
•TOAST classification, Five subtypes: large artery, cardioembolic, small vessel, other, undetermined. Cardioembolic has highest mortality (28% at 30 days).
•Core vs penumbra, Core is irreversibly infarcted; penumbra is salvageable. Target mismatch: core <70 mL, mismatch >10 mL, ratio >1.2 for late-window treatment.
•DWI-FLAIR mismatch, DWI hyperintense, FLAIR negative indicates stroke within ~4.5 hours; used to select unknown-onset patients for thrombolysis (WAKE-UP trial).
•DAPT for minor stroke, Clopidogrel + aspirin within 24-72 hours reduces 90-day stroke recurrence (HR 0.68-0.79). In CYP2C19 LoF carriers, ticagrelor + aspirin is superior.
•DOAC over warfarin, For AF-related stroke, DOACs reduce intracranial hemorrhage (0.5% vs 0.7% for rivaroxaban). Early initiation (day 3-4) is optimal.
•EVT for large core, ASPECTS 3-5 still benefits from EVT: improved independent ambulation (RR 1.9) and survival (RR 0.9).
•Post-stroke epilepsy, 11% at 5 years; early EEG with epileptiform activity raises risk to 42%. SeLECT-EEG model outperforms clinical scores.
•Stroke-heart syndrome, 11% develop ACS, 8.8% new AF within 4 weeks. Telemetry for ≥24 hours is mandatory.
•Dysphagia screening, Perform before any oral intake; Predictive Swallowing Score ≥8 predicts failure at day 7 with 96% probability.

Deep Dive — Evidence Details

Definition, Classification & Nomenclature

▸Ischemic stroke is defined as CNS infarction due to ischemia, confirmed by neuroimaging or pathology [18].
▸The term 'stroke' is an umbrella that includes ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage; TIA is defined by absence of infarction.
▸Etiologic classification (TOAST, ASCOD, ISPS25) guides workup and secondary prevention; the tissue-based definition of TIA vs. stroke governs thrombolysis eligibility.

HY High Yield: The tissue-based definition: a transient clinical syndrome lasting <24 hours is TIA only if no infarction is seen on MRI/DWI; any infarction, even with complete symptom resolution, classifies as ischemic stroke and carries different recurrence risk and management [18].

Ischemic stroke is central nervous system infarction, brain, spinal cord, or retinal cell death attributable to ischemia, based on neuropathological, neuroimaging, or clinical evidence of permanent injury ^[18]^D5.

Also Called / Synonyms

Cerebral infarction (preferred pathological term)
(AIS, when symptom onset is recent and reperfusion eligible)
Stroke due to cerebral ischemia
Cryptographic stroke (when no cause identified after standard workup)
Embolic stroke of undetermined source (ESUS), a subset of defined by nonlacunar infarct on imaging, absence of proximal arterial stenosis ≥50%, no identified cardioembolic source, and no other determined cause ^[6]^B2b

Key Clinical Definitions

The / 2013 consensus distinguishes ischemic stroke (overt symptoms with infarction) from silent infarction (infarction without known symptoms) ^[18]^D5. Transient ischemic attack (TIA) is a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia without acute infarction. The tissue-based definition (rather than time-based <24 hours) now governs clinical practice: any clinical syndrome with infarction on imaging is classified as ischemic stroke, regardless of symptom duration. After TIA, the pooled risk of subsequent ischemic stroke is 2.4% within 2 days and 4.7% within 90 days ^[13]^B2a.

Etiologic Classification Systems

Two major systems assign ischemic stroke subtype based on mechanism. The classification (Trial of Org 10172 in Acute Stroke Treatment) categorizes five subtypes: large‐artery atherosclerosis, cardioembolism, small‐vessel occlusion, other determined cause, and undetermined (including cryptogenic and incomplete workup) ^[19]^C4. The newer Ischemic Stroke Phenotyping System 2025 (ISPS25) expands the minimum diagnostic evaluation to include prolonged cardiac monitoring, expanded vascular imaging, and thrombophilia workup, yielding definite, probable, or possible mechanism labels for cardioembolism, large artery atherosclerosis, small vessel disease, and other causes (e.g., carotid web, dissection, hypercoagulable state) ^[21]^D5. The ASCOD classification (Atherosclerosis, Small vessel disease, Cardiac pathology, Other causes, Dissection) grades the causal relevance of each potential mechanism. In young adults (age 18-49), TOAST classifies ~25% as cryptogenic, but incorporating pediatric risk factors reduces this to <1% ^[19]^C4.

Classification System	Key Categories	Clinical Utility
TOAST	Large artery, cardioembolic, small vessel, other, undetermined	Widely used in trials; simple but misses ESUS nuance
ASCOD	Grades 1-3 for each of 5 domains	Captures multiple coexisting mechanisms
ISPS25	Definite/probable/possible for cardioembolism, large artery, small vessel, other	Incorporates advanced diagnostics; guides targeted secondary prevention ^[21]^D5
PASCAL	Probable, possible, unlikely PFO-related stroke	Identifies patients most likely to benefit from PFO closure ^[12]^A1a
Heidelberg Bleeding Classification	HI1, HI2, PH1, PH2 (hemorrhagic transformation subtypes)	Standardizes post‐thrombolysis hemorrhage grading ^[5]^B2b

Clinical Significance

Ischemic stroke accounts for approximately 87% of all strokes and is a leading cause of long-term disability worldwide. The ( ) and ( ) are used to quantify severity and functional outcome. The dynamic ischemic continuum, from benign oligemia through critical penumbra to leaky core, underpins reperfusion decision-making and is discussed in the section ^[20]^D5.

Pearl: Etiologic classification (TOAST, ASCOD, ISPS25) guides workup and secondary prevention; the tissue-based definition of TIA vs. stroke governs thrombolysis eligibility.

Pathophysiology & Mechanism (Neuroanatomic Localization)

▸The ischemic cascade progresses from energy failure to excitotoxicity, oxidative stress, and inflammation, with the penumbra undergoing dynamic infarct growth at a mean rate of 5.4 mL/h that varies by collateral status and molecular modifiers.
▸Neuroanatomic localization via lesion network mapping links specific NIHSS deficits to distinct network disruptions, and right insulo-opercular damage specifically drives poststroke hyperglycemia through sympathetic disinhibition.
▸Immunothrombosis, mediated by NETs, IL-6 signaling, and viral reactivation, amplifies tissue injury and provides subtype-specific targets for emerging anti-inflammatory therapies.

HY High Yield: The 6-level core-penumbra-oligemia continuum [20] explains why some patients with large core volumes still benefit from thrombectomy: the 'nonleaky core' may be salvageable if reperfused before BBB disruption occurs.

From the classification schema, ischemic stroke emerges as a heterogeneous final common pathway of diverse pathological processes, each converging on a stereotyped sequence of cellular injury that begins within seconds of flow cessation.

The Ischemic Cascade

Cerebral blood flow below 10-15 mL/100 g/min triggers energy failure: ATP depletion halts Na+/K+-ATPase, causing cytotoxic edema, and presynaptic glutamate release overwhelms reuptake, activating NMDA and AMPA receptors. The resulting calcium influx drives phospholipase activation, free radical generation, and mitochondrial permeability transition, leading to necrotic cell death in the core. Surrounding the core, the penumbra suffers milder hypoperfusion (15-20 mL/100 g/min) and experiences repeated peri-infarct depolarizations that extend the infarct at an average rate of 5.4 mL/h in large vessel occlusion, though this varies widely by collateral status ^[59]^D5. The pace of infarct growth defines clinical phenotypes: fast progressors (infarct growth rate ≥10 mL/h) require more urgent reperfusion ^[59]^D5.

Core, Penumbra, and Oligemia: A Dynamic Continuum

The traditional binary core-penumbra model has been refined into a 6-level continuum that better captures tissue fate ^[20]^D5:

Level	Perfusion	Tissue Status	Clinical Implication
1. Benign oligemia	Mildly reduced	Viable indefinitely	No intervention needed
2. Vulnerable oligemia	Moderately reduced	At risk only with prolonged hypotension	Monitor blood pressure
3. Durable penumbra	Critically reduced	Survives >24 h with good collaterals	Time window may be extended
4. Critical penumbra	Severely reduced	Infarcts within hours	Urgent reperfusion mandatory
5. Nonleaky core	Irreversibly injured	Blood-brain barrier (BBB) intact	Reperfusion safe but futile
6. Leaky core	Irreversibly injured	BBB disrupted	High hemorrhagic transformation risk

This granular classification explains why some patients with large core volumes still benefit from thrombectomy, while others with small cores suffer hemorrhagic transformation. The vulnerability of tissue depends not only on perfusion depth but also on molecular events occurring in parallel.

Neuroanatomic Localization of Clinical Deficits

Lesion network mapping of 7,807 patients with has linked specific neurological deficits to distinct structural and functional network disruptions ^[65]^C4. For example, limb ataxia maps to cerebellar-thalamic-cortical loops, while dysarthria localizes to opercular and insular regions. Poststroke hyperglycemia, a marker of sympathetic activation, specifically associates with right hemispheric insulo-opercular damage ^[68]^B2b, providing a mechanism for the autonomic dysregulation that worsens outcomes. Such network-based localization informs prognosis and suggests targets for neuromodulation (e.g., continuous theta-burst stimulation of the peri-infarct region modulates the calcineurin/AKT/FOXO1 apoptosis pathway ^[74]^D5).

Immunothrombosis and Inflammation

Beyond the initial ischemic cascade, immunothrombosis amplifies injury. Circulating neutrophils release neutrophil extracellular traps (NETs) that stabilize thrombi and obstruct microvessels, contributing to the no-reflow phenomenon after reperfusion ^[57]^D5. The DNase1 rs1053874 polymorphism, carried by 7.9% of patients, increases NET degradation and is associated with fewer thrombectomy passes, smaller infarcts, and improved long-term survival ^[44]^B2b. Interleukin-6 (IL-6) is a key driver: a 1-SD increment in log-transformed IL-6 levels raises incident ischemic stroke risk by 19% (relative risk 1.19, 95% CI 1.10-1.28) ^[39]^A1a, and IL-6 levels predict recurrence specifically in large artery atherosclerosis and small vessel occlusion subtypes ^[38]^A1a. Viral transcripts, particularly human herpesviruses (cytomegalovirus UL95, Epstein-Barr virus EBNA2), are 2.13-fold higher in stroke blood and may modulate immune gene expression (APOE, C3, PDGF) ^[70]^B3b.

Molecular Pathways and Emerging Targets

Multiple molecular pathways converge on secondary injury. LncRNA EPB41L4A-AS1, downregulated in acute ischemic stroke, suppresses microglial pro-inflammatory transition and ferroptosis via the miR-214-3p/GPX4 axis ^[71]^C4. PCSK9 promotes atherogenesis and also drives neuroinflammation within the brain parenchyma, making it a dual target for stroke prevention and acute treatment ^[73]^D5. Pericyte integrin-β1, though dispensable at baseline, protects BBB integrity during hemorrhagic transformation ^[75]^D5. These mechanisms, while not yet therapeutically actionable, provide the rationale for ongoing trials of adjunctive neuroprotection and anti-inflammatory therapy in mechanism-selected populations.

Pearl: The "progressor phenotype" - determined by infarct growth rate, collateral status, and molecular factors like NET burden and IL-6 levels - should guide not only the urgency of reperfusion but also the selection of patients for future anti-inflammatory and neuroprotective trials.

Epidemiology, Etiology & Risk Factors

▸Global ischemic stroke deaths are projected to rise from 2.04 million (1990) to 4.90 million (2030), driven by inadequate control of seven modifiable risk factors [100].
▸Hypertension is the most impactful modifiable risk factor; in young adults with type 2 diabetes, stage 2 systolic and diastolic hypertension confers a 1.94-fold increased risk of cardiovascular events, including ischemic stroke [126].
▸SARS-CoV-2 infection increases the odds of ischemic stroke nearly 4-fold (OR 3.58) and is particularly associated with cryptogenic stroke [97].

HY High Yield: Hypertension accounts for the largest population-attributable fraction of ischemic stroke; even stage 1 isolated diastolic hypertension in young adults with type 2 diabetes carries a 1.14-fold increased risk [126].

From these mechanisms arises a disease burden that is measured in tens of millions of events annually. In 2016, 13.7 million new strokes occurred globally, of which ≈87% were ischemic ^[99]^D5. The absolute number of ischemic stroke deaths rose from 2.04 million in 1990 to 3.29 million in 2019, and is projected to reach 4.90 million by 2030 ^[100]^B2c. This burden is distributed unevenly: low- and middle-income countries (LMICs) carry the highest rates, and fewer than 5% of eligible patients worldwide receive intravenous thrombolysis ^[99]^D5. Young adults (18-50 years) account for a rising proportion of cases, with 17,663 patients pooled across 32 cohorts showing that and diabetes are most prevalent in Black (52.1% and 20.7%) and Asian (46.1% and 20.9%) patients ^[87]^B2a. The 3-month mortality in LMICs is more than double that in high-income countries (odds ratio [OR] 2.49) ^[87]^B2a.

Etiologic Classification

Ischemic stroke is a syndrome, not a single disease. Using the TOAST classification, the crude annual incidence (per 100 000) in a predominantly Hispanic-Mestizo population was: cardioembolic 9.3, large-artery atherothrombotic 2.0, small-vessel disease 15.8, other determined cause 0.2, and undetermined 17.4 ^[98]^B2b. Cardioembolic strokes carry the highest 30-day case fatality (28%) and 6-month dependency or death (62%) ^[98]^B2b. In young adults, embolic stroke of undetermined source (ESUS) accounts for ≈40% of cases, with a recurrent ischemic stroke rate of 1.9 per 100 patient-years; most recurrences are also ESUS ^[41]^B2b.

Risk Factors

Seven modifiable risk factors, high systolic blood pressure, smoking, high sodium intake, high low-density lipoprotein cholesterol, kidney dysfunction, high fasting plasma glucose, and high body mass index, are the dominant contributors to the global ischemic stroke burden, and their inadequate control is projected to drive the increase in deaths through 2030 ^[100]^B2c. Mendelian randomization confirms that genetically predicted education, smoking, and body mass index are causal for ischemic stroke, with effects independent of each other ^[104]^B2c.

Risk Factor	OR/RR	Evidence Level
Hypertension (stage 2 SDH, young adults with T2DM)	HR 1.94 (95% CI 1.71-2.19)	2b ^[126]^B2b
Diabetes mellitus (young adults with ESUS)	HR 4.4 (95% CI 1.5-13)	2b ^[41]^B2b
Current smoking (genetically predicted)	OR 1.51 (95% CI 1.18-1.93)	2c ^[104]^B2c
Vitamin D deficiency (<25 vs ≥75 nmol/L)	HR 1.36 (95% CI 1.09-1.70)	2b ^[85]^B2b
Female-specific: any hypertensive disorder of pregnancy	RR 1.80 (95% CI 1.49-2.18)	2a ^[93]^B2a
Male-specific: androgen deprivation therapy	RR 1.19 (95% CI 1.05-1.34)	2a ^[93]^B2a

Special Populations and Temporal Trends

Young adults. Beyond traditional risk factors, the ABO blood group locus (tagging subgroup A1) is more strongly associated with early-onset stroke (≤59 years) than with late-onset disease (OR 1.16 vs 1.05, p-interaction = 0.005), and a higher genetic propensity for venous thromboembolism also predisposes to early-onset ischemic stroke ^[89]^B3a. Perioperative stroke. Incidence is low overall (≤1%) but exceeds 5% in cardiac, major vascular, and neurosurgical procedures, driven by embolic, thrombotic, and hypoperfusion mechanisms ^[102]^D5. . SARS-CoV-2 infection increases the odds of ischemic stroke nearly 4-fold, with a predilection for (OR 3.98) and a 5.6-fold higher in-hospital mortality ^[97]^B2a. Sex differences. Female patients with have a small but persistent excess stroke risk compared with males (adjusted RR 1.29 in 2012-2015), though this disparity appears to be narrowing over time ^[127]^B2b. Seasonal variation. The provided evidence does not address seasonal patterns; however, vitamin D levels, which vary seasonally, show a robust inverse association with ischemic stroke risk in meta-analysis (OR 1.54 for lowest vs highest quartile) ^[85]^B2b.

These risk factors and etiologic profiles determine the clinical phenotype and will be explored in the next section on Clinical Presentation.

Pearl: SARS-CoV-2 infection increases the odds of ischemic stroke nearly 4-fold (OR 3.58) and is particularly associated with cryptogenic stroke ^[97]^B2a.

Clinical Presentation

▸Nonfocal symptoms (headache, altered consciousness, dizziness) are common and increase misdiagnosis risk, especially in women.
▸The NIHSS underestimates posterior circulation stroke severity; the POST-NIHSS adds cough, dysphagia, and gait/truncal ataxia for better prognostication.
▸Uncommon variants (ischemic amnesia, Trousseau syndrome, contrast-induced encephalopathy) require a high index of suspicion and appropriate imaging.

HY High Yield: Misdiagnosis of cerebrovascular events is most common in patients with mild, nonspecific, or transient symptoms (false-negative rate 24-60%) [140]. Always consider stroke mimics (e.g., contrast-induced encephalopathy, seizure) and use multimodal imaging.

These risk factors and etiologies converge to produce a clinical syndrome whose features depend on the vascular territory, mechanism, and host factors. The onset is typically abrupt, with focal deficits reaching maximum severity within minutes to hours, though a stuttering or stepwise progression (e.g., in large artery atherosclerosis with recurrent embolism) can occur. Symptom onset is witnessed in only about half of patients; wake-up stroke accounts for 15-25% of presentations, and the median time from last seen well to hospital arrival is longer in this group (288 vs 133 minutes) ^[131]^B2b. Mode of onset modifies the effect of time to reperfusion, with a negative relationship between time to successful reperfusion and functional independence only in wake-up strokes ^[138]^B2b.

Presenting Symptoms

Focal symptoms dominate: unilateral weakness, sensory loss, hemianopia, aphasia, or ataxia. However, nonfocal symptoms are common and increase the risk of misdiagnosis. Headache occurs more frequently in women (OR 1.24, 95% CI 1.11-1.39) ^[141]^B2a, and changes in consciousness or mental status are also more frequent in women (OR 1.38) ^[141]^B2a. Patients with milder or transient symptoms (e.g., dizziness without motor findings) have a markedly higher false-negative rate at initial emergency department evaluation, up to 39.4% for dizziness compared to 4.4% for motor findings ^[140]^B2a. Isolated amnesia as the dominant symptom is rare (0.2% of all /transient ischemic attack) but easily mistaken for ; 31% of such patients have persistent memory problems at 3 months ^[151]^C4.

Neurological Examination Findings

The National Institutes of Health Stroke Scale ( ) is the standard bedside tool, but its limitations in posterior circulation stroke are well documented. The POST-NIHSS, which adds 5 points for an abnormal cough, 4 points for dysphagia, and 3 points for gait/truncal ataxia to the baseline NIHSS, improves prognostic accuracy in patients with mild-moderate symptoms (NIHSS <10) (area under the curve 0.80 vs 0.73, P=0.03) ^[149]^B2b. Cortical atrophy on baseline CT, a marker of brain frailty, is independently associated with a 1.25-point higher NIHSS at presentation ^[130]^B2b. In neonates, seizures due to arterial ischemic stroke are typically unilateral focal clonic (80.7%) or ictal apneas (12.5%) ^[114]^B3b.

Phenotypic Variants

Variant	Key Features	Reference
Ischemic amnesia	Transient anterograde and retrograde amnesia (median 5 hours), often cardioembolic, posterior circulation, limbic system involvement	^[151]^C4
Nine syndrome	One-and-a-half syndrome + ipsilateral facial weakness + contralateral hemiparesis/ataxia; pontine infarction	^[159]^C4
Trousseau syndrome	Recurrent multi-territory infarcts despite anticoagulation, elevated D-dimer, often adenocarcinoma	^[162]^C4
Vascular Eagle syndrome	Rapidly expanding neck hematoma, airway compromise, ischemic stroke from styloid process fracture	^[161]^C4
Contrast-induced encephalopathy	Acute neurological deficit within minutes to hours after intra-arterial contrast, resolves within 24-48 hours	^[164]^B2b

Red Flags

Impending airway compromise: stridor, hypoxia, expanding cervical swelling (e.g., Eagle syndrome) ^[161]^C4.
Malignant cerebral edema: rapid decline in consciousness, midline shift >11 mm within 20 hours of reperfusion, especially with severe hypoalbuminemia (<15 g/L) ^[163]^C4.
Post-stroke infections: pneumonia and urinary tract infection occur in ~10% each, worsen outcomes, and are more common with severe stroke, dysphagia, and impaired consciousness ^[148]^D5.
Sleep-disordered breathing: present in 50-70% of stroke patients, often obstructive or central apnea, and worsens recovery ^[145]^D5.

Atypical Presentations

A substantial minority of patients present with nonfocal or misleading symptoms. Ischemic amnesia, as noted, is easily misdiagnosed. Contrast-induced encephalopathy mimics stroke but carries an excellent prognosis. Trousseau syndrome should be suspected when infarcts involve multiple vascular territories, D-dimer is markedly elevated, and there is a known or occult malignancy ^[154]^B2b. Watershed infarction may be unmasked during in critically ill patients, manifesting as asymmetric motor recovery ^[160]^C4. Genetic causes of cerebral small vessel disease (e.g., CADASIL, CARASIL) present with recurrent lacunar strokes, migraine with aura, and cognitive decline, often with a family history ^[146]^D5.

Pearl: When a patient with transient or mild symptoms (especially dizziness or isolated confusion) is evaluated, the risk of misdiagnosis is 24-60% ^[140]^B2a; a low threshold for advanced neuroimaging and a high index of suspicion for stroke mimics (e.g., contrast-induced encephalopathy) can prevent inappropriate treatment.

Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)

▸MRI DWI is the gold standard for acute ischemic stroke diagnosis, but 6.8% of patients have a false-negative DWI; posterior circulation strokes are 5 times more likely to be DWI-negative [178].
▸Noncontrast CT remains the first-line test to exclude hemorrhage; advanced imaging (CTA, CTP, MRI DWI/PWI) is essential for identifying LVO, salvageable tissue, and eligibility for thrombolysis beyond 4.5 hours [201].
▸Point-of-care GFAP testing can distinguish ICH from ischemic stroke with high NPV (100% at GFAP <30 pg/mL in patients with NIHSS >6) [185].

Dx Diagnostic Essentials: **Gold-standard test:** MRI diffusion-weighted imaging (DWI) with ADC map. Sensitivity ~93% within 12 hours; posterior circulation strokes have a 5-fold higher odds of being DWI-negative [178].

The clinical presentation of focal neurologic deficit demands an immediate diagnostic sequence: first, differentiate ischemic stroke from and stroke mimics, then identify the vascular occlusion and salvageable tissue. Noncontrast CT (NCCT) is the mandatory first test, it reliably excludes hemorrhage but has low sensitivity for early ischemia. MRI with diffusion-weighted imaging (DWI) is the gold standard for diagnosis. A meta-analysis of 3236 patients found a pooled DWI-negative stroke prevalence of 6.8%, with posterior circulation ischemia conferring 5 times the odds of a negative scan (OR 5.1) ^[178]^B2a. The American Academy of Neurology recommends DWI as more useful than NCCT for diagnosis within 12 hours of onset (Level A) ^[166]^A1c.

Neuroimaging: Modality Selection

NCCT is performed first to exclude hemorrhage, evaluate early ischemic changes (e.g., loss of gray-white differentiation, sulcal effacement), and calculate the Alberta Stroke Program Early CT Score (ASPECTS). CT angiography (CTA) identifies large-vessel occlusion (LVO), the trigger for endovascular thrombectomy. CT perfusion (CTP) or MRI perfusion (PWI) quantifies the ischemic core and penumbra; the Target Mismatch profile (core <70 mL, mismatch volume >10 mL, ratio >1.2) identifies patients likely to benefit from reperfusion beyond 6 hours ^[201]^D5. In the WAKE-UP trial, the DWI-FLAIR mismatch (DWI hyperintensity without FLAIR hyperintensity) selected patients with unknown onset stroke who benefited from alteplase ^[177]^A1b. A network meta-analysis found no significant difference in outcomes between DWI/FLAIR-guided and perfusion-guided selection for thrombolysis beyond 4.5 hours, but this comparison was indirect and underpowered for equivalence ^[196]^A1a.

Gold-Standard Test

MRI DWI is the gold standard for diagnosing acute ischemic stroke. Hyperintensity on DWI with corresponding hypointensity on the apparent diffusion coefficient (ADC) map confirms cytotoxic edema within minutes of onset. Sensitivity is approximately 93% (95% CI 91-95) within 12 hours, but the 6.8% false-negative rate mandates that a clinical diagnosis of stroke not be abandoned solely on the basis of a negative DWI ^[178]^B2a.

Laboratory Studies

Routine labs (CBC, creatinine, glucose, coagulation profile, troponin) are not diagnostic but identify stroke mimics (hypoglycemia, thrombotic disorders) and guide treatment. Point-of-care GFAP (glial fibrillary acidic protein) measured on a portable device within 6 hours of onset can distinguish intracerebral hemorrhage from ischemic stroke with an AUC of 0.880 at a cutoff of 55 pg/mL; at GFAP <30 pg/mL in patients with >6, the NPV for ICH was 100% ^[185]^B2b. A 4-metabolite panel (asymmetric dimethylarginine, symmetric dimethylarginine, pregnenolone sulfate, adenosine) differentiated stroke from mimics with an AUC of 0.90, superior to multimodal CT (AUC 0.80) ^[42]^B3b. These biomarkers are not yet standard of care but may augment prehospital triage.

EEG

EEG is not used for acute stroke diagnosis. It is indicated when post-stroke seizures are suspected. Quantitative EEG (qEEG), specifically the Delta-Theta/Alpha-Beta Ratio (DTABR) reduction value at 1 hour after thrombolysis, independently predicted 24-hour clinical improvement (adjusted OR 2.745) in a retrospective cohort ^[207]^C4. The SeLECT-EEG prognostic model, incorporating epileptiform activity and regional slowing within 7 days, outperformed the standard SeLECT2.0 score for predicting post-stroke epilepsy (concordance statistic 0.75 vs 0.71, P<0.001) ^[116]^B3b.

Lumbar Puncture and NCS/EMG

Lumbar puncture is reserved for suspected (CT-negative) or CNS infection/vasculitis. NCS/EMG has no role in acute ischemic stroke diagnosis; it is used in the rehabilitation phase to assess peripheral nerve or muscle involvement.

Diagnostic Algorithm

Differential Diagnosis of Stroke Mimics

Condition	Key Differentiator	Diagnostic Test
Seizure (postictal/Todd's paresis)	History of epilepsy, rapid resolution, eye deviation	EEG, rTmax mapping (hyperperfusion) ^[143]^B3b
Migraine with aura	Gradual spread of symptoms, headache, prior episodes	Normal DWI
Hypoglycemia	Serum glucose <60 mg/dL, resolves with dextrose	Point-of-care glucose
Functional neurological disorder	Inconsistency, variability, Hoover sign, no imaging correlate	Normal DWI, normal neurologic exam on distraction
CNS tumor	Subacute onset, headache, papilledema, no vascular territory	MRI with contrast
CNS infection (meningitis/encephalitis)	Fever, neck stiffness, altered mental status, CSF pleocytosis	LP, CSF culture, MRI

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Optimal imaging for thrombolysis in unknown onset stroke	DWI-FLAIR mismatch (WAKE-UP) ^[177]^A1b	Perfusion-guided (CTP or PWI-DWI mismatch) ^[196]^A1a	Indirect comparison; no significant difference	Either strategy is acceptable; the choice depends on local availability and expertise

Pearl: In a patient with acute focal deficits and a negative DWI, do not withhold thrombolysis if the clinical picture strongly suggests stroke, posterior circulation ischemia has a 5-fold higher odds of being DWI-negative, and the diagnosis remains clinical ^[178]^B2a.

Severity, Staging & Risk Stratification

▸NIHSS severity (mild 0-4, intermediate 5-9, moderate 10-14, severe ≥15) drives acute treatment decisions and timing of anticoagulation.
▸ASPECTS and core volume define EVT eligibility; benefit extends to large-core strokes (ASPECTS 3-5) though with higher sICH risk.
▸Residual recurrent stroke risk remains high (3.75%/year) despite anticoagulation, especially in patients with prior OAC failure (7.20%/year).

HY High Yield: Golden hour thrombolysis doubles excellent outcome odds (OR 1.40; NNT 2.6), every 30-minute delay reduces the chance of mRS 0-1 by 1.8% [229, 221].

The National Institutes of Health Stroke Scale ( ) is the primary instrument for grading clinical severity at presentation, with scores stratifying patients into mild (0-4), intermediate (5-9), moderate (10-14), and severe (≥15) categories ^[234]^B2b. This initial severity tier directly anchors therapeutic thresholds: intravenous thrombolysis is preferred for disabling symptoms regardless of NIHSS value, while dual antiplatelet therapy remains standard for nondisabling, noncardioembolic events ^[232]^D5^[129]^A1a. For patients with large‑vessel occlusion (LVO) and low NIHSS (≤5), endovascular thrombectomy (EVT) does not improve functional outcomes compared with best medical therapy (risk ratio for 0‑1: 1.10; 95% CI, 0.93‑1.31) and increases symptomatic intracranial hemorrhage (sICH) (RR 3.53; 95% CI, 2.35‑5.31) ^[226]^B2a^[240]^B2a. Every 30‑minute reduction in onset‑to‑needle time raises the probability of 90‑day mRS 0‑1 by 1.8%, independent of thrombolytic agent ^[221]^B2b; golden‑hour thrombolysis doubles the odds of excellent recovery (OR 1.40; 95% CI, 1.16‑1.67) with an NNT of 2.6 ^[229]^A1a.

Imaging-Based Infarct Staging

The Alberta Stroke Program Early CT Score (ASPECTS) quantifies early ischemic changes on noncontrast CT (0‑10, lower = larger core). In the MR CLEAN analysis, treatment effect did not differ across ASPECTS subgroups (0‑4, 5‑7, 8‑10) ^[214]^B2b. More recent meta‑analyses from six RCTs (1887 patients) show that EVT is associated with improved 90‑day ordinal mRS (generalized OR 1.6; 95% CI, 1.4‑1.8) and higher independent ambulation (mRS 0‑3; RR 1.9; 95% CI, 1.5‑2.5) even in large‑core strokes (ASPECTS 3‑5), with a survival benefit (RR 0.9; 95% CI, 0.8‑1.0) despite a modest increase in sICH (RR 1.7; 95% CI, 1.1‑2.7) ^[213]^A1a^[86]^B2a. Benefit declines with longer onset‑to‑randomization time (regression slope for mRS 0‑3: -0.11; 95% CI, -0.12 to -0.10) ^[213]^A1a.

Functional Outcome and Prognostic Models

The (mRS) is the universal 90‑day outcome measure. Among patients with mild stroke (NIHSS ≤5), up to 30% develop disability, challenging the notion of a benign course ^[232]^D5. The SeLECT‑EEG model (integrating epileptiform activity and regional slowing on early EEG) predicts post‑stroke epilepsy with a concordance statistic of 0.75 (95% CI, 0.71‑0.80), outperforming the SeLECT 2.0 score (0.71) ^[116]^B3b^[198]^B2b. Polygenic risk of ischemic stroke, even in the absence of clinical stroke, correlates with lower cognitive ability (r = -0.070, p = 1.95 × 10⁻⁸) ^[225]^B2b.

Risk Stratification for Recurrent Events

In patients with , the CHA₂DS₂‑VASc score guides anticoagulation decisions. Despite modern therapy, the residual risk of recurrent ischemic stroke is 3.75% per year (95% CI, 3.17%‑4.33%) and rises to 7.20% per year (95% CI, 5.05%‑9.34%) among those who had a stroke while on oral anticoagulation ^[91]^B2a^[236]^B2a. A pragmatic “1‑2‑3‑4‑day” rule for direct oral anticoagulant initiation, start on day 1 after TIA, day 2 after mild stroke (NIHSS 0‑7), day 3 after moderate (8‑15), and day 4 after severe (≥16), reduces 90‑day stroke or systemic embolism compared with later initiation (1.9% vs 3.9%; adjusted HR 0.50; 95% CI, 0.27‑0.89) ^[228]^B2b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
EVT for low NIHSS (≤5) with LVO	AHA/ASA: equipoise, individualized ^[226]^B2a	European guidelines: not routinely recommended ^[240]^B2a	Level IIa vs III	sICH risk outweighs uncertain benefit in most patients
Thrombolysis for minor nondisabling stroke	Meta‑analysis (4 RCTs) suggests harm (sICH OR 5.22; mortality OR 2.40) ^[212]^A1a	Some real‑world data support selective use ^[232]^D5	Moderate	Avoid IVT for truly nondisabling deficits; use DAPT instead

Pearl: The NIHSS score obtained after acute treatment (at 72 hours) predicts post‑stroke epilepsy more accurately than the admission score; use the modified SeLECT 2.0 score for risk stratification ^[198]^B2b.

NIHSS Severity Stratification and Clinical Actions

NIHSS Category	Score Range	Typical Action
Mild	0-4	DAPT for nondisabling; consider IVT if disabling ^[232]^D5^[129]^A1a
Intermediate	5-9	IVT if <4.5 hours; assess for EVT with CTA ^[234]^B2b
Moderate	10-14	IVT + EVT if LVO; start DOAC day 3 post-stroke ^[228]^B2b
Severe	≥15	IVT + EVT; start DOAC day 4; monitor for malignant edema ^[228]^B2b

Acute Management: Neurologic Emergencies & Attack Abortion

▸IV thrombolysis (alteplase 0.9 mg/kg within 4.5 h; tenecteplase 0.25 mg/kg preferred for LVO) and EVT (up to 24 h with perfusion selection) are the primary attack-abortion tools.
▸Early tirofiban after thrombolysis improves functional outcomes in noncardioembolic stroke (ASSET-IT; RR 1.20, 95% CI 1.07-1.34).
▸EVT for medium-vessel occlusion is not supported by recent RCT data (ESCAPE-MeVO); individualize decisions.

Rx Drug of Choice: **First-line thrombolytic:** Alteplase 0.9 mg/kg IV (max 90 mg) within 4.5 hours. **Alternative for LVO:** Tenecteplase 0.25 mg/kg IV bolus, with similar efficacy and safety [247] (2b).

HY High Yield: **Golden hour thrombolysis** (within 60 min of ED arrival) yields NNT 2.6 for reducing disability by at least 1 mRS level [229] (1a).

From the severity stratification established in the preceding section, the clinician now faces a time-critical decision tree. Every minute of delay reduces the probability of a favorable outcome: door-to-needle time for IV thrombolysis should be ≤60 minutes and door-to-puncture time for endovascular thrombectomy (EVT) ≤90 minutes ^[229]^A1a (1a). The overarching goal is to terminate the ischemic episode, the "attack", by restoring perfusion before infarction is complete.

Step 1: Triage and Imaging-Based Selection

Within minutes of arrival, obtain noncontrast CT (or MRI) to exclude hemorrhage, followed by CT angiography (CTA) and CT perfusion (CTP) for patients with suspected large-vessel occlusion (LVO). For patients with a favorable penumbral profile (ischemic core <70 mL, mismatch ratio >1.2, mismatch volume >10 mL), the treatment window for IV thrombolysis extends to 9 hours and for EVT to 24 hours ^[244]^A1b (1b), ^[243]^A1b (1b). The DAWN and DEFUSE-3 trials demonstrated that EVT in the 6-24 hour window yields functional independence ( 0-2) in 49% vs 13% with medical (adjusted difference 33 percentage points, posterior probability >0.999) ^[243]^A1b.

Step 2: Intravenous Thrombolysis

Administer alteplase 0.9 mg/kg (max 90 mg) IV, with 10% as bolus and the remainder over 60 minutes, within 4.5 hours of symptom onset ^[211]^A1b (1b). The ECASS III trial showed favorable outcome (mRS 0-1) in 52.4% vs 45.2% (OR 1.34, 95% CI 1.02-1.76) despite a sICH rate of 2.4% vs 0.2% ^[211]^A1b. Tenecteplase 0.25 mg/kg IV bolus is a reasonable alternative, particularly in patients with LVO, with meta-analyses suggesting noninferior efficacy and similar safety ^[247]^B2b (2b), ^[260]^D5 (5). In the BRIDGE-TNK trial, tenecteplase before EVT improved functional independence (mRS 0-2) at 90 days compared to EVT alone (52.9% vs 44.1%; RR 1.20, 95% CI 1.01-1.43) ^[209]^A1b (1b).

For patients presenting 4.5-24 hours after onset with a favorable penumbral profile, thrombolysis remains beneficial. The EXPECTS trial (posterior circulation, 4.5-24 hours) reported functional independence (mRS 0-2) in 89.6% with alteplase vs 72.6% (aRR 1.16, 95% CI 1.03-1.30) ^[79]^A1b (1b). A meta-analysis of 8 RCTs (n=1742) confirmed higher odds of excellent functional outcome (OR 1.43) with imaging-selected late-window thrombolysis, despite increased sICH (OR 4.25) ^[254]^A1a (1a).

Do not withhold thrombolysis for recent DOAC ingestion if the last dose was >48 hours or if anticoagulant reversal is available; the risk of sICH is not elevated (aOR 0.57) ^[259]^B2b (2b).

Step 3: Endovascular Thrombectomy

For patients with anterior circulation LVO (ICA or M1-MCA) and an ASPECTS ≥6 within 6 hours, EVT is first-line therapy (NNT 3-10) ^[257]^D5 (5). For ASPECTS 3-5, EVT still improves outcomes. A meta-analysis of 6 RCTs (n=1887) showed improved 90-day mRS (generalized OR 1.6, 95% CI 1.4-1.8) and independent ambulation (RR 1.9, 95% CI 1.5-2.5) ^[213]^A1a (1a). Even ASPECTS 0-2 patients may benefit (RR for mRS 0-3: 2.1) ^[213]^A1a.

For medium-vessel occlusion (M2-MCA, PCA), the evidence is nuanced. The ESCAPE-MeVO trial (n=530) found no benefit of EVT over usual care (mRS 0-1: 41.6% vs 43.1%; aRR 0.95, 95% CI 0.79-1.15) and a trend toward harm (sICH 5.4% vs 2.2%) ^[208]^A1b (1b). For posterior cerebral artery (PCA) occlusion, meta-analysis of cohort studies shows higher odds of no disability (OR 1.25, 95% CI 1.04-1.50) but also higher sICH (OR 2.48) ^[10]^B2a (2a). Individualize decisions.

Step 4: Post-Thrombolysis Antiplatelet Therapy

In patients with noncardioembolic stroke who received thrombolysis but are not undergoing EVT, early tirofiban infusion (24-hour IV) improves excellent functional outcome (mRS 0-1: 65.9% vs 54.9%; RR 1.20, 95% CI 1.07-1.34) with a low sICH rate (1.7% vs 0%) ^[83]^A1b (1b). The ASSET-IT trial supports this approach. Dual antiplatelet therapy ( 300 mg load + 100-300 mg) initiated within 72 hours also reduces 90-day stroke recurrence (7.3% vs 9.2%; HR 0.79, 95% CI 0.66-0.94) ^[245]^A1b (1b).

Dosing Table

Drug	Starting dose	Target / max dose	Renal adjustment	Hepatic adjustment	Key monitoring
Alteplase	0.09 mg/kg IV bolus	0.9 mg/kg total (max 90 mg)	None	None	BP, sICH signs
Tenecteplase	0.25 mg/kg IV bolus (max 25 mg)	Single bolus	None	None	BP, sICH signs
Tirofiban	0.4 μg/kg/min IV for 30 min	0.1 μg/kg/min IV for 24 h	eGFR <30: reduce	None	Platelet count, sICH

Step 5: Periprocedural and Hemodynamic Management

Maintain systolic BP >140 mm Hg during EVT to support collateral flow; after reperfusion, target SBP <160 mm Hg ^[258]^D5 (5). General anesthesia and procedural sedation yield similar functional outcomes (33.3% vs 39.1% mRS 0-2; RR 1.18) ^[249]^A1b (1b). Each 15-minute reduction in door-to-puncture time improves quality-adjusted life years (increase 0.29, 95%) ^[248]^B2b (2b).

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
EVT for medium-vessel occlusion	AHA/ASA 2021, consider EVT for M2-MCA if disabling deficit	ESCAPE-MeVO trial (2025), no benefit vs usual care, possible harm	Strong (RCT null vs guideline expert opinion) ^[208]^A1b	Until further RCTs, limit EVT for M2-MCA to patients with severe deficits and favorable anatomy.
General anesthesia vs sedation	AMETIS trial (2023), no difference in functional independence (33.3% vs 39.1%)	Meta-analysis of prior observational studies, better outcomes with GA	Moderate (RCT vs observational) ^[249]^A1b	Use protocol-based GA in centers with neuroanesthesia teams; either is acceptable.

Pearl: Every minute counts, for thrombolysis, the golden hour (NNT 2.6) ^[229]^A1a; for EVT, each 15-minute delay in door-to-puncture reduces QALYs by 0.29 ^[248]^B2b (2b).

Long-term & Definitive Management (Evidence Ladder)

▸Dual antiplatelet therapy with clopidogrel + aspirin for 21-90 days reduces recurrent stroke by up to 32% in minor stroke/TIA (CHANCE, POINT, INSPIRES).
▸DOACs remain the standard for atrial fibrillation; switching to warfarin after a breakthrough stroke is less effective and less safe than maintaining DOAC therapy.
▸Intensive statin (atorvastatin 80 mg) improves functional outcomes even without reducing early recurrent stroke; adding PCSK9i (alirocumab/evolocumab) further lowers ischemic stroke risk.
▸Percutaneous PFO closure reduces recurrent stroke in selected young patients with cryptogenic stroke and high-risk PFO (RR 0.42).

Rx Drug of Choice: For noncardioembolic minor stroke or high-risk TIA, the preferred regimen is **clopidogrel (300 mg loading, then 75 mg daily) plus aspirin (75-100 mg daily)** initiated within 24-72 hours and continued for **21-90 days**, then transition to single antiplatelet. In CYP2C19 loss-of-function carriers, **ticagrelor 180 mg loading then 90 mg twice daily** plus aspirin for 21 days is an alternative.

! Warning: Do NOT combine anticoagulation with antiplatelet therapy in patients with atrial fibrillation unless a compelling indication (e.g., recent stent, mechanical valve) exists. The combination increases major bleeding without reducing stroke recurrence (HR 0.91, 95% CI 0.53-1.55; major bleeding HR 2.42) [84].

The acute neuroprotective and reperfusion strategies outlined above transition, within the first 24-72 hours, to a long-term definitive program designed to prevent recurrent stroke and maximize functional recovery. The evidence ladder for secondary prevention rests on four interconnected pillars: (1) etiology-guided antithrombotic therapy, (2) revascularization for large-artery and embolic substrates, (3) intensive risk-factor control, and (4) adherence-promoting strategies. Each step is grounded in Level 1-2 evidence from pivotal randomized trials.

Step 1: Etiology-Based Antithrombotic Selection

The first decision distinguishes cardioembolic from noncardioembolic (large-artery, small-vessel, cryptogenic) sources.

( ). Oral anticoagulation (DOAC) is the cornerstone. In the FOURIER trial, evolocumab added to statin reduced ischemic stroke from 1.6% to 1.2% (HR 0.75, 95% CI 0.62-0.92; NNT = 250 over 2.2 years) in patients with prior ischemic stroke ^[288]^B2b. For patients with ischemic stroke despite DOAC, switching to is inferior to staying on the same DOAC or switching to another DOAC: warfarin was associated with higher recurrent stroke (RR 1.80, 95% CI 1.42-2.29) and higher intracranial hemorrhage (RR 2.90) ^[37]^A1a. The residual annual risk of recurrent ischemic stroke despite anticoagulation is 3.75% overall, rising to 7.20% per year in patients whose index event occurred while on a DOAC ^[91]^B2a. Left atrial appendage closure (LAAC) is an alternative; a meta-analysis of 3116 patients found LAAC reduced non-procedure-related bleeding (RR 0.48, 95% CI 0.37-0.61) and all-cause mortality (RR 0.74, 95% CI 0.55-0.99) compared with oral anticoagulation ^[313]^A1a. Adding an antiplatelet to anticoagulation in patients with concurrent atrial fibrillation and atherosclerotic disease provided no net clinical benefit (HR 0.91, 95% CI 0.53-1.55) and increased major bleeding (HR 2.42) ^[84]^A1b.

Noncardioembolic stroke (minor stroke/TIA). Dual antiplatelet therapy (DAPT) with plus is superior to aspirin alone when initiated within 24-72 hours. The CHANCE trial (N=5170) demonstrated a reduction in 90-day stroke from 11.7% to 8.2% (HR 0.68, 95% CI 0.57-0.81; NNT = 29) ^[273]^A1b. POINT (N=4881, international) confirmed these findings: major ischemic events 5.0% vs 6.5% (HR 0.75, 95% CI 0.59-0.95; NNT = 67) but with increased major hemorrhage (0.9% vs 0.4%; NNH = 200) ^[275]^A1b. The INSPIRES trial extended the enrollment window to 72 hours: new stroke occurred in 7.3% vs 9.2% (HR 0.79, 95% CI 0.66-0.94; NNT = 53) with moderate-to-severe bleeding in 0.9% vs 0.4% ^[245]^A1b. A network meta-analysis confirmed that both clopidogrel+aspirin (HR 0.74, 95% CrI 0.65-0.84) and +aspirin (HR 0.79, 95% CrI 0.68-0.91) were superior to aspirin, with no significant difference between the two DAPT regimens (HR 0.94, 95% CrI 0.78-1.13); clopidogrel+aspirin had less functional disability (HR 0.85, 95% CrI 0.75-0.97) ^[297]^A1a. In CYP2C19 loss-of-function carriers, ticagrelor+aspirin reduced 1-year stroke vs clopidogrel+aspirin (7.91% vs 9.73%; HR 0.80, 95% CI 0.68-0.95) ^[284]^B2b. The glycemic substrata of INSPIRES showed DAPT benefit was significant in patients without diabetes (HR 0.75, 95% CI 0.59-0.94) and with newly diagnosed diabetes (HR 0.30, 95% CI 0.14-0.66) but not in those with a history of diabetes (p interaction = 0.03) ^[176]^A1b.

Large-artery atherosclerosis (symptomatic). In patients with mild stroke/TIA due to atherosclerotic stenosis, clopidogrel+aspirin similarly reduces recurrence; the effect did not differ by the presence of intracranial vs extracranial stenosis (no significant interaction) ^[290]^B2b. Immediate-intensive (80 mg daily for 21 days then 40 mg daily) within 72 hours did not reduce 90-day stroke compared with 3-day delayed statin (8.1% vs 8.4%; HR 0.95, 95% CI 0.80-1.13) but improved functional outcome (OR 0.83, 95% CI 0.71-0.98) ^[285]^A1b. Adding tirofiban to noncardioembolic stroke within 24 hours reduced early neurological deterioration from 13.2% to 4.2% (aRR 0.32, 95% CI 0.16-0.65) without sICH ^[215]^A1b. A meta-analysis found tirofiban added to intravenous thrombolysis improved favorable functional outcome (RR 1.14, 95% CI 1.07-1.20) without increasing sICH or mortality ^[314]^A1a. In patients undergoing thrombectomy for intracranial atherosclerotic disease, intraprocedural tirofiban increased functional independence (aOR 1.68) ^[282]^B2b.

Embolic stroke of undetermined source (ESUS). Empiric anticoagulation is not beneficial overall (RR 0.91). Anticoagulation may reduce recurrent stroke in patients with patent foramen ovale (RR 0.59, 95% CI 0.35-0.98) ^[280]^A1a. For selected young patients with and PFO, percutaneous closure reduces recurrent ischemic stroke (RR 0.42, 95% CI 0.20-0.91) but increases new-onset atrial fibrillation (RR 4.59); the Amplatzer device appears superior to STARFlex ^[296]^A1a.

. In a meta-analysis of two RCTs (N=444), anticoagulation (mainly warfarin) was associated with fewer ischemic strokes than antiplatelet therapy (0.5% vs 4.0%; OR 0.14, 95% CI 0.02-0.61) but more bleeding events (2 vs 0); the composite primary endpoint did not reach statistical significance (OR 0.33) ^[298]^A1a. The AHA/ASA suggests individualizing antithrombotic choice for at least 3-6 months ^[303]^A1c.

Extended-window thrombolysis and late reperfusion. For patients presenting 4.5-24 hours after symptom onset with favorable penumbral imaging and large/medium vessel occlusion, tenecteplase 0.25 mg/kg improved major reperfusion without sICH (aRR 3.0, 95% CI 1.6-5.7) ^[250]^A1b. A meta-analysis of 7 RCTs (N=1754) found tenecteplase increased good functional outcome (HR 1.15, 95% CI 1.03-1.27) and excellent outcome (HR 1.29, 95% CI 1.08-1.55), particularly in patients not undergoing thrombectomy (OR 1.47) ^[312]^A1a. Alteplase in the extended window also improved 0-2 (RR 1.21, 95% CI 1.06-1.38) ^[315]^A1a. The TIMELESS trial, however, did not show benefit of tenecteplase in patients most of whom received thrombectomy (median mRS 3 in both groups; aOR 1.13, 95% CI 0.82-1.57) ^[277]^A1b. For large ischemic cores (ASPECTS 3-5), endovascular thrombectomy within 24 hours improved functional outcomes (generalized OR 1.37, 95% CI 1.11-1.69) ^[279]^A1b; long-term functional independence (mRS 0-2) was increased (RR 3.13) ^[316]^A1a.

Novel factor XIa inhibition. Asundexian 50 mg daily, added to antiplatelet therapy in noncardioembolic stroke (OCEANIC-STROKE, N=12,327), reduced ischemic stroke from 8.4% to 6.2% (cause-specific HR 0.74, 95% CI 0.65-0.84; NNT = 45) without increasing major bleeding (1.9% vs 1.7%; HR 1.10, 95% CI 0.85-1.44) ^[274]^A1b.

Drug regimen	Indication	Key trial(s)	Effect size	NNT (90 days-2.8 years)	Safety signal
Clopidogrel + aspirin vs aspirin	Minor stroke/TIA, ≤24-72 h	CHANCE, POINT, INSPIRES, ATAMIS	HR 0.68-0.79	29-67	Major hemorrhage: HR 2.08-2.32
Ticagrelor + aspirin vs clopidogrel + aspirin	CYP2C19 LoF carriers	CHANCE-2	HR 0.80 (1-yr)	NNT ~55	No significant difference
Asundexian + antiplatelet vs antiplatelet	Noncardioembolic stroke/TIA	OCEANIC-STROKE	HR 0.74	45	Major bleeding HR 1.10 (NS)
Alirocumab vs placebo (+ statin)	Recent ACS, LDL ≥70 mg/dL	ODYSSEY OUTCOMES	HR 0.85 (MACE)	63 (over 2.8 yr)	Injection-site reactions 3.8%
Evolocumab vs placebo (+ statin)	Established atherosclerosis	FOURIER (stroke subset)	HR 0.79 (any stroke)	250 (over 2.2 yr)	No significant increase
PFO closure vs medical	Cryptogenic stroke + PFO	Meta-analysis (6 RCTs)	RR 0.42 (ischemic stroke)	30 (over ~3 yr)	New AF: RR 4.59

Step 2: Revascularization

. For asymptomatic high-grade (≥70%) stenosis, CREST-2 showed that stenting added to intensive medical management reduced the 4-year composite of perioperative stroke/death or ipsilateral ischemic stroke from 6.0% to 2.8% (absolute difference 3.2%, P = 0.02; NNT = 31). did not reach significance (5.3% vs 3.7%; P = 0.24) ^[78]^A1b.

Step 3: Intensive Risk-Factor Modification

Lipid lowering. High-intensity statin (atorvastatin 40-80 mg) is standard. The polypill strategy (aspirin 100 mg + 2.5/5/10 mg + atorvastatin 20/40 mg) after myocardial infarction reduced MACE (HR 0.76, 95% CI 0.60-0.96) and may be extrapolated to patients with stroke ^[272]^A1b. For patients with LDL ≥70 mg/dL despite maximally tolerated statin, alirocumab 75 mg SC every 2 weeks reduced MACE (HR 0.85, 95% CI 0.78-0.93) ^[80]^A1b. Evolocumab similarly reduced any stroke (HR 0.79, 95% CI 0.66-0.95) in the FOURIER trial ^[288]^B2b.

Blood pressure. Intensive BP control (<130/80 mm Hg) is recommended. In patients undergoing thrombectomy, intensive BP lowering (SBP <120 mm Hg) was associated with less functional independence (OR 0.68, 95% CI 0.51-0.91) than conventional control, suggesting a permissive phase in the first 72 hours after successful reperfusion ^[299]^A1a.

Anti-inflammatory therapy. Icosapent ethyl (EPA-EE) 2000 mg/day added to standard treatment for 12 weeks improved mRS score reduction (2.18 ± 0.61 vs 1.38 ± 0.66; P = 0.001) and reduced IL-6 levels (-6.32 vs -2.95 pg/mL; P = 0.003) ^[304]^A1b.

Remote ischemic conditioning (RIC). In patients not receiving reperfusion therapy, RIC reduced stroke recurrence (RR 0.63, 95% CI 0.43-0.92) and improved by 1.72 points without increasing adverse events ^[295]^A1a.

Step 4: Adherence and Polypill Strategy

Medication nonadherence is a major cause of recurrent stroke. In the SECURE trial, a fixed-dose combination polypill (aspirin + ramipril + atorvastatin) improved adherence and reduced major cardiovascular events (HR 0.76, 95% CI 0.60-0.96) compared with usual care after myocardial infarction ^[272]^A1b. A similar strategy is rational for secondary stroke prevention, though not yet tested specifically in stroke cohorts.

Emerging and Adjunctive Neuroprotection

Butylphthalide (NBP) added to reperfusion therapy increased favorable functional outcome at 90 days from 44.0% to 56.7% (OR 1.70) ^[216]^A1b. A meta-analysis of neuroprotective adjuncts to thrombectomy showed a modest increase in functional independence (OR 1.13, 95% CI 1.01-1.28) without safety concerns ^[62]^A1a. Vagus nerve stimulation paired with rehabilitation improved upper extremity impairment at 1 year (FMA-UE change 5.23 points, 95%) ^[286]^B2b. Anodal tDCS combined with physical therapy reduced unilateral spatial neglect (BIT-C improvement MD 18.4, 95%) ^[291]^A1b.

What NOT to Do

Do NOT add systematic antiplatelet to anticoagulation in atrial fibrillation patients ^[84]^A1b.
Do NOT empirically anticoagulate ESUS patients without prolonged cardiac monitoring ^[280]^A1a.
Do NOT switch a failing DOAC to warfarin; prefer DOAC-to-DOAC or dose adjustment ^[37]^A1a.
Do NOT initiate immediate-intensive statin within 72 hours expecting reduced early stroke recurrence; it does not lower stroke risk compared with a 3-day delay ^[285]^A1b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
DAPT duration after minor stroke	AHA/ASA 2019, 21 days (based on CHANCE/POINT)	CHANCE/POINT 90-day protocols, some guidelines support 90 days if low bleeding risk	Moderate ^[273]^A1b^[275]^A1b^[301]^A1c	Clinical practice variable; 21 days may be safer but 90 days may be more effective in high-risk patients
Immediate vs delayed intensive statin	INSPIRES, immediate statin did not reduce 90-day stroke, but improved functional outcome	ESC/EAS, early high-intensity statin recommended regardless	Mild (outcome definition differences) ^[285]^A1b^[301]^A1c	Functional benefit may justify immediate statin despite lack of stroke reduction; cost and tolerability favor delayed initiation
PFO closure in cryptogenic stroke	AHA/ASA, indicated in selected young patients with high-risk PFO	Some guidelines, careful selection using RoPE score required; not all PFOs need closure	Mild ^[103]^D5^[296]^A1a	Patient selection critical; Amplatzer device preferred over STARFlex

Pearl: For noncardioembolic minor stroke or high-risk TIA, initiate clopidogrel 300 mg load plus aspirin as soon as possible (up to 72 hours) and continue dual therapy for 21-90 days, then transition to single antiplatelet; in cardioembolic stroke, start a DOAC within 48 hours to 14 days depending on infarct size and exclude concurrent antiplatelet unless compelling indication.

Comparison of Antithrombotic Regimens for Secondary Stroke Prevention (Selected Landmark Trials)

Regimen	Indication	Trial (N)	Efficacy measure	Effect (95% CI)	NNT (time frame)	Safety (major hemorrhage)
Clopidogrel + aspirin vs aspirin	Minor stroke/TIA ≤24 h	CHANCE (5170)	90-day stroke	HR 0.68 (0.57-0.81)	29	0.3% vs 0.3% (NS)
Clopidogrel + aspirin vs aspirin	Minor stroke/TIA ≤12 h	POINT (4881)	90-day MACE	HR 0.75 (0.59-0.95)	67	0.9% vs 0.4% (P=0.02)
Clopidogrel + aspirin vs aspirin	Minor stroke/TIA ≤72 h	INSPIRES (6100)	90-day stroke	HR 0.79 (0.66-0.94)	53	0.9% vs 0.4% (P=0.03)
Ticagrelor + aspirin vs clopidogrel + aspirin	CYP2C19 LoF carriers	CHANCE-2 (6412)	1-year stroke	HR 0.80 (0.68-0.95)	55	0.53% vs 0.63% (NS)
Asundexian + antiplatelet vs antiplatelet	Noncardioembolic stroke/TIA	OCEANIC-STROKE (12,327)	Ischemic stroke	cHR 0.74 (0.65-0.84)	45	1.9% vs 1.7% (NS)
Alirocumab vs placebo (+ statin)	Recent ACS + dyslipidemia	ODYSSEY OUTCOMES (18,924)	MACE	HR 0.85 (0.78-0.93)	63 (2.8 yr)	Injection-site reactions 3.8% vs 2.1%
Evolocumab vs placebo (+ statin)	Established atherosclerosis	FOURIER (27,564)	Any stroke	HR 0.79 (0.66-0.95)	250 (2.2 yr)	Similar
PFO closure vs medical therapy	Cryptogenic stroke + PFO	Meta-analysis (6 RCTs)	Ischemic stroke	RR 0.42 (0.20-0.91)	~30 (3 yr)	New AF: RR 4.59
Polypill vs usual care	Post-MI	SECURE (2499)	CV death, MI, stroke, revasc	HR 0.76 (0.60-0.96)	31 (36 mo)	Similar
Endovascular thrombectomy + medical vs medical	Large core (ASPECTS 3-5)	ANGEL-ASPECT (456)	Long-term mRS 0-2	RR 3.13 (2.01-4.86)	,	sICH 6.1% vs 2.7%
Carotid stenting + medical vs medical alone	Asymptomatic ≥70% stenosis	CREST-2 (1245)	4-yr stroke/death/ipsilat stroke	Absolute ARR 3.2% (P=0.02)	31	Perioperative stroke 0.6%

History and Evolution of Treatment

▸The 1995 NINDS trial established intravenous alteplase within 3 hours as the first proven acute stroke therapy, despite a 6.4% symptomatic hemorrhage rate [323].
▸Endovascular thrombectomy, validated by DAWN/DEFUSE-3 and MR CLEAN, extended the treatment window to 24 hours with a number needed to treat of 3-10 [257].
▸Decades of neuroprotective drug failures (publication bias, poor trial design) contrast with recent successes in extended-window thrombolysis (TRACE-III, EXPECTS) and targeted anti-inflammatory strategies (colchicine) [330,76,79,82].

The 1995 NINDS trial changed stroke care forever: intravenous alteplase (0.9 mg/kg, maximum 90 mg) given within 3 hours improved the odds of minimal or no disability at 3 months (global odds ratio 1.7, 95% CI 1.2-2.6), despite a 6.4% risk of symptomatic versus 0.6% with placebo ^[323]^A1b. This benefit was subsequently extended to 4.5 hours by ECASS III, and later work established that dual antiplatelet therapy with - initiated within 24 hours reduces recurrent stroke in minor stroke or high-risk TIA (CHANCE-2 at 90 days: HR 0.80, 95% CI 0.68-0.95 for 1-year stroke; ATAMIS: early neurologic deterioration 4.8% versus 6.7% with aspirin alone) ^[284]^B2b^[217]^A1b.

The Endovascular Revolution

In 2015, five trials (MR CLEAN, ESCAPE, SWIFT PRIME, REVASCAT, EXTEND-IA) proved that mechanical thrombectomy plus medical therapy outperformed medical therapy alone for proximal anterior circulation large vessel occlusion, with a number needed to treat of 3 to 10 ^[257]^D5. DAWN (2017) and DEFUSE-3 (2018) extended the time window to 24 hours in patients selected by perfusion imaging, establishing a tissue-based rather than clock-based paradigm. The 2025 CREST-2 trial demonstrated that carotid stenting plus intensive medical reduced the 4-year composite of perioperative stroke/death or ipsilateral ischemic stroke compared with medical management alone in asymptomatic ≥70% stenosis (2.8% versus 6.0%; P = 0.02) ^[78]^A1b.

Evolution of Antiplatelet and Anticoagulant Strategy

Early trials (International Stroke Trial) confirmed aspirin’s modest net benefit; the era of dual antiplatelet therapy began with CHANCE and was refined by CHANCE-2, which showed superiority of -aspirin over clopidogrel-aspirin in CYP2C19 loss-of-function carriers ^[284]^B2b. The INSPIRES trial (2024) found that immediate intensive (80 mg daily for 21 days, then 40 mg) did not reduce 90-day stroke but improved functional outcome (OR 0.83, 95% CI 0.71-0.98) ^[285]^A1b. For , ROCKET AF (2011) established 20 mg daily as noninferior to with less intracranial hemorrhage ^[324]^A1b. The ELAN trial (2023) and its post hoc analysis showed that early DOAC initiation (within 48 hours for minor/moderate stroke) likely reduces recurrent ischemic stroke without excess symptomatic intracranial hemorrhage (risk difference -1.18 percentage points; 95% CI -2.84 to 0.47) ^[81]^A1b^[328]^B2b. The STABLED trial (2026) found that catheter ablation did not reduce the composite outcome (HR 1.11, 95% CI 0.62-2.01) ^[171]^A1b.

Neuroprotection: A History of Failed Promise

Dozens of neuroprotective agents succeeded in animal models but failed in phase 3 trials, publication bias, poor study design, and low statistical power contributed (true report probability <50%) ^[330]^B2a. Recent efforts have been more targeted: the TRACE-III trial (2024) demonstrated that tenecteplase 0.25 mg/kg given 4.5-24 hours after onset in patients with large vessel occlusion without thrombectomy improved the rate of 0-1 (33.0% versus 24.2%; relative rate 1.37, 95% CI 1.04-1.81) with 3.0% symptomatic intracranial hemorrhage ^[76]^A1b. The EXPECTS trial (2025) showed a similar benefit for alteplase in posterior circulation stroke (89.6% versus 72.6% functional independence; adjusted RR 1.16, 95% CI 1.03-1.30) ^[79]^A1b. Tirofiban after intravenous thrombolysis (ASSET-IT) increased excellent outcomes (65.9% versus 54.9%; RR 1.20, 95% CI 1.07-1.34) ^[83]^A1b, and butylphthalide added to reperfusion improved favorable outcome at 90 days (OR 1.70) ^[216]^A1b. However, the MOST trial stopped for futility, neither argatroban nor eptifibatide added benefit to intravenous thrombolysis, and both were associated with higher mortality ^[4]^B2b. Cell therapy (MultiStem) given 18-36 hours after onset was safe but did not improve outcomes ^[170]^A1b. Drug-induced hypothermia with chlorpromazine-promethazine is in early-phase testing ^[339]^C4.

Secondary Prevention: Beyond Antiplatelets

The FOURIER trial (2017, evolocumab) and ODYSSEY OUTCOMES (2018, alirocumab) proved that PCSK9 inhibition added to statin reduces ischemic stroke (HR 0.75 for evolocumab) ^[288]^B2b^[80]^A1b; VESALIUS-CV (2025) extended this benefit to patients without prior myocardial infarction or stroke (HR 0.75 for 3-point MACE) ^[77]^A1b. Colchicine 0.5 mg daily reduced ischemic stroke in patients with chronic coronary disease (LoDoCo2: HR 0.69, 95% CI 0.57-0.83) ^[82]^A1b. LACI-2 (2023) suggested that isosorbide mononitrate and cilostazol may reduce recurrent stroke and cognitive impairment after , but the trial was exploratory ^[327]^A1b.

Abandoned Approaches

and heparinoids (e.g., tinzaparin, danaparoid) were abandoned after trials showed no net benefit or increased bleeding risk. The use of high-dose heparin after stroke was associated with excess intracranial hemorrhage without improved functional outcome ^[25]^B2b. Prophylactic glucose-potassium-insulin infusion (GKI) for poststroke hyperglycemia did not reduce infarct growth and was associated with greater growth in patients with persistent occlusion, along with high rates of asymptomatic hypoglycemia ^[333]^A1b.

Pearl: The number needed to treat for endovascular thrombectomy (3-10) is among the most powerful in medicine, rivalling that of early thrombolysis, the 2015-2018 trials transformed large vessel occlusion from a devastating diagnosis to a treatable emergency ^[257]^D5.

Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation

▸Screening for Fabry disease, CADASIL, and ATTR-CA identifies stroke subtypes now amenable to disease-modifying therapy, with ATTR-CA found in ~10% of elderly cardioembolic stroke patients [354, 355].
▸De-escalation from ticagrelor to clopidogrel after 1 month is safe in stabilised post-MI patients with high ischemic risk, reducing bleeding without increasing ischemic events [351].
▸Pharmacogenomic screening for GPIIb/IIIa PlA2 and statin responsiveness may soon personalise antiplatelet and lipid-lowering therapy, though further validation is needed [357, 356].

! Warning: In Trousseau syndrome (cancer-associated hypercoagulability), de-escalating anticoagulation based on normalised D-dimer can precipitate recurrent stroke and death. Maintain [[low-molecular-weight heparin]] indefinitely in high-risk patients [162].

HY High Yield: For elderly men with cardioembolic stroke, check for unexplained left ventricular hypertrophy and elevated troponin T, these are red flags for unrecognised ATTR-CA, a treatable cause with disease-modifying therapy available [354].

As the history of stroke treatment has evolved from generalised antithrombotics to targeted pathophysiological interventions, a new therapeutic axis has emerged: identifying stroke subtypes driven by monogenic or acquired mechanisms amenable to disease-modifying therapy, and personalising the intensity and duration of immunomodulatory and antithrombotic regimens through dynamic risk assessment and pharmacogenomics. This section moves beyond acute care into the sequencing, safety monitoring, and de-escalation strategies that define modern definitive .

Step 1: Identify Candidates for Disease-Modifying Therapy

An estimated 0.2% of young adults (age 20-55) with ischemic stroke harbour undiagnosed , rising to 0.3% among young males in Taiwanese cohorts ^[355]^B2b (2b). The AHA/ASA 2023 scientific statement on inherited small vessel diseases recommends that clinicians recognise early and secure molecular diagnosis, even though no proven disease-modifying treatment exists yet ^[346]^A1c (1c). Among Taiwanese patients, the NOTCH3 p.R544C variant confers an 11.05-fold increased risk for small vessel occlusion stroke (p = 3.9 × 10⁻¹⁰) ^[345]^B3b (3b). For elderly patients with , (ATTR-CA) is found in 9.8% (95% CI 5.4-16.0%), with half newly diagnosed after stroke ^[354]^B2b (2b). Screening indicators include troponin T >0.058 ng/mL, , and musculoskeletal signs such as and Popeye sign ^[354]^B2b.

Action: In patients aged <55 years with or unexplained cardioembolism, perform dry blood spot (male) or lyso-Gb3 (female) testing for Fabry disease, and consider NOTCH3 sequencing if cystic medial necrosis or family history is suggestive. In elderly men with cardioembolic stroke, cardiac troponin elevation and echocardiographic hypertrophy should trigger ⁹⁹ᵐTc-pyrophosphate scintigraphy for ATTR-CA. The presence of treatable ATTR-CA with disease-modifying therapies (e.g., ) makes this screening mandatory ^[354]^B2b.

Step 2: Pharmacogenomic Screening Before and During Therapy

Pharmacogenomics has yet to be fully leveraged in stroke, but emerging evidence supports pre-treatment genotyping for specific variants. A meta-analysis of 31 studies (N = 13,871) demonstrates that the glycoprotein IIb/IIIa PlA2 (rs5918(C)) allele is associated with a 20% increased odds of ischemic stroke (OR 1.20, 95% CI 1.04-1.38; power >80%), though not with hemorrhagic stroke ^[357]^A1a (1a). This variant may identify patients who derive less benefit from standard antiplatelet agents or who require higher-intensity therapy ^[352]^D5 (5).

Statin pharmacogenomics is another frontier. The ISMARDD meta-analysis (51 studies, N = 521,126) found that statin therapy reduces all-cause mortality within 3 months (OR 0.32), at 1 year (OR 0.35), and beyond 1 year (OR 0.56), with benefits extending even to patients with low-baseline LDL cholesterol and those with cardioembolic/ strokes ^[356]^A1a (1a). Although the effects of statin intensity, type, and solubility were inconsistent, the anti-inflammatory and pleiotropic mechanisms (including CRP reduction) support broad use ^[356]^A1a.

Action: Consider GPIIb/IIIa PlA2 genotyping in patients with recurrent ischemic strokes on antiplatelet therapy. Initiate high-potency (e.g., ) within 24 hours of stroke onset unless contraindicated, as early initiation is associated with reduced recurrence ^[356]^A1a.

Step 3: De-Escalation of Antiplatelet and Anticoagulant Regimens

De-escalation must balance ischemic protection against bleeding risk. The TALOS-AMI trial (N = 2,697) randomised patients with acute myocardial infarction and high ischemic risk after 1 month of -based dual antiplatelet therapy (DAPT) to de-escalation to versus continued ticagrelor. De-escalation showed no significant difference in ischemic outcomes (HR 0.88) and a trend toward lower bleeding (HR 0.64) in the high-risk group, with consistent safety ^[351]^B2b (2b).

For complex scenarios such as left ventricular thrombus (LVT) after ST-elevation myocardial infarction complicated by stroke, case studies highlight the value of phased, dynamic de-escalation guided by serial imaging and biomarker trends. One report describes a six-phase strategy including acute-phase de-escalation from ticagrelor to clopidogrel, sequential anticoagulation with then , and eventual transition to dual-pathway inhibition, achieving complete LVT resolution in 6 months ^[358]^C4 (4).

Warning: In (cancer-associated hypercoagulability), de-escalation of anticoagulation based solely on normalised D-dimer can be catastrophic. Two cases demonstrated that D-dimer normalisation does not reliably indicate sustained control of hypercoagulability; (LMWH) provides more consistent protection than DOACs in selected patients ^[162]^C4 (4).

Action: In stabilised patients after the first month of DAPT, de-escalation from ticagrelor to clopidogrel is safe and reduces bleeding. For LVT-associated stroke, use a phased approach with imaging follow-up. In Trousseau syndrome, maintain LMWH-based anticoagulation indefinitely; do not de-escalate on D-dimer trend alone.

Step 4: Emerging Immunotherapies for Disease Modification

Several immunotherapeutic strategies are in preclinical development for ischemic stroke, targeting neuroprotection, regeneration, and extended thrombolysis windows.

Anti-Nogo-A antibody: In a rat model of chronic stroke, treatment with anti-Nogo-A antibody (11C7) starting 9 weeks after permanent middle cerebral artery occlusion significantly improved forelimb function beginning 3 weeks after treatment, with enhanced corticorubral axonal sprouting from the contralesional motor cortex ^[349]^D5 (5). This suggests a window for restoring function even months after ischemic injury.

Anti-tPA antibodies (αATD-NR1): In a murine thromboembolic stroke model, antibodies preventing tPA from interacting with NMDA receptors reduced brain injury, blood-brain barrier leakage, and extended the therapeutic window of recombinant tPA-driven thrombolysis ^[348]^D5 (5). This approach limits the neurotoxic side effects of tPA while preserving its fibrinolytic benefit.

Anti-amyloid immunotherapy and dipyridamole: In Tg2576 mice (a model of ), passive anti-amyloid immunotherapy worsened cerebral microhemorrhage. However, dietary (generating plasma levels >790 ng/mL) did not exacerbate microscopic bleeding, suggesting that dipyridamole might be a safe agent when ischemic and hemorrhagic lesions coexist ^[347]^D5 (5).

rFGF21 (recombinant human fibroblast growth factor 21): In diabetic db/db mice subjected to permanent focal ischemia, daily rFGF21 started 6 hours post-stroke for 14 days normalised metabolic dysregulation, rescued PPARγ activity, reduced proinflammatory microglia/macrophage activation, and decreased white matter integrity loss and neurological deficits ^[350]^D5 (5). This positions rFGF21 as a candidate disease-modifying strategy for the subset of diabetic stroke patients.

Action: These immunotherapies are not yet available outside clinical trials. Enrol eligible patients (e.g., those with chronic deficits for anti-Nogo-A, or those with cerebral amyloid angiopathy and coexisting ischemia for dipyridamole) in ongoing studies.

Step 5: Safety Monitoring for Disease-Modifying Agents

Even established (MS) carry stroke risk implications. A systematic review (21 studies) found that DMT exposure overall reduces stroke risk by 50% compared with no DMT exposure in MS patients. However, is linked to elevated risk of ischemic heart disease and , while ‑associated complications, though rare, require heightened clinical vigilance ^[353]^B2a (2a). β‑interferons have been linked to thrombotic thrombocytopenic purpura‑hemolytic uremic syndrome (TTP-HUS).

For ATTR‑CA, disease-modifying therapy (e.g., tafamidis) requires monitoring for heart failure progression and arrhythmia. For Fabry disease, enzyme replacement therapy or chaperone therapy demands regular renal function and cardiac imaging surveillance.

Action: Before initiating any DMT for MS, obtain baseline ECG, blood pressure, and renal function. During therapy, monitor for hypertension (fingolimod), thyroid autoimmunity and cytopenias (alemtuzumab), and microangiopathic haemolytic anaemia (β-interferons). For Fabry disease treatments, follow approved safety monitoring schedules.

Pearl: In ischemic stroke management, disease modification begins with systematic screening for treatable monogenic (Fabry, CADASIL) and acquired (ATTR-CA) causes; de-escalation of antiplatelet therapy after the first month is safe in stabilised patients, but cancer-associated hypercoagulability requires persistent LMWH coverage regardless of D-dimer levels ^[354]^B2b^[351]^B2b^[162]^C4.

Disease-Modifying Therapy Candidates in Ischemic Stroke: Screening Yield

Condition	Prevalence in Stroke Population	Screening Method	Treatable (Evidence Level)
	0.2-0.3% of young adults (age 20-55) ^[355]^B2b (2b)	α-galactosidase activity (male); lyso-Gb3 (female); GLA sequencing	Enzyme replacement or chaperone (FDA-approved)
(NOTCH3 p.R544C)	2.1% of ischemic stroke, 6.5% of SVO stroke in Taiwanese ^[345]^B3b (3b)	NOTCH3 sequencing	No proven DMT yet; risk factor control ^[346]^A1c
ATTR-CA	9.8% of elderly cardioembolic stroke ^[354]^B2b (2b)	⁹⁹ᵐTc-pyrophosphate scintigraphy	(FDA-approved)

Pharmacogenomic Variants Relevant to Stroke Therapy

Variant	Gene	Effect	Clinical Implication	Evidence Level
rs5918(C) (PlA2)	GPIIb/IIIa	Increased ischemic stroke risk (OR 1.20) ^[357]^A1a	Consider alternative antiplatelet; monitor for resistance	1a
NOTCH3 p.R544C	NOTCH3	11.05-fold risk SVO stroke ^[345]^B3b	Screen for CADASIL; manage vascular risk factors	3b
Statin response modifiers	HMGCR, LDLR, etc.	Variable efficacy and myopathy risk ^[356]^A1a	Use high-potency statin regardless of genotype; monitor	1a (meta-analysis)

Neurorehabilitation, Symptomatic & Supportive Care

▸Early rehabilitation within 30 days improves motor recovery; Bobath therapy and VNS paired with task-specific training show significant gains at discharge and 1 year, respectively.
▸Dysphagia persists in 64% at day 7; the Predictive Swallowing Score (C statistic 0.84) guides early enteral feeding decisions.
▸Stroke-heart syndrome (acute coronary syndrome 11.1%, heart failure 6.4%) increases 5-year mortality; telemetry and non-intensive BP targets are recommended.

HY High Yield: The Predictive Swallowing Score (age, NIHSS at admission, lesion location, initial aspiration risk, and impairment of oral intake) is validated to predict failure of oral intake at day 7 (C statistic 0.84) [370]. A score ≥8 indicates 96% probability of needing enteral feeding.

Once the acute reperfusion phase and disease-modifying immunotherapy program are established, the clinical focus shifts to restoring function and managing the chronic neurologic symptoms that determine long-term quality of life. The first year after stroke is the period of greatest neuroplastic potential, and early, intensive rehabilitation captures this window.

Early Mobilization and Rehabilitation

Rehabilitation should begin as soon as the patient is medically stable, ideally within 30 days of ictus ^[382]^B3b. The Bobath concept, a problem-solving approach emphasizing postural control and task-specific training, improved motor function by a mean 5.7 points on the Fugl-Meyer Assessment (FMA) at discharge compared with conventional therapy (adjusted mean difference, 95% CI 3.4-8.0) ^[382]^B3b. Gains persisted at 3 months but attenuated by 12 months, highlighting the need for sustained therapy. Vagus nerve stimulation paired with upper-limb rehabilitation produced durable improvements: FMA-UE increased by 5.23 points at 1 year, with parallel gains in activity and participation ^[286]^B2b. For unilateral spatial neglect, anodal transcranial direct current stimulation combined with physical therapy reduced neglect severity on the Behavioural Inattention Test by 18.4 points (95% CI 3.9-32.8) compared with sham ^[291]^A1b. at true acupoints enhanced motor recovery and modulated default-mode network dynamics, correlating with improved FMA scores ^[377]^A1b. A mixture model of upper-limb recovery identified five subgroups with distinct recovery trajectories; endpoint FMA can be predicted with a median absolute error of 4.8 points at 1 week poststroke ^[200]^B2b.

Dysphagia and Respiratory Care

Dysphagia affects two-thirds of patients acutely: 64% fail to recover functional oral intake by day 7, and 30% by day 30 ^[370]^B2b. The Predictive Swallowing Score (age, stroke severity, lesion location, initial aspiration risk, oral intake impairment) stratifies risk; a score ≥8 predicts persistent dysphagia at 7 days with 96% probability (C statistic 0.84) ^[370]^B2b. Intensive speech-language therapy is the cornerstone of recovery. Bilateral anodal tDCS may confer additional benefit in infratentorial strokes, where it improved Mann Assessment of Swallowing Ability scores ^[305]^A1b. The 2026 AHA/ASA guideline reinforces dysphagia screening before any oral intake and recommends nasogastric tube feeding if impairment persists ≥7 days, with percutaneous endoscopic gastrostomy considered after 30 days ^[375]^A1c. For respiratory monitoring, a forced vital capacity <20 mL/kg or declining trend signals impending respiratory failure requiring ICU transfer; intubation is indicated for airway protection in patients with compromised consciousness or refractory aspiration.

Cardiovascular and Autonomic Complications

The stroke-heart syndrome is common: within 4 weeks of ischemic stroke, 11.1% develop acute coronary syndrome, 8.8% , 6.4% heart failure, 1.2% severe , and 0.1% ^[105]^B3b. These complications carry a 5-year mortality odds ratio of 1.49 (ACS), 1.83 (heart failure), and 2.08 (severe ventricular arrhythmias) ^[105]^B3b. Telemetry is recommended for at least 24-48 hours. After endovascular thrombectomy, intensive blood pressure lowering (<120 mmHg) was associated with worse health-related quality of life on the EQ-5D index (mean difference -0.06) compared with less intensive targets (140-180 mmHg), consistent with worse functional outcomes ^[376]^B2b. Autonomic instability also manifests as ileus (managed with bowel regimen) and urinary retention (avoid indwelling catheters; use intermittent catheterization).

DVT Prophylaxis and Pain

Venous thromboembolism prophylaxis is indicated for all patients with restricted mobility. 40 mg subcutaneously daily or unfractionated 5000 units subcutaneously twice daily should be initiated within 24-48 hours of stroke onset after excluding hemorrhage [label]. Pain after stroke has two main phenotypes: central post-stroke pain (neuropathic, often burning or shooting) and shoulder pain from spasticity or subluxation. First-line agents for neuropathic pain include gabapentin (300-900 mg/day), pregabalin (75-300 mg/day), or amitriptyline (10-50 mg nightly). For spasticity-related pain, oral baclofen (10-80 mg/day) or localized intramuscular botulinum toxin injections are effective.

Hospital-Acquired Complications

Post-stroke pneumonia and urinary tract infection each occur in approximately 10% of patients and are associated with immunodepression, dysphagia, and catheterization ^[148]^D5. Pneumonia prevention strategies include dysphagia screening, upright positioning during feeding, meticulous oral care, and early mobilization. Catheter-associated UTI is reduced by avoiding indwelling catheters whenever possible and removing them within 24 hours. Pressure injuries are prevented with scheduled turning (every 2 hours), pressure-relieving mattresses, and daily skin inspection.

Complication Table

Complication	Frequency	Prevention	Management
Pneumonia	~10% ^[148]^D5	Dysphagia screening, oral care, early mobilization	, respiratory support
Urinary tract infection	~10% ^[148]^D5	Avoid catheters, remove early	Antibiotics per culture
Venous thromboembolism	2-20%	Enoxaparin 40 mg SC daily or UFH 5000 U SC bid [label]	Therapeutic anticoagulation
Pressure injury	5-15%	Turning every 2 hours, support surfaces	Wound care, offloading
Post-stroke depression	30-50%	Screening at 3 months, psychosocial support	SSRIs, CBT
Seizures	2-5%	Antiepileptic only for recurrent events	, lacosamide

Pearl: Use the Predictive Swallowing Score (age, , lesion location, aspiration risk, oral impairment) on day 1 to identify patients who will fail oral intake at day 7 (score ≥8 → 96% probability) and proactively plan for nasogastric feeding, reducing risk ^[370]^B2b.

Complications: Anticipating and Intercepting Deterioration

▸Respiratory compromise is predicted by FVC < 15 mL/kg; intubation is indicated at FVC < 10 mL/kg or GCS < 8.
▸DVT prophylaxis with enoxaparin 40 mg SC daily or heparin 5000 U SC BID reduces thromboembolic risk by 30-50% in immobilized patients.
▸Hospital-acquired complications (pneumonia, pressure injury, UTI, seizures) are common but preventable with structured nursing protocols and early dysphagia screening.

HY High Yield: **Dysphagia screening** is the most impactful single intervention to prevent aspiration pneumonia → reduced rates by up to 50% [321].

! Warning: Do not administer oral medications or food until a formal swallow evaluation is performed, silent aspiration is common in up to 40% of acute stroke patients [321].

From the rehabilitation framework, the focus now turns to the medical complications that can derail recovery. In the intensive care unit and ward, vigilance for respiratory failure, autonomic instability, thromboembolism, pain, and hospital-acquired infections is as critical as the initial reperfusion therapy. The AHA/ASA 2021 nursing care statement provides a comprehensive framework for anticipating and managing these events ^[321]^A1c.

Respiratory Monitoring

Forced vital capacity (FVC) < 15 mL/kg or a decline of > 20% from baseline signals impending respiratory failure, particularly in patients with brainstem or large hemispheric strokes. Intubation is indicated when FVC falls below 10 mL/kg, when oxygen saturation remains < 92% despite supplemental oxygen, or when the patient cannot protect the airway ( < 8, absent cough or gag). The following table summarizes intubation criteria:

Indication	Threshold	Rationale
FVC < 10 mL/kg	Absolute	Impending hypoventilation
SpO₂ < 92% on 40% FiO₂	Relative	Ensure adequate oxygenation
< 8 or absent airway reflexes	Absolute	Airway protection
Rapidly declining mental status	Relative	Risk of aspiration

Noninvasive ventilation may be attempted in select patients, but intubation should not be delayed if criteria are met ^[321]^A1c.

Autonomic Complications

Arrhythmias, is the most common, occurring in up to 25% of patients with insular cortex involvement. Continuous telemetry for at least 24 hours is recommended. Blood pressure instability, both and hypotension can exacerbate ischemic penumbra. The 2026 AHA/ASA guideline recommends maintaining systolic blood pressure between 130 and 180 mm Hg in the acute phase ^[375]^A1c. Ileus and urinary retention are common due to neurogenic bowel and bladder. Urinary retention occurs in approximately 40% of patients and increases the risk of urinary tract infection. Bladder scanning and intermittent catheterization are preferred over indwelling catheters to reduce infection risk ^[321]^A1c.

DVT/PE Prophylaxis

Low molecular weight ( 40 mg subcutaneously once daily) or unfractionated heparin 5000 units subcutaneously twice daily is recommended for all patients without contraindications (e.g., active bleeding, coagulopathy) ^[321]^A1c. The risk of deep vein thrombosis in immobilized stroke patients is 30-50% without prophylaxis. In patients with large ischemic core or hemorrhagic transformation, the decision must balance thrombotic and bleeding risks; pneumatic compression devices are an alternative until anticoagulation is safe.

Pain

Post-stroke pain includes central post-stroke pain (burning, allodynia), shoulder pain (from hemiplegia or subluxation), and headache (often due to reperfusion or meningeal irritation). First-line agents for central pain include gabapentin 300-1200 mg/day or amitriptyline 25-100 mg at bedtime, titrated to effect ^[321]^A1c. Shoulder pain is managed with proper positioning, range-of-motion exercises, and nonsteroidal anti-inflammatory drugs. Headache typically resolves with acetaminophen or avoidance of triggers.

Hospital-Acquired Complications

Complication	Frequency	Prevention	Management
	10-20%	Dysphagia screening, NPO until swallow assessment, semi-upright positioning	, , speech therapy
Pressure injury	15-30%	Turning every 2 hours, pressure-relief surfaces, skin inspection	Wound care, debridement, nutrition support
Urinary tract infection	10-20%	Avoid indwelling catheters, intermittent catheterization, early removal	Targeted antibiotics, catheter removal
Seizures	3-5% (acute), 10-15% (late)	if post-stroke seizure occurs (not for primary prophylaxis)	Antiseizure medication (levetiracetam 500-1500 mg/day) ^[115]^B3b^[152]^B2b
Hemorrhagic transformation	2-8%	Avoid thrombolysis in patients with severe hypertension or coagulopathy	Reverse anticoagulation if applicable, neurosurgical consultation

Seizures occur in about 3% within the first 24 hours, with higher rates in hemorrhagic stroke and younger patients ^[63]^B2b. Levetiracetam is the most commonly initiated antiseizure medication after stroke (81% of cases) ^[115]^B3b. The risk of symptomatic intracranial hemorrhage after thrombolysis is approximately 2-3% with alteplase and 3-8% with tenecteplase, depending on the cohort ^[76]^A1b^[209]^A1b. Persistent monitoring and early detection of these complications through structured nursing protocols improve outcomes ^[321]^A1c.

Pearl: The single most actionable intervention to prevent hospital-acquired complications in stroke patients is early dysphagia screening, identifying aspiration risk before the first oral intake reduces pneumonia by up to 50% and shortens hospital stay ^[321]^A1c.

Prognosis & Natural History

▸Five-year poor functional outcome (mRS >1) after TIA/minor stroke occurs in 22.9% of patients; age, diabetes, atrial fibrillation, and prior stroke are the strongest predictors [95].
▸Cardioembolic stroke carries the highest 30-day case fatality (28%) and 6-month dependency/death (62%), in contrast to small-vessel disease (0% and 21%) [98].
▸Post-stroke epilepsy develops in 11% of survivors; early EEG epileptiform activity raises the 5-year risk to 42%, yet post-ischemic stroke epilepsy has the most favorable antiseizure medication response of all focal epilepsies [116,111].

HY High Yield: The NNT for golden hour thrombolysis to reduce disability by one mRS level is 2.6 [229]. Every minute saved translates to measurable gains.

After addressing complications that can arise, attention turns to the long-term trajectory, a trajectory shaped powerfully by stroke mechanism, acute treatment, and early post-stroke modifiers. Five years after a transient ischemic attack or minor stroke, 22.9% of patients have a ( ) score >1, and the factors driving that outcome include age (per decade), diabetes, (OR 1.52), and prior stroke or TIA ^[95]^B2b. Regular pre-stroke physical activity cut the odds of poor 5-year outcome by nearly half ^[95]^B2b.

Mortality by Subtype and Treatment

Thirty-day case fatality varies dramatically by mechanism: 28% for vs 0% for small-vessel disease in community-based cohorts, with dependency or death at 6 months ranging from 62% (cardioembolic) to 21% (small-vessel) ^[98]^B2b. In young adults (18-50 years), 3-month mortality is higher in low- and middle-income countries than in high-income countries (OR 2.49) ^[87]^B2a. Active treatment changes these numbers. Endovascular thrombectomy for large ischemic core improves independent ambulation (mRS 0-3; RR 1.9, 95% CI 1.5-2.5) and reduces mortality (RR 0.9, 95% CI 0.8-1.0) compared with medical ^[213]^A1a. Thrombolysis within the first "golden hour" yields an NNT of 2.6 to reduce disability by at least one mRS level ^[229]^A1a.

Predictors of Poor Outcome and Recovery

Beyond clinical factors, composite inflammatory markers independently forecast 1-year stroke recurrence: the systemic inflammatory response index (SIRI) in the highest quartile carried a hazard ratio of 1.38 (95% CI 1.18-1.61) ^[390]^B2b. Lesion network mapping identifies strategic white-matter disconnection sites that, when added to the score, improve outcome prediction ^[65]^C4. For motor recovery, a longitudinal mixture model identifies five subgroups with distinct upper-limb trajectories; endpoint Fugl-Meyer scores can be predicted within a median absolute error of 4.8 points at 1 week ^[200]^B2b.

Post-Stroke Epilepsy and Seizure Prognosis

Post-stroke epilepsy develops in 11% of survivors within five years. Early EEG within 7 days stratifies risk: epileptiform activity raises 5-year epilepsy risk to 42% (vs 13% without), and the SeLECT-EEG model (concordance statistic 0.75) outperforms clinical-only scores ^[116]^B3b. Remarkably, post-ischemic stroke epilepsy carries the most favorable antiseizure medication response of any focal epilepsy etiology (for 12-month seizure freedom) and requires the lowest drug load ^[109]^B3b^[111]^B3b.

Prognostication Tools

Deep learning models fusing diffusion-weighted MRI with clinical variables achieve an AUC of 0.92 for predicting unfavorable 90-day outcome (mRS >2) ^[172]^B2b. The modified SeLECT 2.0 score, which substitutes post-treatment NIHSS at 72 hours for admission NIHSS, improves discrimination for late post-stroke epilepsy ^[198]^B2b. These tools enable individualized risk communication and guide intensity of follow-up.

These prognostic factors directly inform discussions with patients and families and set the stage for tailored management in special populations, younger adults, pregnant women, and those with intellectual disability, covered in the next section.

Pearl: The single most modifiable predictor of 5-year functional outcome after minor stroke is regular pre-stroke physical activity ^[95]^B2b, a factor clinicians can reinforce during rehabilitation planning.

Prognostic Factors at 5 Years After TIA or Minor Stroke

Risk Factor	Odds Ratio (95% CI)
Age (per 10-year increase)	2.18 (1.93-2.46)
Diabetes (any type)	1.45 (1.18-1.78)
Prior stroke or TIA	1.74 (1.37-2.22)
Atrial fibrillation or flutter	1.52 (1.04-1.94)
Congestive heart failure	1.73 (1.22-2.46)
Valvular disease	2.47 (1.70-3.58)
Regular physical activity (protective)	0.52 (0.42-0.66)

Special Populations & Pregnancy

▸Pediatric LVO stroke benefits from thrombectomy with safety comparable to adults; children with symptomatic moyamoya require surgical revascularization.
▸Pregnancy complications (HDP, preterm delivery) double the long-term risk of ischemic stroke, indicating a need for early cardiovascular risk reduction.
▸In very elderly patients, EVT improves functional independence but increases ICH risk; polygenic risk may guide aspirin use for primary prevention.

HY High Yield: Up to 36% of adolescent strokes are initially misdiagnosed, posterior circulation strokes are particularly prone to delay [186].

The preceding sections have outlined the general approach to ischemic stroke, but several populations require tailored strategies that depart from the standard adult paradigm.

Pediatrics

Pediatric ischemic stroke differs fundamentally from adult disease in etiology, presentation, and . Up to 36% of adolescent strokes are initially misevaluated, particularly posterior circulation strokes ^[186]^B2b. Etiologies are dominated by cerebral arteriopathies, congenital heart disease, and prothrombotic states such as ADAMTS13 deficiency (OR 7.30 for levels below the 10th percentile) ^[398]^B3b^[66]^D5. For large vessel occlusion (LVO), thrombectomy improves functional outcomes at 3 months (OR 3.76) even in the absence of randomized trials, this benefit extends to isolated M2 occlusions (median ped- 1 vs 2) ^[133]^B3b^[397]^B2b. Endovascular recanalization appears safe, with symptomatic ICH rates comparable to adults ^[403]^B2b. Tenecteplase safety data are emerging, with no major safety concerns reported in early surveillance ^[184]^C4. Outcomes remain sobering: 30-day mortality is 7.7%, and 20.2% of survivors have moderate-severe neurologic impairment ^[189]^B2b. The risk of autism is tripled (aHR 3.02) ^[395]^B2b. Age between 28 days and 1 year is a particularly vulnerable period for poor recovery, and children with symptomatic arteriopathy benefit from surgical revascularization (HR 0.15 for ipsilateral ischemic event) ^[411]^B2b^[415]^B2b.

Pregnancy

Pregnancy-related conditions are potent risk factors for ischemic stroke. increase the risk of ischemic stroke nearly 2-fold (RR 1.80), and preterm delivery carries a 66% increased risk (aRR 1.66) ^[93]^B2a^[413]^B2a. These associations persist for decades, identifying women who warrant aggressive cardiovascular risk factor modification ^[399]^B3b. Perinatal ischemic stroke is a distinct entity affecting term and near-term infants, often resulting in congenital hemiplegia; maternal and infant thrombophilias contribute to pathogenesis ^[108]^D5. Acute management during pregnancy requires balancing maternal benefit with fetal risk, thrombolysis and thrombectomy are not contraindicated but must be individualized with multidisciplinary input ^[375]^A1c. For secondary prevention, low-molecular-weight is preferred over to avoid teratogenicity ^[406]^A1c.

Elderly

Very elderly patients (≥80 years) with face competing risks. and provide similar thromboembolism prevention, but edoxaban is associated with a 42% higher risk of major bleeding (aHR 1.42) ^[391]^B2b. Endovascular thrombectomy in patients aged ≥80 years improves functional independence (aOR 2.84) but increases symptomatic ICH (aOR 4.11), careful patient selection is essential ^[414]^B2b. Elevated lipoprotein(a) and C-reactive protein-to-albumin ratio independently predict poor 90-day outcome in elderly AIS patients (OR 2.12 and 1.59, respectively) ^[416]^B2b. Polygenic risk stratification may identify older adults who benefit from for primary prevention, those in the highest quintile had a 51% reduction in ischemic stroke without excess bleeding ^[408]^B2b.

Immunocompromised

Immunocompromised hosts face elevated stroke risk from infections (e.g., SARS-CoV-2, varicella zoster), vasculitis, and hypercoagulable states. During the early pandemic, 0.82% of hospitalized pediatric SARS-CoV-2 patients had ischemic stroke, and 3.6% of childhood AIS cases tested positive for SARS-CoV-2 ^[410]^C4. In children, sickle cell disease and autoimmune vasculitis are established causes ^[66]^D5^[186]^B2b. Identification of the underlying immunosuppressive condition guides both acute management and long-term prevention.

Pearl: For pediatric LVO stroke, thrombectomy is the standard of care despite the absence of RCTs, the natural history of conservative management is poor, with 73% experiencing moderate-severe disability or death ^[402]^B2b.

Prevention, Screening & Surveillance

▸Primary prevention centers on the AHA/ASA Life's Essential 8, with a Mediterranean diet reducing stroke risk by 29% [427].
▸For noncardioembolic minor stroke/TIA, dual antiplatelet therapy with ticagrelor-aspirin or clopidogrel-aspirin is superior to aspirin alone [418][297].
▸Implantable cardiac monitoring in cryptogenic stroke detects paroxysmal atrial fibrillation and reduces recurrence (NNT ≈ 13) [429].

HY High Yield: In patients with a breakthrough stroke on a DOAC, switching to warfarin increases recurrent stroke risk (RR 1.80, 95%); continuing the same DOAC or switching to another DOAC is safer [37].

Building on the tailored approaches needed for special populations, prevention strategies for ischemic stroke span the entire at-risk spectrum, from primordial risk factor control to aggressive secondary prevention after an index event.

Primary Prevention

The 2024 AHA/ASA guideline frames prevention around Life's Essential 8, blood pressure, lipids, glucose, smoking, diet, physical activity, sleep, and weight ^[317]^A1c. Adherence to a reduces stroke risk by 29% (RR 0.71) ^[427]^B2a, while processed red meat confers a modest increase (RR 1.12) ^[434]^B2a. A comprehensive lifestyle score (including nutrition, physical activity, sleep, stress, social connection, and smoking) was associated with a 32% lower risk of ischemic stroke (HR 0.68, 95% CI 0.62-0.74) ^[432]^B2b. The major modifiable metabolic and behavioral risks, high systolic blood pressure, high LDL cholesterol, kidney dysfunction, high fasting glucose, high BMI, smoking, and high sodium intake, are projected to drive the global burden of ischemic stroke to 4.9 million deaths by 2030 ^[100]^B2c.

Secondary Prevention

Subtype	Strategy	Key Evidence	NNT (if calculable)
Cardioembolic (AF)	DOAC (e.g., 20 mg daily) over	ROCKET AF: rivaroxaban noninferior, less intracranial hemorrhage (0.5% vs 0.7%, P=0.02) ^[324]^A1b	NNT not calculable from reported data
Noncardioembolic minor stroke/TIA	DAPT: + or +aspirin for 21-30 days	THALES: ticagrelor+aspirin reduced stroke/death (HR 0.83, 95% CI 0.71-0.96) ^[418]^A1b; CHANCE-2 in CYP2C19 LOF carriers: ticagrelor superior to clopidogrel (HR 0.77, 95% CI 0.64-0.94) ^[420]^A1b	THALES: NNT ≈ 91; CHANCE-2: NNT ≈ 63
Noncardioembolic (any)	Asundexian 50 mg daily added to antiplatelet	OCEANIC-STROKE: reduced ischemic stroke (6.2% vs 8.4%; HR 0.74, 95% CI 0.65-0.84) without excess major bleeding ^[274]^A1b	NNT ≈ 45
ESUS	Antiplatelet (aspirin); anticoagulation not beneficial	NAVIGATE ESUS: rivaroxaban 15 mg daily vs aspirin (HR 1.07, 95% CI 0.87-1.33) ^[421]^B2b; PFO subgroup benefits from anticoagulation (RR 0.59, 95% CI 0.35-0.98) ^[280]^A1a	,
Cryptogenic with PFO	PFO closure + antiplatelet	REDUCE: closure reduced stroke (HR 0.23, 95% CI 0.09-0.62) ^[422]^A1b	NNT ≈ 25
	Consider ISMN (40-60 mg/d) and/or cilostazol (200 mg/d)	LACI-2: ISMN reduced recurrent stroke (aOR 0.23, 95% CI 0.07-0.74); cilostazol reduced dependence (aHR 0.31, 95% CI 0.14-0.72) ^[327]^A1b	,
	Anticoagulation preferred over antiplatelet	IPD meta-analysis: fewer strokes (0.5% vs 4.0%; OR 0.14, 95% CI 0.02-0.61) but more bleeding ^[298]^A1a	NNT ≈ 29
Atherosclerosis (large artery)	High-intensity statin ( 80 mg) initiated within 72 h	INSPIRES: no reduction in 90-day stroke (HR 0.95, 95% CI 0.80-1.13) but improved functional outcome (OR 0.83, 95% CI 0.71-0.98) ^[285]^A1b	,
Secondary prevention post-MI	Polypill (aspirin 100 mg, 2.5-10 mg, atorvastatin 20-40 mg)	SECURE: reduced MACE (HR 0.76, 95% CI 0.60-0.96) ^[272]^A1b	NNT ≈ 31

For patients with AF who have a breakthrough stroke on a DOAC, switching to warfarin increases recurrent ischemic stroke risk (RR 1.80) ^[37]^A1a; continuing the same DOAC or switching to another DOAC is preferred. Early initiation of DOACs (day 3-4 after stroke) may be optimal, with a posterior probability of 0.41 for being the best timing ^[219]^A1b.

Screening and Surveillance

In , implantable cardiac monitoring (ICM) detects paroxysmal (21.1% vs 7.5% with conventional monitoring) and reduces stroke recurrence (HR 0.32, 95% CI 0.11-0.90; NNT ≈ 13) ^[429]^B2b. Prehospital large vessel occlusion screening using the RACE or FAST-ED scales (sensitivity ~0.75, specificity ~0.76) guides appropriate triage ^[431]^B2a. Post-stroke, screening for cognitive and emotional problems is recommended, although a cluster-randomized trial found no improvement in participation at 1 year (MD 0.77, 95% CI -2.46 to 4.06) ^[3]^A1b. Seizures occur in 3.3% of patients early and 18 per 1000 person-years later; no single AED is superior ^[425]^B2a.

Vaccine Considerations

vaccination is associated with 4.7 cases of ischemic stroke per 100,000 vaccinations, comparable to the background population rate, and thrombotic thrombocytopenia syndrome is rare (3.1% of post-vaccination strokes) ^[426]^B2a. The benefits of routine vaccination far exceed this risk. Influenza vaccination is recommended by the AHA/ASA for secondary prevention ^[317]^A1c.

Patient Education

Lifestyle counseling should emphasize the Mediterranean diet, at least 150 minutes of moderate-intensity physical activity per week, smoking cessation, and adherence to prescribed antithrombotics and . The 2024 AHA/ASA guideline endorses shared decision-making and addressing social determinants of health ^[317]^A1c.

Pearl: For noncardioembolic minor stroke/TIA, DAPT with ticagrelor-aspirin or clopidogrel-aspirin for 21-30 days prevents 1 recurrent stroke for every 63-91 patients treated; in CYP2C19 loss-of-function carriers, ticagrelor is the preferred P2Y12 inhibitor ^[420]^A1b.

Secondary Prevention Strategies by Ischemic Stroke Subtype

Subtype	Strategy	Key Evidence	NNT (if calculable)
Cardioembolic (AF)	DOAC (e.g., rivaroxaban 20 mg daily) over warfarin	ROCKET AF: noninferior, less intracranial hemorrhage (0.5% vs 0.7%, P=0.02) ^[324]^A1b	NNT not calculable from reported data
Noncardioembolic minor stroke/TIA	DAPT: ticagrelor+aspirin or clopidogrel+aspirin for 21-30 days	THALES: HR 0.83, 95% CI 0.71-0.96 ^[418]^A1b; CHANCE-2: HR 0.77, 95% CI 0.64-0.94 ^[420]^A1b	THALES: NNT ≈ 91; CHANCE-2: NNT ≈ 63
Noncardioembolic (any)	Asundexian 50 mg daily added to antiplatelet	OCEANIC-STROKE: HR 0.74, 95% CI 0.65-0.84 ^[274]^A1b	NNT ≈ 45
ESUS	Antiplatelet (aspirin); anticoagulation not beneficial	NAVIGATE ESUS: HR 1.07, 95% CI 0.87-1.33 ^[421]^B2b; PFO subgroup benefits from anticoagulation (RR 0.59, 95% CI 0.35-0.98) ^[280]^A1a	,
Cryptogenic with PFO	PFO closure + antiplatelet	REDUCE: HR 0.23, 95% CI 0.09-0.62 ^[422]^A1b	NNT ≈ 25
Lacunar stroke	Consider ISMN (40-60 mg/d) and/or cilostazol (200 mg/d)	LACI-2: ISMN aOR 0.23, 95% CI 0.07-0.74; cilostazol aHR 0.31, 95% CI 0.14-0.72 ^[327]^A1b	,
Cervical artery dissection	Anticoagulation preferred over antiplatelet	IPD meta-analysis: OR 0.14, 95% CI 0.02-0.61 ^[298]^A1a	NNT ≈ 29
Atherosclerosis (large artery)	High-intensity statin (atorvastatin 80 mg) initiated within 72 h	INSPIRES: HR 0.95, 95% CI 0.80-1.13 ^[285]^A1b	,
Secondary prevention post-MI	Polypill (aspirin, ramipril, atorvastatin)	SECURE: HR 0.76, 95% CI 0.60-0.96 ^[272]^A1b	NNT ≈ 31

References

[1]
Bonaca MP, Bauersachs RM, Anand SS et al.. “Rivaroxaban in Peripheral Artery Disease after Revascularization.” The New England journal of medicine (2020). PMID: 32222135 ↗
L1RCTCited in: Definition, Classification & Nomenclature
[2]
Alexander JH, Lopes RD, James S et al.. “Apixaban with antiplatelet therapy after acute coronary syndrome.” The New England journal of medicine (2011). PMID: 21780946 ↗
L1RCTCited in: Definition, Classification & Nomenclature
[3]
Slenders JPL, Van Den Berg-Vos RM, Van Heugten CM et al.. “Screening and Care for Emotional and Cognitive Problems After Ischemic Stroke: Results of a Multicenter, Cluster-Randomized Controlled Trial.” Neurology (2025). PMID: 40489719 ↗
L1RCTCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, History and Evolution of Treatment, Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History, Prevention, Screening & Surveillance
[4]
Roy A, Elm J, Ingles JR et al.. “Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial.” Neurology (2025). PMID: 41071964 ↗
L2RCTCited in: Definition, Classification & Nomenclature, Acute Management: Neurologic Emergencies & Attack Abortion, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[5]
Wang Y, Maeda T, You S et al.. “Patterns and Clinical Implications of Hemorrhagic Transformation After Thrombolysis in Acute Ischemic Stroke: Results From the ENCHANTED Study.” Neurology (2024). PMID: 39541551 ↗
L2RCTCited in: Definition, Classification & Nomenclature, History and Evolution of Treatment, Neurorehabilitation, Symptomatic & Supportive Care
[6]
Veltkamp R, Pearce LA, Korompoki E et al.. “Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial.” JAMA neurology (2020). PMID: 32628266 ↗
L2RCTCited in: Definition, Classification & Nomenclature
[7]
Diederichsen SZ, Frederiksen KS, Xing LY et al.. “Severity and Etiology of Incident Stroke in Patients Screened for Atrial Fibrillation vs Usual Care and the Impact of Prior Stroke: A Post Hoc Analysis of the LOOP Randomized Clinical Trial.” JAMA neurology (2022). PMID: 36036546 ↗
L2RCTCited in: Definition, Classification & Nomenclature
[8]
Li S, Wang X, Jin A et al.. “Safety and Efficacy of Reteplase Versus Alteplase for Acute Ischemic Stroke: A Phase 2 Randomized Controlled Trial.” Stroke (2023). PMID: 38152962 ↗
L1RCTCited in: Definition, Classification & Nomenclature
[9]
Wagenaar N, Baak LM, van der Aa NE et al.. “Perinatal Arterial Stroke Treated With Stromal Cells Intranasally: 2-Year Safety and Neurodevelopment.” Stroke (2025). PMID: 40654084 ↗
L3TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature
[10]
Chen H, Khunte M, Colasurdo M et al.. “Thrombectomy vs Medical Management for Posterior Cerebral Artery Stroke: Systematic Review, Meta-Analysis, and Real-World Data.” Neurology (2024). PMID: 38626383 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Acute Management: Neurologic Emergencies & Attack Abortion
[11]
Zhou Y, Zhang L, Cavalcante F et al.. “Intracranial Hemorrhage in Patients With Stroke After Endovascular Treatment With or Without IV Alteplase: An Individual Participant Data Meta-Analysis.” JAMA neurology (2025). PMID: 40788598 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Acute Management: Neurologic Emergencies & Attack Abortion
[12]
Saver JL, Kent DM, Kasner SE et al.. “Patent Foramen Ovale Closure in Stroke and the PASCAL Classification System.” JAMA neurology (2026). PMID: 41587059 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature
[13]
Shahjouei S, Sadighi A, Chaudhary D et al.. “A 5-Decade Analysis of Incidence Trends of Ischemic Stroke After Transient Ischemic Attack: A Systematic Review and Meta-analysis.” JAMA neurology (2021). PMID: 33044505 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[14]
Tsivgoulis G, Zand R, Katsanos AH et al.. “Risk of Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis in Patients With Acute Ischemic Stroke and High Cerebral Microbleed Burden: A Meta-analysis.” JAMA neurology (2016). PMID: 27088650 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature
[15]
Ma G, Mo R, Yao X et al.. “Clinical and Safety Outcomes of Edaravone Dexborneol in Acute Ischemic Stroke: A Multicenter, Prospective, Cohort Study.” Neurology (2025). PMID: 40763317 ↗
L2COHORTCited in: Definition, Classification & Nomenclature
[16]
Lusk JB, Wilson LE, Moore C et al.. “Calcitonin Gene-Related Peptide Inhibitors and Cardiovascular Events in Patients With Migraine: A Retrospective, Observational Cohort Study.” Neurology (2026). PMID: 41499728 ↗
L3COHORTCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[17]
Flint AC, Conell C, Ren X et al.. “Effect of Systolic and Diastolic Blood Pressure on Cardiovascular Outcomes.” The New England journal of medicine (2019). PMID: 31314968 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[18]
Sacco RL, Kasner SE, Broderick JP et al.. “An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association.” Stroke (2013). PMID: 23652265 ↗
L5OTHERCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism (Neuroanatomic Localization)
[19]
Ekker MS, Verhoeven JI, Schellekens MMI et al.. “Risk Factors and Causes of Ischemic Stroke in 1322 Young Adults.” Stroke (2022). PMID: 36511150 ↗
L4OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Special Populations & Pregnancy
[20]
Pensato U, Ospel JM, Ganesh A et al.. “Redefining the Cerebral Ischemic Core-Penumbra-Oligemia Continuum.” Stroke (2026). PMID: 42100815 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism (Neuroanatomic Localization)
[21]
Yaghi S, Johansen MC, Ghannam M et al.. “Proposal for the Ischemic Stroke Phenotyping System 2025: ISPS25.” Stroke (2025). PMID: 41121616 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
[22]
Teo KSH, Ong JM, Yeo JYP et al.. “Neurology® Journal Club: Meta-Analysis of Randomized Controlled Trials on IV Thrombolysis in Patients With Minor Acute Ischemic Stroke.” Neurology (2026). PMID: 42335433 ↗
L1SR_MA_RCTCited in: Definition, Classification & Nomenclature
[23]
Mayer J, Mbizvo GK, Bucci T et al.. “Association of antiseizure medications and adverse cardiovascular events: A global health federated network analysis.” Epilepsia (2024). PMID: 38411304 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Prognosis & Natural History
[24]
Pan Y, Gao Y, Chen W et al.. “Dual Antiplatelet Therapy and Immediate Intensive Statin in Mild Ischemic Stroke: A Randomized Trial.” Neurology (2026). PMID: 42348803 ↗
L1RCTCited in: Definition, Classification & Nomenclature, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[25]
Calabrò RS, Calderone A, Arcadi FA et al.. “Early-event pathways to 6-month death or dependency after ischemic stroke: Secondary analysis of the international stroke trial.” Journal of the neurological sciences (2026). PMID: 42263448 ↗
L2RCTCited in: Definition, Classification & Nomenclature, History and Evolution of Treatment
[26]
Dani KA, Thomas RG, Chappell FM et al.. “Computed tomography and magnetic resonance perfusion imaging in ischemic stroke: definitions and thresholds.” Annals of neurology (2011). PMID: 21796665 ↗
L2REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
[27]
Kirton A, Deveber G, Pontigon AM et al.. “Presumed perinatal ischemic stroke: vascular classification predicts outcomes.” Annals of neurology (2008). PMID: 18306227 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[28]
Bruce SS, Zhang C, Liberman AL et al.. “Prevalence of Cerebral Amyloid Angiopathy and Associated Risk of Subsequent Ischemic and Hemorrhagic Stroke and Mortality in a Nationwide Cohort.” Annals of neurology (2025). PMID: 40309957 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[29]
Shu L, Jiang W, Xiao H et al.. “Perioperative Acute Ischemic Stroke in Patients with Atrial Fibrillation.” Annals of neurology (2023). PMID: 37183768 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[30]
Baik M, Shim CY, Gwak SY et al.. “Patent Foramen Ovale and Risk of Recurrence in Stroke of Determined Etiology.” Annals of neurology (2022). PMID: 35753038 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[31]
Morgenstern LB, Escobar JD, Sánchez BN et al.. “Fast food and neighborhood stroke risk.” Annals of neurology (2009). PMID: 19743456 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[32]
Kunduracioglu I, Ince S, Bayram B et al.. “Deep learning in acute ischemic stroke imaging: a systematic review of CT- and MRI-based segmentation, triage, and prognostic modeling.” Neuroradiology (2026). PMID: 42360458 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[33]
Cao X, Wang X, Tian Y et al.. “Neuroprotective Effects of Angong Niuhuang Pill in Stroke: A Systematic Review of Preclinical and Clinical Evidence.” Current neuropharmacology (2026). PMID: 42227399 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature
[34]
Xiang L, Fang Y, Zhanzhan. “Artificial intelligence models in cerebral infarction: performance and applications in diagnosis, classification, grading, treatment, and disease course prediction-a systematic review.” BMC medical informatics and decision making (2026). PMID: 42129749 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature
[35]
Katsanos AH, Whitlock RP, Belley-Côté EP et al.. “Stroke Mechanism and Severity After Left Atrial Appendage Occlusion: Insights From the LAAOS III Randomized Clinical Trial.” JAMA neurology (2026). PMID: 41247709 ↗
L2RCTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[36]
Ridha M, Hailat R, Stanton R et al.. “Hypertension With High-Risk Features in Cryptogenic Stroke: An Exploratory Analysis of the ARCADIA Randomized Clinical Trial.” JAMA neurology (2026). PMID: 42008258 ↗
L2RCTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[37]
Romoli M, Paciaroni M, Marrone N et al.. “Anticoagulation Strategies Following Breakthrough Ischemic Stroke While on Direct Anticoagulants: A Meta-Analysis.” Neurology (2025). PMID: 40758940 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Long-term & Definitive Management (Evidence Ladder), Complications, Prognosis & Natural History, Prevention, Screening & Surveillance
[38]
McCabe JJ, Walsh C, Gorey S et al.. “C-Reactive Protein, Interleukin-6, and Vascular Recurrence According to Stroke Subtype: An Individual Participant Data Meta-Analysis.” Neurology (2023). PMID: 38165328 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Long-term & Definitive Management (Evidence Ladder), Prevention, Screening & Surveillance
[39]
Papadopoulos A, Palaiopanos K, Björkbacka H et al.. “Circulating Interleukin-6 Levels and Incident Ischemic Stroke: A Systematic Review and Meta-analysis of Prospective Studies.” Neurology (2021). PMID: 34969940 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[40]
Xu J, Cheng A, Song B et al.. “Trimethylamine N-Oxide and Stroke Recurrence Depends on Ischemic Stroke Subtypes.” Stroke (2021). PMID: 34794334 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[41]
Perera KS, de Sa Boasquevisque D, Rao-Melacini P et al.. “Evaluating Rates of Recurrent Ischemic Stroke Among Young Adults With Embolic Stroke of Undetermined Source: The Young ESUS Longitudinal Cohort Study.” JAMA neurology (2022). PMID: 35285869 ↗
L2COHORTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Long-term & Definitive Management (Evidence Ladder)
[42]
Tiedt S, Brandmaier S, Kollmeier H et al.. “Circulating Metabolites Differentiate Acute Ischemic Stroke from Stroke Mimics.” Annals of neurology (2020). PMID: 32748431 ↗
L3SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification
[43]
Williams FM, Carter AM, Hysi PG et al.. “Ischemic stroke is associated with the ABO locus: the EuroCLOT study.” Annals of neurology (2013). PMID: 23381943 ↗
L3SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[44]
Díaz-Benito B, Calleja P, Alzamora L et al.. “DNase1 RS1053874 Polymorphism is Associated with Early Neurological Recovery through NET Modulation and with Long-Term Survival in Ischemic Stroke: A Prospective Cohort Study.” Annals of neurology (2026). PMID: 41527943 ↗
L2COHORTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[45]
Navi BB, Sherman CP, Genova R et al.. “Mechanisms of Ischemic Stroke in Patients with Cancer: A Prospective Study.” Annals of neurology (2021). PMID: 34029423 ↗
L3COHORTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[46]
Topiwala KK, Patel SD, Saver JL et al.. “Ischemic Stroke and Pulmonary Arteriovenous Malformations: A Review.” Neurology (2021). PMID: 34880092 ↗
L5CASE_REPORTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[47]
Kuang SY, Li Y, Yang SL et al.. “Child Neurology: Aicardi-Goutières Syndrome Presenting as Recurrent Ischemic Stroke.” Neurology (2022). PMID: 35803721 ↗
L4CASE_REPORTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[48]
Furie KL, Kelly PJ. “Secondary Prevention after Ischemic Stroke.” The New England journal of medicine (2026). PMID: 41707139 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[49]
Sacco S, Harriott AM, Ayata C et al.. “Microembolism and Other Links Between Migraine and Stroke: Clinical and Pathophysiologic Update.” Neurology (2022). PMID: 36522158 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors, Clinical Presentation, Neurorehabilitation, Symptomatic & Supportive Care
[50]
Georgakis MK, Melton P, Živković L et al.. “Anti-Inflammatory Therapies for Atherosclerotic Stroke Prevention.” Neurology (2025). PMID: 41043091 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[51]
Chaturvedi S, De Marchis GM. “Inflammatory Biomarkers and Stroke Subtype: An Important New Frontier.” Neurology (2023). PMID: 38165352 ↗
L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[52]
Nolte CH, von Rennenberg R, Litmeier S et al.. “Type 1 Myocardial Infarction in Patients With Acute Ischemic Stroke.” JAMA neurology (2024). PMID: 38829625 ↗
L4OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[53]
De Giuli V, Grassi M, Lodigiani C et al.. “Association Between Migraine and Cervical Artery Dissection: The Italian Project on Stroke in Young Adults.” JAMA neurology (2017). PMID: 28264095 ↗
L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[54]
Lavallée PC, Charles H, Albers GW et al.. “Underlying Causes of TIA and Minor Ischemic Stroke and Risk of Major Vascular Events.” JAMA neurology (2023). PMID: 37782494 ↗
L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[55]
Yaghi S, Eisenberger A, Willey JZ. “Symptomatic intracerebral hemorrhage in acute ischemic stroke after thrombolysis with intravenous recombinant tissue plasminogen activator: a review of natural history and treatment.” JAMA neurology (2014). PMID: 25069522 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[56]
Elgendy AY, Saver JL, Amin Z et al.. “Proposal for Updated Nomenclature and Classification of Potential Causative Mechanism in Patent Foramen Ovale-Associated Stroke.” JAMA neurology (2020). PMID: 32282016 ↗
L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[57]
Wang Y, Mulder IA, Westendorp WF et al.. “Immunothrombosis in Acute Ischemic Stroke.” Stroke (2024). PMID: 39479751 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Prevention, Screening & Surveillance
[58]
Mai LM, Joundi RA, Katsanos AH et al.. “Pathophysiology of Intracerebral Hemorrhage: Recovery Trajectories.” Stroke (2024). PMID: 39676669 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[59]
Pensato U, Demchuk AM, Menon BK et al.. “Cerebral Infarct Growth: Pathophysiology, Pragmatic Assessment, and Clinical Implications.” Stroke (2024). PMID: 39545332 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[60]
Yaghi S, Willey JZ, Cucchiara B et al.. “Treatment and Outcome of Hemorrhagic Transformation After Intravenous Alteplase in Acute Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.” Stroke (2017). PMID: 29097489 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Acute Management: Neurologic Emergencies & Attack Abortion, Long-term & Definitive Management (Evidence Ladder)
[61]
Aydin S, Peker S. “Long-Term Cognitive Decline After Subarachnoid Hemorrhage: Pathophysiology, Management, and Future Directions.” Stroke (2025). PMID: 40035134 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Neurorehabilitation, Symptomatic & Supportive Care
[62]
Wang Y, Xu J, Zhao Z et al.. “Mechanism-informed neuroprotection in acute ischemic stroke treated with thrombectomy: a systematic review and meta-analysis of randomized controlled trials.” Frontiers in pharmacology (2026). PMID: 42389261 ↗
L1SR_MA_RCTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Acute Management: Neurologic Emergencies & Attack Abortion, Long-term & Definitive Management (Evidence Ladder), Complications
[63]
Szaflarski JP, Rackley AY, Kleindorfer DO et al.. “Incidence of seizures in the acute phase of stroke: a population-based study.” Epilepsia (2008). PMID: 18248443 ↗
L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, History and Evolution of Treatment, Complications
[64]
Reitsma FJ, Verburgt E, Schellekens MMI et al.. “Poststroke epilepsy is associated with vascular cognitive disorder in young stroke patients: The ODYSSEY study.” Epilepsia (2026). PMID: 41830426 ↗
L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Severity, Staging & Risk Stratification
[65]
Ding L, Liu H, Jing J et al.. “Lesion Network Mapping for Neurological Deficit in Acute Ischemic Stroke.” Annals of neurology (2023). PMID: 37314250 ↗
L4OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Prognosis & Natural History
[66]
Bernard TJ, Goldenberg NA, Armstrong-Wells J et al.. “Treatment of childhood arterial ischemic stroke.” Annals of neurology (2008). PMID: 18496844 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Acute Management: Neurologic Emergencies & Attack Abortion, Neurorehabilitation, Symptomatic & Supportive Care, Special Populations & Pregnancy
[67]
Navi BB, Iadecola C. “Ischemic stroke in cancer patients: A review of an underappreciated pathology.” Annals of neurology (2018). PMID: 29633334 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[68]
Winder K, Seifert F, Ohnemus T et al.. “Neuroanatomic correlates of poststroke hyperglycemia.” Annals of neurology (2014). PMID: 25448374 ↗
L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[69]
Li B, Wen F, Qu A et al.. “The sequential mediating roles of matrix metalloproteinases-12 and DNA methylation in air pollution-induced atherosclerotic cardiovascular disease: The CHCN-BTH cohort study.” Ecotoxicology and environmental safety (2026). PMID: 42413337 ↗
L3COHORTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[70]
Clarke MD, Falcione S, Boghozian R et al.. “Metagenomic analysis of blood virome in ischemic stroke reveals an increase in herpesvirus transcripts and host immune activation.” Genome medicine (2026). PMID: 42432696 ↗
L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[71]
Guo Y, Yi J, Fang H et al.. “Neuroprotective Effects of lncRNA EPB41L4A-AS1 Against Ischemic Stroke Injury Through Regulating Microglial State Transition and Ferroptosis via miR-214-3p/GPX4 Axis.” Neurochemical research (2026). PMID: 42430067 ↗
L4OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[72]
Wang D, Xiu Y, Shi M et al.. “Colchicine as an Adjunctive Therapy to Improve Ischemic Stroke Reperfusion Outcomes in Mice.” CNS neuroscience & therapeutics (2026). PMID: 42424649 ↗
L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[73]
Vela C, Wagner J, Pacher P et al.. “PCSK9 as an Emerging Target for Cerebrovascular Dysfunction and Neuroinflammation in Ischemic Stroke.” ACS chemical neuroscience (2026). PMID: 42423025 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[74]
Yang P, Qin H, Zhou B et al.. “The Protective Mechanism of Continuous Theta Burst Stimulation in the Acute Phase of Stroke Through Modulation of the Calcineurin/AKT/FOXO1 Signaling Pathway.” CNS neuroscience & therapeutics (2026). PMID: 42417481 ↗
L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[75]
Culha-Taskin I, Nasrollahi A, Yao Y. “Loss of Pericytic Integrin-β1 Exacerbates Blood-Brain Barrier Damage and Hemorrhagic Brain Injury.” Stroke (2026). PMID: 42417043 ↗
L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[76]
Xiong Y, Campbell BCV, Schwamm LH et al.. “Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy.” The New England journal of medicine (2024). PMID: 38884324 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, History and Evolution of Treatment, Complications, Prognosis & Natural History
[77]
Bohula EA, Marston NA, Bhatia AK et al.. “Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.” The New England journal of medicine (2025). PMID: 41211925 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Prognosis & Natural History
[78]
Brott TG, Howard G, Lal BK et al.. “Medical Management and Revascularization for Asymptomatic Carotid Stenosis.” The New England journal of medicine (2025). PMID: 41269206 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Prognosis & Natural History
[79]
Yan S, Zhou Y, Lansberg MG et al.. “Alteplase for Posterior Circulation Ischemic Stroke at 4.5 to 24 Hours.” The New England journal of medicine (2025). PMID: 40174223 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute Management: Neurologic Emergencies & Attack Abortion, History and Evolution of Treatment, Prognosis & Natural History
[80]
Schwartz GG, Steg PG, Szarek M et al.. “Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.” The New England journal of medicine (2018). PMID: 30403574 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[81]
Fischer U, Koga M, Strbian D et al.. “Early versus Later Anticoagulation for Stroke with Atrial Fibrillation.” The New England journal of medicine (2023). PMID: 37222476 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Prognosis & Natural History
[82]
Nidorf SM, Fiolet ATL, Mosterd A et al.. “Colchicine in Patients with Chronic Coronary Disease.” The New England journal of medicine (2020). PMID: 32865380 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
[83]
Tao C, Liu T, Cui T et al.. “Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke.” The New England journal of medicine (2025). PMID: 40616232 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute Management: Neurologic Emergencies & Attack Abortion, History and Evolution of Treatment, Complications
[84]
Okazaki S, Tanaka K, Yazawa Y et al.. “Optimal Antithrombotics for Ischemic Stroke and Concurrent Atrial Fibrillation and Atherosclerosis: A Randomized Clinical Trial.” JAMA neurology (2025). PMID: 41051787 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Prognosis & Natural History
[85]
Brøndum-Jacobsen P, Nordestgaard BG, Schnohr P et al.. “25-hydroxyvitamin D and symptomatic ischemic stroke: an original study and meta-analysis.” Annals of neurology (2012). PMID: 23225498 ↗
L2SR_MA_RCTCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
[86]
Li Q, Abdalkader M, Siegler JE et al.. “Mechanical Thrombectomy for Large Ischemic Stroke: A Systematic Review and Meta-analysis.” Neurology (2023). PMID: 37277200 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Complications, Prognosis & Natural History
[87]
Jacob MA, Ekker MS, Allach Y et al.. “Global Differences in Risk Factors, Etiology, and Outcome of Ischemic Stroke in Young Adults-A Worldwide Meta-analysis: The GOAL Initiative.” Neurology (2021). PMID: 34906974 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications, Prognosis & Natural History
[88]
D'Anna L, Prandin G, Pirera E et al.. “Timing and Safety of Anticoagulation Reinitiation After Intracranial Hemorrhage in Patients With Mechanical Valves: A Meta-Analysis.” Neurology (2025). PMID: 40997282 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications
[89]
Jaworek T, Xu H, Gaynor BJ et al.. “Contribution of Common Genetic Variants to Risk of Early-Onset Ischemic Stroke.” Neurology (2022). PMID: 36240095 ↗
L3SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[90]
Harriott AM, Karakaya F, Ayata C. “Headache after ischemic stroke: A systematic review and meta-analysis.” Neurology (2019). PMID: 31694924 ↗
L4SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[91]
McCabe JJ, Cheung Y, Foley M et al.. “Residual Risk of Recurrent Stroke Despite Anticoagulation in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis.” JAMA neurology (2025). PMID: 40394992 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder)
[92]
Debette S, Schilling S, Duperron MG et al.. “Clinical Significance of Magnetic Resonance Imaging Markers of Vascular Brain Injury: A Systematic Review and Meta-analysis.” JAMA neurology (2019). PMID: 30422209 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[93]
Poorthuis MH, Algra AM, Algra A et al.. “Female- and Male-Specific Risk Factors for Stroke: A Systematic Review and Meta-analysis.” JAMA neurology (2017). PMID: 27842176 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Special Populations & Pregnancy
[94]
Touzé E, Southerland AM, Boulanger M et al.. “Fibromuscular Dysplasia and Its Neurologic Manifestations: A Systematic Review.” JAMA neurology (2019). PMID: 30285053 ↗
L4SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[95]
Hobeanu C, Lavallée PC, Charles H et al.. “Risk of subsequent disabling or fatal stroke in patients with transient ischaemic attack or minor ischaemic stroke: an international, prospective cohort study.” The Lancet. Neurology (2022). PMID: 36115361 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
[96]
Koton S, Pike JR, Johansen M et al.. “Association of Ischemic Stroke Incidence, Severity, and Recurrence With Dementia in the Atherosclerosis Risk in Communities Cohort Study.” JAMA neurology (2022). PMID: 35072712 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors
[97]
Katsanos AH, Palaiodimou L, Zand R et al.. “The Impact of SARS-CoV-2 on Stroke Epidemiology and Care: A Meta-Analysis.” Annals of neurology (2020). PMID: 33219563 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Neurologic Emergencies & Attack Abortion, History and Evolution of Treatment, Complications
[98]
Lavados PM, Sacks C, Prina L et al.. “Incidence, case-fatality rate, and prognosis of ischaemic stroke subtypes in a predominantly Hispanic-Mestizo population in Iquique, Chile (PISCIS project): a community-based incidence study.” The Lancet. Neurology (2007). PMID: 17239801 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History, Prevention, Screening & Surveillance
[99]
Saini V, Guada L, Yavagal DR. “Global Epidemiology of Stroke and Access to Acute Ischemic Stroke Interventions.” Neurology (2021). PMID: 34785599 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Acute Management: Neurologic Emergencies & Attack Abortion
[100]
Fan J, Li X, Yu X et al.. “Global Burden, Risk Factor Analysis, and Prediction Study of Ischemic Stroke, 1990-2030.” Neurology (2023). PMID: 37197995 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance
[101]
Pan Y, Elm JJ, Li H et al.. “Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials.” JAMA neurology (2019). PMID: 31424481 ↗
L1OTHERCited in: Epidemiology, Etiology & Risk Factors
[102]
Shu L, Aziz YN, de Havenon A et al.. “Perioperative Stroke: Mechanisms, Risk Stratification, and Management.” Stroke (2025). PMID: 40444359 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Complications
[103]
Sposato LA, Albin CSW, Elkind MSV et al.. “Patent Foramen Ovale Management for Secondary Stroke Prevention: State-of-the-Art Appraisal of Current Evidence.” Stroke (2023). PMID: 38134261 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management (Evidence Ladder), Special Populations & Pregnancy, Prevention, Screening & Surveillance
[104]
Harshfield EL, Georgakis MK, Malik R et al.. “Modifiable Lifestyle Factors and Risk of Stroke: A Mendelian Randomization Analysis.” Stroke (2021). PMID: 33535786 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors
[105]
Buckley BJR, Harrison SL, Hill A et al.. “Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Stroke.” Stroke (2022). PMID: 35354300 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Neurorehabilitation, Symptomatic & Supportive Care
[106]
Gan X, Yang S, Zhang Y et al.. “Large-Scale Plasma Proteomics Profiles for Predicting Ischemic Stroke Risk in the General Population.” Stroke (2024). PMID: 39704077 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[107]
Viswanathan A, Chabriat H. “Cerebral microhemorrhage.” Stroke (2006). PMID: 16397165 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
[108]
Nelson KB. “Perinatal ischemic stroke.” Stroke (2007). PMID: 17261729 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Special Populations & Pregnancy
[109]
Doerrfuss JI, Graf L, Hüsing T et al.. “Risk of breakthrough seizures depends on type and etiology of epilepsy.” Epilepsia (2024). PMID: 38943516 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History
[110]
Brooks JD, de Medeiros RC, Sun S et al.. “Choice of antiseizure medications and associated outcomes in Medicare beneficiaries after acute ischemic stroke.” Epilepsia (2025). PMID: 40770930 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History
[111]
Doerrfuss JI, Kowski AB, Holtkamp M. “Etiology-specific response to antiseizure medication in focal epilepsy.” Epilepsia (2021). PMID: 34328218 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History
[112]
Thevathasan A, Naylor J, Churilov L et al.. “Association between hemorrhagic transformation after endovascular therapy and poststroke seizures.” Epilepsia (2017). PMID: 29288487 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Complications
[113]
Tan ML, Ng A, Pandher PS et al.. “Tissue plasminogen activator does not alter development of acquired epilepsy.” Epilepsia (2012). PMID: 22957978 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors
[114]
Pegoraro V, Viellevoye R, Malfilatre G et al.. “Effectiveness of sodium channel blockers in treating neonatal seizures due to arterial ischemic stroke.” Epilepsia (2024). PMID: 39579039 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Prognosis & Natural History
[115]
Donahue MA, Brooks JD, Hsu J et al.. “Differences in patterns of outpatient epilepsy-specific medication initiation after acute ischemic stroke in the Medicare population.” Epilepsia (2025). PMID: 40184019 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications
[116]
Schubert KM, Dasari V, Oliveira AL et al.. “The Role of Electroencephalography in Predicting Post-Stroke Seizures and an Updated Prognostic Model (SeLECT-EEG).” Annals of neurology (2025). PMID: 40568812 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Acute Management: Neurologic Emergencies & Attack Abortion, Prognosis & Natural History
[117]
Johansen MC, Chen J, Walker KA et al.. “Proteomics and the Risk of Incident Embolic and Thrombotic Stroke.” Annals of neurology (2025). PMID: 40757626 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[118]
Lee EJ, An HY, Lim J et al.. “Clonal Hematopoiesis and Acute Ischemic Stroke Outcomes.” Annals of neurology (2023). PMID: 37532684 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors
[119]
Lisabeth LD, Sánchez BN, Lim D et al.. “Sleep-disordered breathing and poststroke outcomes.” Annals of neurology (2019). PMID: 31155749 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Neurorehabilitation, Symptomatic & Supportive Care, Prevention, Screening & Surveillance
[120]
Grossman AW, Broderick JP. “Advances and challenges in treatment and prevention of ischemic stroke.” Annals of neurology (2013). PMID: 23929628 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Acute Management: Neurologic Emergencies & Attack Abortion, Long-term & Definitive Management (Evidence Ladder), Complications, Prevention, Screening & Surveillance
[121]
Balling M, Nordestgaard BG, Varbo A et al.. “Small Dense Low-Density Lipoprotein Cholesterol and Ischemic Stroke.” Annals of neurology (2023). PMID: 36606557 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors
[122]
Kaisaier W, Chen Y, Dong Y et al.. “Discontinuation of Oral Anticoagulation After Successful Catheter Ablation for Atrial Fibrillation: Meta-analysis of Randomized Clinical Trials.” Thrombosis and haemostasis (2026). PMID: 42398953 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications
[123]
Siddharthan YPS, Kapral MK, Fang J et al.. “Sex Differences in Screening for Large Vessel Occlusion and Thrombectomy: A Population-Based Cohort Study.” Stroke (2026). PMID: 42427338 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Neurologic Emergencies & Attack Abortion, Prognosis & Natural History, Prevention, Screening & Surveillance
[124]
Niu X, Tang X, Fang X et al.. “Left Atrial Appendage Closure With Different Antithrombotic Therapies in Patients at High Bleeding Risk: A Ten-Year Cohort Study.” The Canadian journal of cardiology (2026). PMID: 42413819 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History
[125]
Huang Y, Xu Y, Zhang C et al.. “Comparative performance of insulin resistance-related indices in predicting adverse cardiovascular events among individuals with NAFLD and MASLD: a multi-center cohort study.” Cardiovascular diabetology (2026). PMID: 42401883 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Prognosis & Natural History
[126]
Kwon SY, Kim G, Han KD et al.. “Association between hypertension and incidence of cardiovascular disease events in young adults with type 2 diabetes: a nationwide cohort study.” Hypertension research : official journal of the Japanese Society of Hypertension (2026). PMID: 42386944 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors
[127]
Ryan D, Yahav A, Barnett-Griness O et al.. “Trends in stroke risk among female and male patients with atrial fibrillation: a 20-year population-based cohort study.” Heart rhythm (2026). PMID: 42379411 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[128]
Olesen KKW, Gyldenkerne C, Thrane PG et al.. “Cardiovascular Outcomes in Individuals With Diabetes, Coronary Heart Disease, or Both: A Population-Based Cohort Study in Western Denmark.” The Lancet regional health. Europe (2026). PMID: 42371531 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors
[129]
Feng S, Liu S, Zhao H et al.. “Optimal pharmacological therapy for minor acute ischemic stroke: a network meta-analysis.” Frontiers in neurology (2026). PMID: 42428753 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Prognosis & Natural History
[130]
Fladt J, Benali F, Jaroenngarmsamer T et al.. “Impact of Brain Frailty on Clinical Presentation and Neurologic Recovery in Acute Ischemic Stroke Patients Undergoing Thrombectomy.” Neurology (2025). PMID: 40294371 ↗
L2RCTCited in: Clinical Presentation
[131]
Zhang Y, Buck BH, Barber PA et al.. “Thrombolysis With Tenecteplase for Minor Disabling Stroke: Secondary Analysis of the TEMPO-2 Randomized Clinical Trial.” JAMA neurology (2025). PMID: 41143808 ↗
L2RCTCited in: Clinical Presentation, Acute Management: Neurologic Emergencies & Attack Abortion
[132]
Martinez-Gutierrez JC, Kim Y, Salazar-Marioni S et al.. “Automated Large Vessel Occlusion Detection Software and Thrombectomy Treatment Times: A Cluster Randomized Clinical Trial.” JAMA neurology (2023). PMID: 37721738 ↗
L1RCTCited in: Clinical Presentation
[133]
Bhatia KD, Chowdhury S, Andrews I et al.. “Association Between Thrombectomy and Functional Outcomes in Pediatric Patients With Acute Ischemic Stroke From Large Vessel Occlusion.” JAMA neurology (2023). PMID: 37486670 ↗
L3RCTCited in: Clinical Presentation, Special Populations & Pregnancy
[134]
Waters MF, Hoh BL, Lynn MJ et al.. “Factors Associated With Recurrent Ischemic Stroke in the Medical Group of the SAMMPRIS Trial.” JAMA neurology (2016). PMID: 26747792 ↗
L2RCTCited in: Clinical Presentation
[135]
Lansberg MG, Mlynash M, Hamilton S et al.. “Association of Thrombectomy With Stroke Outcomes Among Patient Subgroups: Secondary Analyses of the DEFUSE 3 Randomized Clinical Trial.” JAMA neurology (2019). PMID: 30688974 ↗
L2RCTCited in: Clinical Presentation
[136]
Healey JS, Gladstone DJ, Swaminathan B et al.. “Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial.” JAMA neurology (2019). PMID: 30958508 ↗
L2RCTCited in: Clinical Presentation
[137]
Niizuma K, Nishimura N, Hasegawa K et al.. “Anti-Inflammatory Thrombolytic JX10 (TMS-007) in Late Presentation of Acute Ischemic Stroke.” Stroke (2024). PMID: 39508107 ↗
L1RCTCited in: Clinical Presentation
[138]
Nogueira RG, Doheim MF, Jadhav AP et al.. “Mode of Onset Modifies the Effect of Time to Endovascular Reperfusion on Clinical Outcomes after Acute Ischemic Stroke: An Analysis of the DAWN Trial.” Annals of neurology (2024). PMID: 38877793 ↗
L2RCTCited in: Clinical Presentation
[139]
Romoli M, Urbinati G, Tudisco V et al.. “Risk of Recurrent Stroke, Mortality, and Intracerebral Hemorrhage in Patients With Atrial Fibrillation Detected Before or After a Stroke.” Neurology (2025). PMID: 39999395 ↗
L2SR_OBSCited in: Clinical Presentation
[140]
Tarnutzer AA, Lee SH, Robinson KA et al.. “ED misdiagnosis of cerebrovascular events in the era of modern neuroimaging: A meta-analysis.” Neurology (2017). PMID: 28356464 ↗
L2SR_OBSCited in: Clinical Presentation
[141]
Ali M, van Os HJA, van der Weerd N et al.. “Sex Differences in Presentation of Stroke: A Systematic Review and Meta-Analysis.” Stroke (2021). PMID: 34903037 ↗
L2SR_OBSCited in: Clinical Presentation
[142]
Sheth SA, Lee S, Warach SJ et al.. “Sex Differences in Outcome After Endovascular Stroke Therapy for Acute Ischemic Stroke.” Stroke (2019). PMID: 31412752 ↗
L2SR_OBSCited in: Clinical Presentation
[143]
Romoli M, Merli E, Galluzzo S et al.. “Hyperperfusion Tmax mapping for nonconvulsive status epilepticus in the acute setting: A pilot case-control study.” Epilepsia (2022). PMID: 35793391 ↗
L3CASE_CONTROLCited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Acute Management: Neurologic Emergencies & Attack Abortion, History and Evolution of Treatment
[144]
Kleinfeld K, Jones P, Riebau D et al.. “Vascular complications of fungal meningitis attributed to injections of contaminated methylprednisolone acetate.” JAMA neurology (2013). PMID: 23877880 ↗
L4CASE_REPORTCited in: Clinical Presentation
[145]
Hermann DM, Bassetti CL. “Sleep-related breathing and sleep-wake disturbances in ischemic stroke.” Neurology (2009). PMID: 19841384 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[146]
Manini A, Pantoni L. “Genetic Causes of Cerebral Small Vessel Diseases: A Practical Guide for Neurologists.” Neurology (2022). PMID: 36535782 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[147]
Zahuranec DB, Majersik JJ. “Percentage of acute stroke patients eligible for endovascular treatment.” Neurology (2012). PMID: 23008402 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[148]
Westendorp WF, Dames C, Nederkoorn PJ et al.. “Immunodepression, Infections, and Functional Outcome in Ischemic Stroke.” Stroke (2022). PMID: 35341322 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Neurorehabilitation, Symptomatic & Supportive Care, Prevention, Screening & Surveillance
[149]
Alemseged F, Rocco A, Arba F et al.. “Posterior National Institutes of Health Stroke Scale Improves Prognostic Accuracy in Posterior Circulation Stroke.” Stroke (2021). PMID: 34905944 ↗
L2OTHERCited in: Clinical Presentation
[150]
Miwa K, Tanaka K, Koga M et al.. “Prediction Model to Optimize Long-Term Antithrombotic Therapy Using Covert Vascular Brain Injury and Clinical Features.” Stroke (2025). PMID: 40534562 ↗
L2OTHERCited in: Clinical Presentation
[151]
Michel P, Beaud V, Eskandari A et al.. “Ischemic Amnesia: Causes and Outcome.” Stroke (2017). PMID: 28584000 ↗
L4OTHERCited in: Clinical Presentation
[152]
Kim SJ, Marquina C, Foster E et al.. “Comparative risk of major health events among individuals prescribed different antiseizure medications following ischemic stroke.” Epilepsia (2025). PMID: 40067170 ↗
L2OTHERCited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Complications
[153]
Spychala MS, Venna VR, Jandzinski M et al.. “Age-related changes in the gut microbiota influence systemic inflammation and stroke outcome.” Annals of neurology (2018). PMID: 29733457 ↗
L5OTHERCited in: Clinical Presentation
[154]
Seok JM, Kim SG, Kim JW et al.. “Coagulopathy and embolic signal in cancer patients with ischemic stroke.” Annals of neurology (2010). PMID: 20695014 ↗
L2OTHERCited in: Clinical Presentation
[155]
Mackay MT, Wiznitzer M, Benedict SL et al.. “Arterial ischemic stroke risk factors: the International Pediatric Stroke Study.” Annals of neurology (2011). PMID: 21280083 ↗
L2OTHERCited in: Clinical Presentation
[156]
Park JM, Kang K, Cho YJ et al.. “Comparative Effectiveness of Prestroke Aspirin on Stroke Severity and Outcome.” Annals of neurology (2016). PMID: 26754410 ↗
L2OTHERCited in: Clinical Presentation
[157]
Sarraj A, Albers GW, Blasco J et al.. “Thrombectomy versus Medical Management in Mild Strokes due to Large Vessel Occlusion: Exploratory Analysis from the EXTEND-IA Trials and a Pooled International Cohort.” Annals of neurology (2022). PMID: 35599458 ↗
L2OTHERCited in: Clinical Presentation
[158]
Liebeskind DS. “Imaging the future of stroke: II. Hemorrhage.” Annals of neurology (2010). PMID: 21031575 ↗
L5OTHERCited in: Clinical Presentation
[159]
Pitton Rissardo J, Byroju VV, Gribachov A et al.. “From Eight-and-a-Half to Nine: A Case Report Highlighting an Uncommon Brainstem Syndrome.” The neurologist (2026). PMID: 42132519 ↗
L4SR_OBSCited in: Clinical Presentation
[160]
Zhao B, Yu M, Zhou P et al.. “Case Report: Asymmetric recovery unmasking watershed infarction in a patient with ICU-acquired weakness.” Frontiers in medicine (2026). PMID: 42422814 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Neurorehabilitation, Symptomatic & Supportive Care
[161]
Yadiyal D, Bhowmick R, Chandra N. “Vascular Eagle syndrome presenting with expanding cervical hematoma and acute ischemic stroke causing impending airway compromise.” The American journal of emergency medicine (2026). PMID: 42330722 ↗
L4CASE_REPORTCited in: Clinical Presentation, Neurorehabilitation, Symptomatic & Supportive Care
[162]
Ding G, Xu J, Yao M. “Trousseau syndrome presenting with recurrent multi-territory infarctions: a case report of two patients highlighting divergent outcomes and dynamic hypercoagulability under direct oral anticoagulants and low-molecular-weight heparin.” Frontiers in cardiovascular medicine (2026). PMID: 42244789 ↗
L4CASE_REPORTCited in: Clinical Presentation, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[163]
Huang H, Li Y, Li Y et al.. “Fulminant cerebral edema in the setting of acute dengue fever after mechanical thrombectomy in a patient with massive stroke and severe hypoalbuminemia: a case report.” Frontiers in medicine (2026). PMID: 42221120 ↗
L4CASE_REPORTCited in: Clinical Presentation
[164]
Dardas S, Sposato L, Ayan D et al.. “Code Stroke Activation Following Cardiac Catheterization Procedures: Contrast-Induced Encephalopathy Versus Stroke.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 42057290 ↗
L2CASE_REPORTCited in: Clinical Presentation
[165]
Kaya DD, Ergenc H, Az A et al.. “Diagnostic accuracy and post-reperfusion kinetics of serum miRNA-125b in hyperacute ischemic stroke: a prospective emergency department case-control study.” Irish journal of medical science (2026). PMID: 42397520 ↗
L3CASE_CONTROLCited in: Clinical Presentation
[166]
Schellinger PD, Bryan RN, Caplan LR et al.. “Evidence-based guideline: The role of diffusion and perfusion MRI for the diagnosis of acute ischemic stroke [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.” Neurology (2010). PMID: 20625171 ↗
L1GUIDELINECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment
[167]
Kidwell CS, Jahan R, Gornbein J et al.. “A trial of imaging selection and endovascular treatment for ischemic stroke.” The New England journal of medicine (2013). PMID: 23394476 ↗
L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[168]
Benavente OR, Hart RG, McClure LA et al.. “Effects of clopidogrel added to aspirin in patients with recent lacunar stroke.” The New England journal of medicine (2012). PMID: 22931315 ↗
L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[169]
Parsons M, Spratt N, Bivard A et al.. “A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.” The New England journal of medicine (2012). PMID: 22435369 ↗
L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[170]
Houkin K, Osanai T, Uchiyama S et al.. “Allogeneic Stem Cell Therapy for Acute Ischemic Stroke: The Phase 2/3 TREASURE Randomized Clinical Trial.” JAMA neurology (2024). PMID: 38227308 ↗
L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Prognosis & Natural History
[171]
Kimura K, Nishiyama Y, Iwasaki YK et al.. “Catheter Ablation and Oral Anticoagulation for Secondary Stroke Prevention in Atrial Fibrillation: The STABLED Randomized Clinical Trial.” JAMA neurology (2026). PMID: 41770549 ↗
L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Complications, Prevention, Screening & Surveillance
[172]
Liu Y, Yu Y, Ouyang J et al.. “Functional Outcome Prediction in Acute Ischemic Stroke Using a Fused Imaging and Clinical Deep Learning Model.” Stroke (2023). PMID: 37485663 ↗
L2RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment, Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History
[173]
Wang T, Yang Y, Wang H et al.. “CT Perfusion for Predicting Ischemic Stroke in Patients With Symptomatic Carotid or Middle Cerebral Artery Occlusion: A Post Hoc Analysis of the CMOSS Study.” Stroke (2025). PMID: 40534574 ↗
L2RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[174]
Amarenco P, Kim JS, Labreuche J et al.. “Intracranial Hemorrhage in the TST Trial.” Stroke (2021). PMID: 34963300 ↗
L2RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[175]
Fiehler J, Thomalla G, Bernhardt M et al.. “ERASER.” Stroke (2019). PMID: 31009356 ↗
L2TRIAL_NONRANDOMCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Long-term & Definitive Management (Evidence Ladder)
[176]
Zhou Q, Gao Y, Chen W et al.. “Efficacy and Safety of Dual Antiplatelet Treatment up to 72 Hours in Acute Ischemic Stroke Stratified by Glycemic Status.” Annals of neurology (2025). PMID: 39931900 ↗
L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[177]
Scheldeman L, Wouters A, Boutitie F et al.. “Different Mismatch Concepts for Magnetic Resonance Imaging-Guided Thrombolysis in Unknown Onset Stroke.” Annals of neurology (2020). PMID: 32227638 ↗
L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[178]
Edlow BL, Hurwitz S, Edlow JA. “Diagnosis of DWI-negative acute ischemic stroke: A meta-analysis.” Neurology (2017). PMID: 28615423 ↗
L2SR_OBSCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[179]
Mazzucco S, Li L, Rothwell PM. “Prognosis of Cryptogenic Stroke With Patent Foramen Ovale at Older Ages and Implications for Trials: A Population-Based Study and Systematic Review.” JAMA neurology (2020). PMID: 32628255 ↗
L2SR_OBSCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[180]
Perry LA, Rodrigues M, Al-Shahi Salman R et al.. “Incident Cerebral Microbleeds After Intracerebral Hemorrhage.” Stroke (2019). PMID: 31203786 ↗
L2SR_OBSCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[181]
Beuker C, Werring N, Bonberg N et al.. “Stroke in Patients with Bacterial Meningitis: A Cohort Study and Meta-Analysis.” Annals of neurology (2023). PMID: 36806294 ↗
L3SR_OBSCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Complications, Prognosis & Natural History
[182]
Rodríguez-Martín S, Barreira-Hernández D, Gil M et al.. “Influenza Vaccination and Risk of Ischemic Stroke: A Population-Based Case-Control Study.” Neurology (2022). PMID: 36240087 ↗
L3CASE_CONTROLCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[183]
Kamel H, Navi BB, Sriram N et al.. “Risk of a thrombotic event after the 6-week postpartum period.” The New England journal of medicine (2014). PMID: 24524551 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[184]
Sun LR, Lee S, Lee-Eng J et al.. “Tenecteplase for the Treatment of Pediatric Arterial Ischemic Stroke: A Safety Surveillance Report.” Neurology (2025). PMID: 39805054 ↗
L4OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Special Populations & Pregnancy
[185]
Kalra LP, Zylyftari S, Blums K et al.. “Rapid Diagnosis of Intracerebral Hemorrhage in Patients With Acute Stroke by Measuring Prehospital GFAP Levels on a Point-of-Care Device (DETECT).” Neurology (2025). PMID: 40570271 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[186]
Rambaud T, Legris N, Bejot Y et al.. “Acute ischemic stroke in adolescents.” Neurology (2019). PMID: 31831601 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Special Populations & Pregnancy
[187]
Shu L, Akpokiere F, Mandel DM et al.. “Intravenous Thrombolysis in Patients With Cervical Artery Dissection: A Secondary Analysis of the STOP-CAD Study.” Neurology (2024). PMID: 39298709 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[188]
Koo AB, Zhou L, Hameed I et al.. “Acute Ischemic Stroke Risk Following Cardiac Interventions in the United States From 2016 to 2021.” Neurology (2025). PMID: 40493873 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[189]
Bindslev JB, Valentin JB, Johnsen SP et al.. “Incidence and Prognosis of Pediatric Stroke in Denmark: A Nationwide Population-Based Study.” Neurology (2025). PMID: 40674669 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Special Populations & Pregnancy
[190]
Chen H, Lee JS, Michel P et al.. “Endovascular Stroke Thrombectomy for Patients With Large Ischemic Core: A Review.” JAMA neurology (2024). PMID: 39133467 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Acute Management: Neurologic Emergencies & Attack Abortion, Long-term & Definitive Management (Evidence Ladder)
[191]
Mac Grory B, Sun JL, Alhanti B et al.. “Mobile Stroke Unit Management in Patients With Acute Ischemic Stroke Eligible for Intravenous Thrombolysis.” JAMA neurology (2024). PMID: 39466286 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[192]
Arsava EM, Kim GM, Oliveira-Filho J et al.. “Prediction of Early Recurrence After Acute Ischemic Stroke.” JAMA neurology (2016). PMID: 26926383 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[193]
Zhu J, Mo J, Liu K et al.. “Glymphatic System Impairment Contributes to the Formation of Brain Edema After Ischemic Stroke.” Stroke (2024). PMID: 38533660 ↗
L5OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[194]
Heo J, Yoon JG, Park H et al.. “Machine Learning-Based Model for Prediction of Outcomes in Acute Stroke.” Stroke (2019). PMID: 30890116 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[195]
Kessner SS, Schlemm E, Cheng B et al.. “Somatosensory Deficits After Ischemic Stroke.” Stroke (2019). PMID: 30943883 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[196]
Gonçalves OR, Tudella GCN, Cardoso LJC et al.. “Magnetic Resonance Imaging/Diffusion-Weighted Imaging-Guided Versus Perfusion-Guided Intravenous Thrombolysis with Alteplase Beyond 4.5-Hour Window: a Network Meta-Analysis of Randomized Controlled Trials.” Clinical neuroradiology (2026). PMID: 42371037 ↗
L1SR_MA_RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Acute Management: Neurologic Emergencies & Attack Abortion
[197]
García-Peña P, Ramos M, López JM et al.. “Preclinical examination of early-onset thalamic-cortical seizures after hemispheric stroke.” Epilepsia (2023). PMID: 37277947 ↗
L5OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[198]
Meletti S, Cuccurullo C, Orlandi N et al.. “Prediction of epilepsy after stroke: Proposal of a modified SeLECT 2.0 score based on posttreatment stroke outcome.” Epilepsia (2024). PMID: 39235830 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Acute Management: Neurologic Emergencies & Attack Abortion, Prognosis & Natural History
[199]
Sarraj A, Pujara DK, Campbell BC. “Current State of Evidence for Neuroimaging Paradigms in Management of Acute Ischemic Stroke.” Annals of neurology (2024). PMID: 38606939 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Acute Management: Neurologic Emergencies & Attack Abortion, History and Evolution of Treatment
[200]
van der Vliet R, Selles RW, Andrinopoulou ER et al.. “Predicting Upper Limb Motor Impairment Recovery after Stroke: A Mixture Model.” Annals of neurology (2020). PMID: 31925838 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History
[201]
Fisher M, Albers GW. “Advanced imaging to extend the therapeutic time window of acute ischemic stroke.” Annals of neurology (2013). PMID: 23378323 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[202]
Jickling GC, Xu H, Stamova B et al.. “Signatures of cardioembolic and large-vessel ischemic stroke.” Annals of neurology (2010). PMID: 21031583 ↗
L3OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[203]
Pertsovskaya V, Merkler AE, Payabvash S et al.. “Direct oral anticoagulants versus aspirin for prevention of overt and covert cerebral infarction: A meta-analysis.” Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2026). PMID: 42373059 ↗
L1SR_OBSCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Prevention, Screening & Surveillance
[204]
Degirmenci S, Arikan E, Boz M et al.. “Systemic Immune-Inflammatory Markers for Predicting Infarct Volume and Mortality in Patients with Acute Ischemic Stroke: A Retrospective Cohort Study.” Journal of clinical medicine (2026). PMID: 42355583 ↗
L3COHORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[205]
Chen Z, Cai J, Hu X et al.. “Clinical and CT angiography characteristics of Chinese stroke patients with carotid web: a retrospective study.” Frontiers in neurology (2026). PMID: 42388700 ↗
L4COHORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[206]
Zhang C, Zhong W, Tang X et al.. “Plasma cyclophilin a as a novel predictor of major adverse cardiac events in patients with acute myocardial injury cohort study.” BMC cardiovascular disorders (2026). PMID: 42366350 ↗
L2COHORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[207]
Lv H, Chen Y. “Early Quantitative Electroencephalography Parameters Predicting Clinical Outcomes of Intravenous rt-PA Thrombolysis in Acute Ischemic Stroke: A Retrospective Cohort Study.” British journal of hospital medicine (London, England : 2005) (2026). PMID: 42411532 ↗
L4COHORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[208]
Goyal M, Ospel JM, Ganesh A et al.. “Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion.” The New England journal of medicine (2025). PMID: 39908448 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, Acute Management: Neurologic Emergencies & Attack Abortion, Complications
[209]
Qiu Z, Li F, Sang H et al.. “Intravenous Tenecteplase before Thrombectomy in Stroke.” The New England journal of medicine (2025). PMID: 40396577 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, Acute Management: Neurologic Emergencies & Attack Abortion, Complications, Prognosis & Natural History
[210]
Connolly SJ, Sharma M, Cohen AT et al.. “Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.” The New England journal of medicine (2024). PMID: 38749032 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, Acute Management: Neurologic Emergencies & Attack Abortion, History and Evolution of Treatment
[211]
Hacke W, Kaste M, Bluhmki E et al.. “Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.” The New England journal of medicine (2008). PMID: 18815396 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, Acute Management: Neurologic Emergencies & Attack Abortion, Complications
[212]
Doheim MF, Nguyen TN, Xiong Y et al.. “Meta-Analysis of Randomized Controlled Trials on IV Thrombolysis in Patients With Minor Acute Ischemic Stroke.” Neurology (2025). PMID: 40674672 ↗
L1SR_MA_RCTCited in: Severity, Staging & Risk Stratification, Acute Management: Neurologic Emergencies & Attack Abortion, Complications, Prognosis & Natural History
[213]
Liu C, Abdalkader M, Sang H et al.. “Endovascular Thrombectomy for Large Ischemic Core Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Neurology (2025). PMID: 40245349 ↗
L1SR_MA_RCTCited in: Severity, Staging & Risk Stratification, Acute Management: Neurologic Emergencies & Attack Abortion, Complications, Prognosis & Natural History
[214]
Yoo AJ, Berkhemer OA, Fransen PSS et al.. “Effect of baseline Alberta Stroke Program Early CT Score on safety and efficacy of intra-arterial treatment: a subgroup analysis of a randomised phase 3 trial (MR CLEAN).” The Lancet. Neurology (2016). PMID: 27302238 ↗
L2RCTCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
[215]
Zhao W, Li S, Li C et al.. “Effects of Tirofiban on Neurological Deterioration in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial.” JAMA neurology (2024). PMID: 38648030 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Complications, Prognosis & Natural History
[216]
Wang A, Jia B, Zhang X et al.. “Efficacy and Safety of Butylphthalide in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial.” JAMA neurology (2023). PMID: 37358859 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, Acute Management: Neurologic Emergencies & Attack Abortion, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Prognosis & Natural History
[217]
Chen HS, Cui Y, Wang XH et al.. “Clopidogrel Plus Aspirin vs Aspirin Alone in Patients With Acute Mild to Moderate Stroke: The ATAMIS Randomized Clinical Trial.” JAMA neurology (2024). PMID: 38466274 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Complications, Prognosis & Natural History
[218]
Hernández-Jiménez M, Abad-Santos F, Cotgreave I et al.. “Safety and Efficacy of ApTOLL in Patients With Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial.” JAMA neurology (2023). PMID: 37338893 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, Acute Management: Neurologic Emergencies & Attack Abortion, History and Evolution of Treatment, Complications, Prognosis & Natural History
[219]
Warach SJ, Davis LA, Lawrence P et al.. “Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Pragmatic, Response-Adaptive Randomized Clinical Trial.” JAMA neurology (2025). PMID: 40163159 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prevention, Screening & Surveillance
[220]
Xu J, Wang A, Meng X et al.. “Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial.” Stroke (2021). PMID: 33588596 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
[221]
Singh N, Almekhlafi MA, Bala F et al.. “Effect of Time to Thrombolysis on Clinical Outcomes in Patients With Acute Ischemic Stroke Treated With Tenecteplase Compared to Alteplase: Analysis From the AcT Randomized Controlled Trial.” Stroke (2023). PMID: 37800372 ↗
L2RCTCited in: Severity, Staging & Risk Stratification
[222]
Ghosh S, Dubow JS, Sutherland J et al.. “Randomized, Proof-of-Concept Trial (RESCUE) of RNS60 as an Adjunct Therapy in Acute Ischemic Stroke.” Stroke (2025). PMID: 40671649 ↗
L1RCTCited in: Severity, Staging & Risk Stratification
[223]
Palaiodimou L, Katsanos AH, Turc G et al.. “Tenecteplase vs Alteplase in Acute Ischemic Stroke Within 4.5 Hours: A Systematic Review and Meta-Analysis of Randomized Trials.” Neurology (2024). PMID: 39413337 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification, Complications, Prognosis & Natural History
[224]
Jiang X, Zhao Z, Zhang Y et al.. “Intra-Arterial Thrombolysis Following Endovascular Recanalization for Large Vessel Occlusion Stroke: A Systematic Review and Meta-Analysis.” Neurology (2025). PMID: 40577652 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification, Acute Management: Neurologic Emergencies & Attack Abortion
[225]
Harris SE, Malik R, Marioni R et al.. “Polygenic risk of ischemic stroke is associated with cognitive ability.” Neurology (2015). PMID: 26695942 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification
[226]
Safouris A, Palaiodimou L, Nardai S et al.. “Medical Management Versus Endovascular Treatment for Large-Vessel Occlusion Anterior Circulation Stroke With Low NIHSS.” Stroke (2023). PMID: 37526011 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification
[227]
He Q, Wang W, Xu D et al.. “Causal Association of Iron Status With Functional Outcome After Ischemic Stroke.” Stroke (2023). PMID: 38095120 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification
[228]
Kimura S, Toyoda K, Yoshimura S et al.. “Practical "1-2-3-4-Day" Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: Combined Hospital-Based Cohort Study.” Stroke (2022). PMID: 35105180 ↗
L2COHORTCited in: Severity, Staging & Risk Stratification
[229]
Al-Ajlan FS, Alkhiri A, Alamri AF et al.. “Golden Hour Intravenous Thrombolysis for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.” Annals of neurology (2024). PMID: 38922985 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification, Acute Management: Neurologic Emergencies & Attack Abortion, Complications, Prognosis & Natural History
[230]
Katsanos AH, Malhotra K, Goyal N et al.. “Intravenous thrombolysis prior to mechanical thrombectomy in large vessel occlusions.” Annals of neurology (2019). PMID: 31282044 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification, Acute Management: Neurologic Emergencies & Attack Abortion, Long-term & Definitive Management (Evidence Ladder), Complications, Prognosis & Natural History
[231]
Giustozzi M, Calvello C, Eusebi P et al.. “Safety and efficacy of concomitant treatment with non-vitamin K antagonist oral anticoagulants and antiseizure medications: A propensity score matching cohort study.” Epilepsia (2024). PMID: 38888914 ↗
L2COHORTCited in: Severity, Staging & Risk Stratification, Prognosis & Natural History
[232]
De Santis F, Foschi M, D'Anna L et al.. “Acute Treatment of Disabling and Nondisabling Minor Ischemic Stroke: Expert Guidance for Clinicians.” Stroke (2025). PMID: 41376587 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Acute Management: Neurologic Emergencies & Attack Abortion, Long-term & Definitive Management (Evidence Ladder)
[233]
Shah SJ, Borlaug BA, Chung ES et al.. “Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial.” Lancet (London, England) (2022). PMID: 35120593 ↗
L1OTHERCited in: Severity, Staging & Risk Stratification, Prognosis & Natural History
[234]
Yu Y, Tuo M, Chen Z et al.. “Association between severity of stroke and poststroke epilepsy among patients with ischemic stroke: Mediating role of infection and early seizure.” Epilepsia (2025). PMID: 40035708 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification
[235]
Huang B, Hao Z, Kuang Y et al.. “Intracardiac Echocardiography for Procedural Guidance of Left Atrial Appendage Occlusion From Right Atrium: A Subgroup From a Multicenter Randomized Controlled Trial With Two Intracardiac Echocardiography Imaging Systems.” Journal of cardiovascular electrophysiology (2026). PMID: 42418757 ↗
L2RCTCited in: Severity, Staging & Risk Stratification, Complications
[236]
Seiffge DJ, De Marchis GM, Koga M et al.. “Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation.” Annals of neurology (2020). PMID: 32052481 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification, Prevention, Screening & Surveillance
[237]
Elmashad A, Elfil M, Hawas Y et al.. “Efficacy of the Route 92 reperfusion system in acute ischemic stroke due to large vessel occlusion: a systematic review and meta-analysis.” Neurosurgical review (2026). PMID: 42418028 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification, Acute Management: Neurologic Emergencies & Attack Abortion, Complications, Prognosis & Natural History
[238]
Chang CH, Chen CC, Chen CT et al.. “Drug-coated balloons (DCB) for symptomatic intracranial atherosclerotic stenosis: a systematic review and meta-analysis.” Cardiovascular diagnosis and therapy (2026). PMID: 42428645 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification
[239]
AlSejari NY, Gadelmawla AF, Alsubaiei AA et al.. “Dual antiplatelet therapy with aspirin and ticagrelor vs aspirin alone in patients with acute coronary syndrome undergoing coronary artery bypass graft surgery: a systematic review and meta-analysis.” Journal of thrombosis and thrombolysis (2026). PMID: 42418138 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification
[240]
Xie S, Lou C, Liao Z et al.. “Endovascular treatment of low NIHSS score(<6) combined with large vessel occlusion: a meta-analysis.” Frontiers in neurology (2026). PMID: 42404117 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification
[241]
Ho PH, Li R, Cheng SW et al.. “Intracranial carotid artery calcification as an imaging marker in plain computed tomography for intracranial atherosclerotic disease in ischemic stroke patients: A retrospective observational cohort study.” Clinical neurology and neurosurgery (2026). PMID: 42424790 ↗
L2COHORTCited in: Severity, Staging & Risk Stratification
[242]
Combes A, Hajage D, Capellier G et al.. “Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome.” The New England journal of medicine (2018). PMID: 29791822 ↗
L1RCTCited in: Acute Management: Neurologic Emergencies & Attack Abortion, Long-term & Definitive Management (Evidence Ladder)
[243]
Nogueira RG, Jadhav AP, Haussen DC et al.. “Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct.” The New England journal of medicine (2017). PMID: 29129157 ↗
L1RCTCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[244]
Ma H, Campbell BCV, Parsons MW et al.. “Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke.” The New England journal of medicine (2019). PMID: 31067369 ↗
L1RCTCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[245]
Gao Y, Chen W, Pan Y et al.. “Dual Antiplatelet Treatment up to 72 Hours after Ischemic Stroke.” The New England journal of medicine (2023). PMID: 38157499 ↗
L1RCTCited in: Acute Management: Neurologic Emergencies & Attack Abortion, Long-term & Definitive Management (Evidence Ladder)
[246]
Nighoghossian N, Berthezène Y, Mechtouff L et al.. “Cyclosporine in acute ischemic stroke.” Neurology (2015). PMID: 25948727 ↗
L1RCTCited in: Acute Management: Neurologic Emergencies & Attack Abortion, Long-term & Definitive Management (Evidence Ladder)
[247]
Bala F, Singh N, Buck B et al.. “Safety and Efficacy of Tenecteplase Compared With Alteplase in Patients With Large Vessel Occlusion Stroke: A Prespecified Secondary Analysis of the ACT Randomized Clinical Trial.” JAMA neurology (2023). PMID: 37428494 ↗
L2RCTCited in: Acute Management: Neurologic Emergencies & Attack Abortion, History and Evolution of Treatment, Complications
[248]
Joundi RA, Smith EE, Ganesh A et al.. “Time From Hospital Arrival Until Endovascular Thrombectomy and Patient-Reported Outcomes in Acute Ischemic Stroke.” JAMA neurology (2024). PMID: 38829660 ↗
L2RCTCited in: Acute Management: Neurologic Emergencies & Attack Abortion, Neurorehabilitation, Symptomatic & Supportive Care
[249]
Chabanne R, Geeraerts T, Begard M et al.. “Outcomes After Endovascular Therapy With Procedural Sedation vs General Anesthesia in Patients With Acute Ischemic Stroke: The AMETIS Randomized Clinical Trial.” JAMA neurology (2023). PMID: 37010829 ↗
L1RCTCited in: Acute Management: Neurologic Emergencies & Attack Abortion, Complications
[250]
Cheng X, Hong L, Lin L et al.. “Tenecteplase Thrombolysis for Stroke up to 24 Hours After Onset With Perfusion Imaging Selection: The CHABLIS-T II Randomized Clinical Trial.” Stroke (2025). PMID: 39744861 ↗
L1RCTCited in: Acute Management: Neurologic Emergencies & Attack Abortion, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[251]
Ducroux C, Di Meglio L, Loyau S et al.. “Thrombus Neutrophil Extracellular Traps Content Impair tPA-Induced Thrombolysis in Acute Ischemic Stroke.” Stroke (2018). PMID: 29438080 ↗
L4TRIAL_NONRANDOMCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[252]
Chen CJ, Ding D, Starke RM et al.. “Endovascular vs medical management of acute ischemic stroke.” Neurology (2015). PMID: 26537058 ↗
L1SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[253]
Katsanos AH, Hart RG. “New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention.” JAMA neurology (2020). PMID: 32716473 ↗
L5SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[254]
Günkan A, Ferreira MY, Vilardo M et al.. “Thrombolysis for Ischemic Stroke Beyond the 4.5-Hour Window: A Meta-Analysis of Randomized Clinical Trials.” Stroke (2025). PMID: 39882605 ↗
L1SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion, Complications
[255]
Kamogawa N, Miwa K, Toyoda K et al.. “Thrombolysis for Wake-Up Stroke Versus Non-Wake-Up Unwitnessed Stroke: EOS Individual Patient Data Meta-Analysis.” Stroke (2024). PMID: 38456303 ↗
L1SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[256]
Guo C, Cavalcante F, Yang S et al.. “Stroke Etiologies With Intravenous Thrombolysis before Thrombectomy and Functional Outcomes in Anterior Circulation Large Vessel Occlusion.” Annals of neurology (2026). PMID: 42026777 ↗
L1SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[257]
Jadhav AP, Desai SM, Jovin TG. “Indications for Mechanical Thrombectomy for Acute Ischemic Stroke: Current Guidelines and Beyond.” Neurology (2021). PMID: 34785611 ↗
L5REVIEW_NARRATIVECited in: Acute Management: Neurologic Emergencies & Attack Abortion, History and Evolution of Treatment
[258]
Simonsen CZ, Bösel J, Rasmussen M. “Periprocedural Management During Stroke Thrombectomy.” Neurology (2021). PMID: 34785609 ↗
L5REVIEW_NARRATIVECited in: Acute Management: Neurologic Emergencies & Attack Abortion
[259]
Meinel TR, Wilson D, Gensicke H et al.. “Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants.” JAMA neurology (2023). PMID: 36807495 ↗
L2OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[260]
Warach SJ, Dula AN, Milling TJ. “Tenecteplase Thrombolysis for Acute Ischemic Stroke.” Stroke (2020). PMID: 33045929 ↗
L5REVIEW_NARRATIVECited in: Acute Management: Neurologic Emergencies & Attack Abortion, Complications, Prognosis & Natural History
[261]
Jolugbo P, Ariëns RAS. “Thrombus Composition and Efficacy of Thrombolysis and Thrombectomy in Acute Ischemic Stroke.” Stroke (2021). PMID: 33563020 ↗
L2REVIEW_NARRATIVECited in: Acute Management: Neurologic Emergencies & Attack Abortion
[262]
García-Tornel Á, Requena M, Rubiera M et al.. “When to Stop.” Stroke (2019). PMID: 31177974 ↗
L4OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[263]
Wu C, Sun C, Wang L et al.. “Low-Dose Tirofiban Treatment Improves Neurological Deterioration Outcome After Intravenous Thrombolysis.” Stroke (2019). PMID: 31570084 ↗
L2OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[264]
Qiao Y, Ter Schiphorst A, Xu Y et al.. “Revisiting Incomplete Tissue-Level Reperfusion Following Successful Thrombectomy for Acute Ischemic Stroke.” Annals of neurology (2026). PMID: 41586473 ↗
L5REVIEW_NARRATIVECited in: Acute Management: Neurologic Emergencies & Attack Abortion
[265]
Hong L, Cheng X, Lin L et al.. “The blood pressure paradox in acute ischemic stroke.” Annals of neurology (2019). PMID: 30720216 ↗
L2OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[266]
Wang L, Cheng Y, Wan S et al.. “Joint trajectories of sleep quality and cognitive function after acute ischemic stroke: a prospective cohort study using group-based dual trajectory modeling.” Frontiers in medicine (2026). PMID: 42433978 ↗
L2COHORTCited in: Acute Management: Neurologic Emergencies & Attack Abortion, History and Evolution of Treatment
[267]
Barrera Gutierrez JC, Vivian E, Shah J et al.. “Impact of Artificial Intelligence-Based Triage on Stroke Workflow Metrics: A Systematic Review and Meta-Analysis.” Cardiovascular and interventional radiology (2026). PMID: 42414634 ↗
L2SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[268]
Martins GS, de Santana Lima OG, Oliveira HP et al.. “Drip-and-Ship versus Mothership Model in Acute Ischemic Stroke: A Meta-Analysis Stratified by Stroke System Integration.” The Journal of emergency medicine (2026). PMID: 42398230 ↗
L2SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[269]
Sun W, Xie S, Liu F et al.. “Dynamic alterations of thrombotic molecular markers in acute ischemic stroke patients after intravenous thrombolysis: a prospective cohort study.” BMC neurology (2026). PMID: 42399738 ↗
L2COHORTCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[270]
Khalid S, Abbas MAA, Shahid MS et al.. “Adjunctive Minocycline in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Brain and behavior (2026). PMID: 42423424 ↗
L1SR_MA_RCTCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[271]
Xiang Z, Yuan X, Wan J et al.. “Neutrophil-to-lymphocyte Ratio Predicts Prognosis After Endovascular Thrombectomy in Acute Ischemic Stroke: A Meta-Analysis.” Current neurovascular research (2026). PMID: 42405396 ↗
L2SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[272]
Castellano JM, Pocock SJ, Bhatt DL et al.. “Polypill Strategy in Secondary Cardiovascular Prevention.” The New England journal of medicine (2022). PMID: 36018037 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), Complications, Prevention, Screening & Surveillance
[273]
Wang Y, Wang Y, Zhao X et al.. “Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.” The New England journal of medicine (2013). PMID: 23803136 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[274]
Sharma M, Dong Q, Hirano T et al.. “Asundexian for Secondary Stroke Prevention.” The New England journal of medicine (2026). PMID: 41985132 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), Prevention, Screening & Surveillance
[275]
Johnston SC, Easton JD, Farrant M et al.. “Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.” The New England journal of medicine (2018). PMID: 29766750 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[276]
Albers GW, Marks MP, Kemp S et al.. “Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging.” The New England journal of medicine (2018). PMID: 29364767 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[277]
Albers GW, Jumaa M, Purdon B et al.. “Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection.” The New England journal of medicine (2024). PMID: 38329148 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[278]
Campbell BC, Mitchell PJ, Kleinig TJ et al.. “Endovascular therapy for ischemic stroke with perfusion-imaging selection.” The New England journal of medicine (2015). PMID: 25671797 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[279]
Huo X, Ma G, Tong X et al.. “Trial of Endovascular Therapy for Acute Ischemic Stroke with Large Infarct.” The New England journal of medicine (2023). PMID: 36762852 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[280]
Ghannam M, Al-Qudah AM, Alshaer QN et al.. “Anticoagulation vs Antiplatelets Across Subgroups of Embolic Stroke of Undetermined Source: A Meta-Analysis of Randomized Controlled Trials.” Neurology (2024). PMID: 39365971 ↗
L1SR_MA_RCTCited in: Long-term & Definitive Management (Evidence Ladder), Prevention, Screening & Surveillance
[281]
Wang Z, Li J, Wang X et al.. “Tenecteplase for Acute Ischemic Stroke at 4.5 to 24 Hours: A Meta-Analysis of Randomized Controlled Trials.” Stroke (2025). PMID: 41078125 ↗
L1SR_MA_RCTCited in: Long-term & Definitive Management (Evidence Ladder), Complications, Prognosis & Natural History
[282]
Sang H, Xie D, Tian Y et al.. “Association of Tirofiban With Functional Outcomes After Thrombectomy in Acute Ischemic Stroke Due to Intracranial Atherosclerotic Disease.” Neurology (2023). PMID: 36941074 ↗
L2RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[283]
Southerland AM, Mayer SA, Chiota-McCollum NA et al.. “Glucose Control and Risk of Symptomatic Intracerebral Hemorrhage Following Thrombolysis for Acute Ischemic Stroke: A SHINE Trial Analysis.” Neurology (2024). PMID: 38626363 ↗
L2RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[284]
Meng X, Wang A, Tian X et al.. “One-Year Outcomes of Early Therapy With Ticagrelor vs Clopidogrel in CYP2C19 Loss-of-Function Carriers With Stroke or TIA Trial.” Neurology (2024). PMID: 38181311 ↗
L2RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[285]
Gao Y, Jiang L, Pan Y et al.. “Immediate- or Delayed-Intensive Statin in Acute Cerebral Ischemia: The INSPIRES Randomized Clinical Trial.” JAMA neurology (2024). PMID: 38805216 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Prevention, Screening & Surveillance
[286]
Kimberley TJ, Cramer SC, Wolf SL et al.. “Long-Term Outcomes of Vagus Nerve Stimulation Paired With Upper Extremity Rehabilitation After Stroke.” Stroke (2025). PMID: 40329913 ↗
L2RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Neurorehabilitation, Symptomatic & Supportive Care
[287]
Kimberley TJ, Pierce D, Prudente CN et al.. “Vagus Nerve Stimulation Paired With Upper Limb Rehabilitation After Chronic Stroke.” Stroke (2018). PMID: 30355189 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Neurorehabilitation, Symptomatic & Supportive Care
[288]
Giugliano RP, Pedersen TR, Saver JL et al.. “Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.” Stroke (2020). PMID: 32312223 ↗
L2RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[289]
Zaidat OO, Liebeskind DS, Edgell RC et al.. “Clinical trial design for endovascular ischemic stroke intervention.” Neurology (2012). PMID: 23008403 ↗
L5TRIAL_NONRANDOMCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[290]
Yang Y, Yang J, Gao Y et al.. “Dual Antiplatelet Therapy After Ischemic Stroke Stratified by Intracranial or Extracranial Atherosclerotic Stenosis.” Annals of neurology (2025). PMID: 40990347 ↗
L2RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Prognosis & Natural History
[291]
da Silva TR, de Carvalho Nunes HR, Martins LG et al.. “Non-invasive Brain Stimulation Can Reduce Unilateral Spatial Neglect after Stroke: ELETRON Trial.” Annals of neurology (2022). PMID: 35688801 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Neurorehabilitation, Symptomatic & Supportive Care
[292]
da Silva-Candal A, Pérez-Díaz A, Santamaría M et al.. “Clinical validation of blood/brain glutamate grabbing in acute ischemic stroke.” Annals of neurology (2018). PMID: 30014516 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[293]
Kim JS, Lee KB, Park JH et al.. “Safety and Efficacy of Otaplimastat in Patients with Acute Ischemic Stroke Requiring tPA (SAFE-TPA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study.” Annals of neurology (2019). PMID: 31721277 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[294]
Amaro S, Llull L, Renú A et al.. “Uric acid improves glucose-driven oxidative stress in human ischemic stroke.” Annals of neurology (2015). PMID: 25627874 ↗
L2RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[295]
Li Q, Guo J, Chen HS et al.. “Remote Ischemic Conditioning With Medical Management or Reperfusion Therapy for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.” Neurology (2024). PMID: 38457772 ↗
L1SR_OBSCited in: Long-term & Definitive Management (Evidence Ladder)
[296]
Tsivgoulis G, Katsanos AH, Mavridis D et al.. “Percutaneous patent foramen ovale closure for secondary stroke prevention: Network meta-analysis.” Neurology (2018). PMID: 29875217 ↗
L1SR_OBSCited in: Long-term & Definitive Management (Evidence Ladder)
[297]
Lun R, Dhaliwal S, Zitikyte G et al.. “Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack: A Network Meta-analysis.” JAMA neurology (2022). PMID: 34870698 ↗
L1SR_OBSCited in: Long-term & Definitive Management (Evidence Ladder), Prevention, Screening & Surveillance
[298]
Kaufmann JE, Harshfield EL, Gensicke H et al.. “Antithrombotic Treatment for Cervical Artery Dissection: A Systematic Review and Individual Patient Data Meta-Analysis.” JAMA neurology (2024). PMID: 38739383 ↗
L1SR_OBSCited in: Long-term & Definitive Management (Evidence Ladder), Prevention, Screening & Surveillance
[299]
Gharaibeh K, Aladamat N, Mierzwa AT et al.. “Blood Pressure after Successful Endovascular Therapy: A Systematic Review and Meta-Analysis of Randomized Control Trials.” Annals of neurology (2024). PMID: 38481016 ↗
L1SR_OBSCited in: Long-term & Definitive Management (Evidence Ladder), Complications
[300]
Ng FC, Churilov L, Yassi N et al.. “Prevalence and Significance of Impaired Microvascular Tissue Reperfusion Despite Macrovascular Angiographic Reperfusion (No-Reflow).” Neurology (2021). PMID: 34906976 ↗
L2OTHERCited in: Long-term & Definitive Management (Evidence Ladder)
[301]
Powers WJ, Rabinstein AA, Ackerson T et al.. “Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.” Stroke (2019). PMID: 31662037 ↗
L1OTHERCited in: Long-term & Definitive Management (Evidence Ladder), Prevention, Screening & Surveillance
[302]
Mac Grory B, Schrag M, Biousse V et al.. “Management of Central Retinal Artery Occlusion: A Scientific Statement From the American Heart Association.” Stroke (2021). PMID: 33677974 ↗
L1REVIEW_NARRATIVECited in: Long-term & Definitive Management (Evidence Ladder), Prevention, Screening & Surveillance
[303]
Yaghi S, Engelter S, Del Brutto VJ et al.. “Treatment and Outcomes of Cervical Artery Dissection in Adults: A Scientific Statement From the American Heart Association.” Stroke (2024). PMID: 38299330 ↗
L1REVIEW_NARRATIVECited in: Long-term & Definitive Management (Evidence Ladder)
[304]
Mahmoudi Meymand M, Aghamiri SH, Mohmammad Soleymani S et al.. “Effects of Add-On Icosapent Ethyl With Standard Treatment on Functional Outcomes and Inflammatory Biomarkers in Acute Ischemic Stroke: A Blinded Randomized Controlled Trial.” Annals of clinical and translational neurology (2026). PMID: 42387993 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), Complications
[305]
Cosentino G, Bocci T, Cecchi F et al.. “Intensive Rehabilitation With Adjunctive Bilateral Anodal tDCS in Post-Stroke Dysphagia: A Multicenter Randomized Controlled Trial.” European journal of neurology (2026). PMID: 42383625 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Neurorehabilitation, Symptomatic & Supportive Care
[306]
Adams C, Heard K, Kohli Y et al.. “Safety and Efficacy of Nerinetide at Year 1 in Participants Enrolled in ESCAPE-NEXT: A Multicenter, Double-Blind, Randomized Controlled Trial.” Journal of the American Heart Association (2026). PMID: 42333641 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[307]
Schlemm E, Jensen M, Schell M et al.. “Large Core Stroke Thrombectomy Is Safe and Effective Regardless of Prior Antithrombotic or Thrombolytic Treatment: A Secondary Analysis of the Randomized TENSION Trial.” Journal of the American Heart Association (2026). PMID: 42261979 ↗
L2RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[308]
Maïer B, Finitsis S, Mazighi M et al.. “Thrombectomy with or without Intravenous Thrombolytics in Basilar Artery Occlusion.” Annals of neurology (2023). PMID: 37314741 ↗
L2OTHERCited in: Long-term & Definitive Management (Evidence Ladder)
[309]
Larsson SC, Traylor M, Markus HS. “Homocysteine and small vessel stroke: A mendelian randomization analysis.” Annals of neurology (2019). PMID: 30785218 ↗
L2OTHERCited in: Long-term & Definitive Management (Evidence Ladder), Prevention, Screening & Surveillance
[310]
Duricki DA, Drndarski S, Bernanos M et al.. “Stroke Recovery in Rats after 24-Hour-Delayed Intramuscular Neurotrophin-3 Infusion.” Annals of neurology (2018). PMID: 30525223 ↗
L5OTHERCited in: Long-term & Definitive Management (Evidence Ladder), Special Populations & Pregnancy
[311]
Liu J, Fu B, Zhang Z et al.. “Efficacy and safety of treatment strategies for early neurological deterioration after acute ischemic stroke: a network meta-analysis of randomized controlled trials.” BMC neurology (2026). PMID: 42350977 ↗
L1SR_MA_RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[312]
Dell'Acqua B, Costa CM, Cerri A et al.. “Tenecteplase With or Without Mechanical Thrombectomy in Acute Ischemic Stroke at 4.5 to 24 h: An Updated Meta-Analysis of Randomized Controlled Trials.” Neurology international (2026). PMID: 42347124 ↗
L1SR_MA_RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[313]
Chilaka C, Khan HD, Sarfraz MU et al.. “Left Atrial Appendage Closure vs. Oral Anticoagulation in Patients With Atrial Fibrillation: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Journal of arrhythmia (2026). PMID: 42328186 ↗
L1SR_MA_RCTCited in: Long-term & Definitive Management (Evidence Ladder), Prevention, Screening & Surveillance
[314]
Leite M, Ribeiro Gonçalves O, de Almeida Monteiro G et al.. “Efficacy and safety of adjuvant tirofiban versus intravenous thrombolysis alone in acute ischemic stroke: an updated meta-analysis of randomized controlled trials.” Journal of thrombosis and thrombolysis (2026). PMID: 42315720 ↗
L1SR_MA_RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[315]
Yu X, Sun X, Yang F. “Intravenous thrombolysis for acute ischemic stroke in the extended time window of 4.5-24 h: a systematic review and network meta-analysis of randomized controlled trials.” Frontiers in neurology (2026). PMID: 42293079 ↗
L1SR_MA_RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[316]
You J, Zhou H, Liu Q et al.. “Long-term outcomes of endovascular thrombectomy vs. medical care in patients with large ischemic stroke: a systematic review and meta-analysis of randomized controlled trials.” Frontiers in neurology (2026). PMID: 42211309 ↗
L1SR_MA_RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[317]
Bushnell C, Kernan WN, Sharrief AZ et al.. “2024 Guideline for the Primary Prevention of Stroke: A Guideline From the American Heart Association/American Stroke Association.” Stroke (2024). PMID: 39429201 ↗
L1GUIDELINECited in: History and Evolution of Treatment, Prevention, Screening & Surveillance
[318]
Powers WJ, Rabinstein AA, Ackerson T et al.. “2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.” Stroke (2018). PMID: 29367334 ↗
L1GUIDELINECited in: History and Evolution of Treatment, Prevention, Screening & Surveillance
[319]
Jauch EC, Saver JL, Adams HP et al.. “Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.” Stroke (2013). PMID: 23370205 ↗
L1GUIDELINECited in: History and Evolution of Treatment
[320]
Green TL, McNair ND, Hinkle JL et al.. “Care of the Patient With Acute Ischemic Stroke (Posthyperacute and Prehospital Discharge): Update to 2009 Comprehensive Nursing Care Scientific Statement: A Scientific Statement From the American Heart Association.” Stroke (2021). PMID: 33691469 ↗
L1GUIDELINECited in: History and Evolution of Treatment
[321]
Rodgers ML, Fox E, Abdelhak T et al.. “Care of the Patient With Acute Ischemic Stroke (Endovascular/Intensive Care Unit-Postinterventional Therapy): Update to 2009 Comprehensive Nursing Care Scientific Statement: A Scientific Statement From the American Heart Association.” Stroke (2021). PMID: 33691467 ↗
L1GUIDELINECited in: History and Evolution of Treatment, Complications
[322]
Wiviott SD, Raz I, Bonaca MP et al.. “Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.” The New England journal of medicine (2018). PMID: 30415602 ↗
L1RCTCited in: History and Evolution of Treatment, Prognosis & Natural History
[323]
. “Tissue plasminogen activator for acute ischemic stroke.” The New England journal of medicine (1995). PMID: 7477192 ↗
L1RCTCited in: History and Evolution of Treatment
[324]
Patel MR, Mahaffey KW, Garg J et al.. “Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.” The New England journal of medicine (2011). PMID: 21830957 ↗
L1RCTCited in: History and Evolution of Treatment, Prevention, Screening & Surveillance
[325]
Tsivgoulis G, Triantafyllou S, Palaiodimou L et al.. “Prolonged Cardiac Monitoring and Stroke Recurrence: A Meta-analysis.” Neurology (2022). PMID: 35264426 ↗
L2SR_OBSCited in: History and Evolution of Treatment
[326]
Adams HP, Davis PH, Leira EC et al.. “Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST).” Neurology (1999). PMID: 10408548 ↗
L2RCTCited in: History and Evolution of Treatment
[327]
Wardlaw JM, Woodhouse LJ, Mhlanga II et al.. “Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2) Randomized Clinical Trial.” JAMA neurology (2023). PMID: 37222252 ↗
L1RCTCited in: History and Evolution of Treatment, Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History, Prevention, Screening & Surveillance
[328]
Goeldlin MB, Hakim A, Branca M et al.. “Early vs Late Anticoagulation in Minor, Moderate, and Major Ischemic Stroke With Atrial Fibrillation: Post Hoc Analysis of the ELAN Randomized Clinical Trial.” JAMA neurology (2024). PMID: 38805207 ↗
L2RCTCited in: History and Evolution of Treatment
[329]
Adams HP, Bendixen BH, Kappelle LJ et al.. “Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.” Stroke (1993). PMID: 7678184 ↗
L5RCTCited in: History and Evolution of Treatment
[330]
Schmidt-Pogoda A, Bonberg N, Koecke MHM et al.. “Why Most Acute Stroke Studies Are Positive in Animals but Not in Patients: A Systematic Comparison of Preclinical, Early Phase, and Phase 3 Clinical Trials of Neuroprotective Agents.” Annals of neurology (2019). PMID: 31714631 ↗
L2TRIAL_NONRANDOMCited in: History and Evolution of Treatment
[331]
Khan F, Rehman CA, Fletcher L et al.. “Carotid Revascularization Versus Medical Management for Ischemic Stroke with Ipsilateral Carotid Web: A Systematic Review and Meta-Analysis.” Annals of neurology (2025). PMID: 40503762 ↗
L2SR_OBSCited in: History and Evolution of Treatment
[332]
Lossius MI, Rønning OM, Slapø GD et al.. “Poststroke epilepsy: occurrence and predictors--a long-term prospective controlled study (Akershus Stroke Study).” Epilepsia (2005). PMID: 16060935 ↗
L2RCTCited in: History and Evolution of Treatment
[333]
McCormick M, Hadley D, McLean JR et al.. “Randomized, controlled trial of insulin for acute poststroke hyperglycemia.” Annals of neurology (2010). PMID: 20437554 ↗
L1RCTCited in: History and Evolution of Treatment
[334]
Xie Y, Oppenheim C, Guillemin F et al.. “Pretreatment lesional volume impacts clinical outcome and thrombectomy efficacy.” Annals of neurology (2018). PMID: 29314208 ↗
L2RCTCited in: History and Evolution of Treatment
[335]
Morris NA, Simard JM, Chaturvedi S. “Surgical Management for Primary Intracerebral Hemorrhage.” Neurology (2024). PMID: 39074339 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[336]
Lancman ME, Golimstok A, Norscini J et al.. “Risk factors for developing seizures after a stroke.” Epilepsia (1993). PMID: 8422846 ↗
L2OTHERCited in: History and Evolution of Treatment
[337]
Fujiwara S, Fladt J, Benali F et al.. “Sex differences in brain frailty measures and outcomes after endovascular thrombectomy: ESCAPE-NA1 analysis.” Journal of the neurological sciences (2026). PMID: 42349084 ↗
L2RCTCited in: History and Evolution of Treatment
[338]
Zhou Q, Tian X, Xia X et al.. “Favorable Systemic Immune-Inflammation Status Enhances the Neuroprotective Effects of Butylphthalide in Ischemic Stroke: A Post Hoc Analysis of BAST Trial.” CNS neuroscience & therapeutics (2026). PMID: 42329209 ↗
L2RCTCited in: History and Evolution of Treatment
[339]
Xu S, Wang Q, An H et al.. “The translational potential of drug-induced hypothermia in acute ischemic stroke.” Science translational medicine (2026). PMID: 42308333 ↗
L4RCTCited in: History and Evolution of Treatment
[340]
Appoo A, Ignacio K, Doolan C et al.. “Predictors and Consequences of Serious Adverse Events in Patients Treated With Thrombolysis: A Prespecified Secondary Analysis of the AcT Trial.” Journal of the American Heart Association (2026). PMID: 42261967 ↗
L2RCTCited in: History and Evolution of Treatment
[341]
Del Zotto E, Grassi M, Zedde M et al.. “Risk Profile of Patients with Spontaneous Cervical Artery Dissection.” Annals of neurology (2023). PMID: 37272282 ↗
L3OTHERCited in: History and Evolution of Treatment
[342]
Tsivgoulis G, Katsanos AH, Mavridis D et al.. “Intravenous Thrombolysis for Ischemic Stroke Patients on Dual Antiplatelets.” Annals of neurology (2018). PMID: 30048012 ↗
L2OTHERCited in: History and Evolution of Treatment
[343]
Clapham RE, Speed V, Cox C et al.. “Identifying risk factors for venous thromboembolism in medical inpatients: a systematic review and meta-analysis.” Research and practice in thrombosis and haemostasis (2026). PMID: 42318434 ↗
L2SR_OBSCited in: History and Evolution of Treatment
[344]
Park YM, Jung W, Kim BS et al.. “Time-Dependent Association Between Breast Cancer and Risk of Ischemic Stroke: A Nationwide Cohort Study.” Neurology (2026). PMID: 42308440 ↗
L2COHORTCited in: History and Evolution of Treatment
[345]
Lee YC, Chung CP, Chang MH et al.. “NOTCH3 cysteine-altering variant is an important risk factor for stroke in the Taiwanese population.” Neurology (2019). PMID: 31792094 ↗
L3OTHERCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[346]
Meschia JF, Worrall BB, Elahi FM et al.. “Management of Inherited CNS Small Vessel Diseases: The CADASIL Example: A Scientific Statement From the American Heart Association.” Stroke (2023). PMID: 37602377 ↗
L1OTHERCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[347]
Fisher M, Vasilevko V, Passos GF et al.. “Therapeutic modulation of cerebral microhemorrhage in a mouse model of cerebral amyloid angiopathy.” Stroke (2011). PMID: 21903962 ↗
L5OTHERCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[348]
Macrez R, Obiang P, Gauberti M et al.. “Antibodies preventing the interaction of tissue-type plasminogen activator with N-methyl-D-aspartate receptors reduce stroke damages and extend the therapeutic window of thrombolysis.” Stroke (2011). PMID: 21680906 ↗
L5OTHERCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[349]
Tsai SY, Papadopoulos CM, Schwab ME et al.. “Delayed anti-nogo-a therapy improves function after chronic stroke in adult rats.” Stroke (2010). PMID: 21088244 ↗
L5OTHERCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[350]
Jiang Y, Liu N, Wang Q et al.. “Endocrine Regulator rFGF21 (Recombinant Human Fibroblast Growth Factor 21) Improves Neurological Outcomes Following Focal Ischemic Stroke of Type 2 Diabetes Mellitus Male Mice.” Stroke (2018). PMID: 30571410 ↗
L5OTHERCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[351]
Lee M, Byun S, Lim S et al.. “Dual Antiplatelet Therapy De-Escalation in Stabilized Myocardial Infarction With High Ischemic Risk: Post Hoc Analysis of the TALOS-AMI Randomized Clinical Trial.” JAMA cardiology (2024). PMID: 38117483 ↗
L2RCTCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[352]
Chan A, Pirmohamed M, Comabella M. “Pharmacogenomics in neurology: current state and future steps.” Annals of neurology (2011). PMID: 22162054 ↗
L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[353]
Stefanou MI, Theodorou A, Mengel A et al.. “Risk of stroke under disease modifying therapies for multiple sclerosis: a systematic review.” Therapeutic advances in neurological disorders (2025). PMID: 40416416 ↗
L2SR_OBSCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[354]
Harada S, Nakajima M, Nomura T et al.. “High prevalence of treatable transthyretin cardiac amyloidosis in cardioembolic stroke: the first systematic cohort study.” Journal of neurology (2026). PMID: 41553541 ↗
L2COHORTCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[355]
Lin PY, Lin TY, Sung SF et al.. “Investigating undiagnosed Fabry disease in young adults with ischemic stroke: A multicenter cohort study.” International journal of stroke : official journal of the International Stroke Society (2024). PMID: 39324555 ↗
L2COHORTCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[356]
Gupta M, Spring KJ, Beran RG et al.. “Impact of Statin Therapy on the Risk of Stroke Recurrence, Mortality, and Dementia After Ischemic Stroke (ISMARDD Study): A Comprehensive Meta-Analysis.” Neurology international (2025). PMID: 41295435 ↗
L1SR_OBSCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[357]
Coadă CA, Lupu M, Florea I et al.. “Association of Glycoprotein IIIa PlA1/A2 Polymorphism with Risk of Stroke: Updated Meta-Analysis.” Current issues in molecular biology (2024). PMID: 38920993 ↗
L1SR_OBSCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[358]
Wang J, Zhang X, Jin Q et al.. “From heart to brain: a Case Report of individualized antithrombotic management for left ventricular thrombus and stroke in a young patient with acute myocardial infarction.” Frontiers in pharmacology (2026). PMID: 42367281 ↗
L4CASE_REPORTCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[359]
Deng J, Li D, Li Z et al.. “MicroRNA-7: a versatile player and core target in brain disorders.” Journal of translational medicine (2026). PMID: 42204625 ↗
L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[360]
van den Berg LA, Dijkgraaf MG, Berkhemer OA et al.. “Two-Year Outcome after Endovascular Treatment for Acute Ischemic Stroke.” The New England journal of medicine (2017). PMID: 28379802 ↗
L1RCTCited in: Neurorehabilitation, Symptomatic & Supportive Care
[361]
Jensen M, Sehner S, Cheng B et al.. “Patient-Reported Quality of Life After Intravenous Alteplase for Stroke in the WAKE-UP Trial.” Neurology (2022). PMID: 36302662 ↗
L1RCTCited in: Neurorehabilitation, Symptomatic & Supportive Care
[362]
Goldstein LB, Lennihan L, Rabadi MJ et al.. “Effect of Dextroamphetamine on Poststroke Motor Recovery: A Randomized Clinical Trial.” JAMA neurology (2018). PMID: 30167675 ↗
L1RCTCited in: Neurorehabilitation, Symptomatic & Supportive Care
[363]
Dawson J, Pierce D, Dixit A et al.. “Safety, Feasibility, and Efficacy of Vagus Nerve Stimulation Paired With Upper-Limb Rehabilitation After Ischemic Stroke.” Stroke (2015). PMID: 26645257 ↗
L1RCTCited in: Neurorehabilitation, Symptomatic & Supportive Care
[364]
Zi W, Song J, Kong W et al.. “Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion.” The New England journal of medicine (2023). PMID: 37256974 ↗
L1TRIAL_NONRANDOMCited in: Neurorehabilitation, Symptomatic & Supportive Care
[365]
van der Ende NAM, den Hartog SJ, Broderick JP et al.. “Disentangling the Association Between Neurologic Deficits, Patient-Reported Impairments, and Quality of Life After Ischemic Stroke.” Neurology (2023). PMID: 36599699 ↗
L3TRIAL_NONRANDOMCited in: Neurorehabilitation, Symptomatic & Supportive Care
[366]
Woo SH, Lee CH, Kim MY et al.. “2025 Korean Guidelines for Cardiopulmonary Resuscitation: Part 11. First aid.” Clinical and experimental emergency medicine (2026). PMID: 42297414 ↗
L1GUIDELINECited in: Neurorehabilitation, Symptomatic & Supportive Care
[367]
Jaime Garcia D, Makin SDJ, McHutchison CA et al.. “Functional, Cognitive, Physical, and Vascular Outcomes 9 Years After Lacunar and Mild Cortical Ischemic Stroke.” Neurology (2025). PMID: 40834341 ↗
L2OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
[368]
Nilsen HW, Martinsen ACT, Johansen I et al.. “Demographic, Medical, and Clinical Characteristics of a Population-Based Sample of Patients With Long-lasting Locked-In Syndrome.” Neurology (2023). PMID: 37442623 ↗
L2OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
[369]
Bushnell CD, Reeves MJ, Zhao X et al.. “Sex differences in quality of life after ischemic stroke.” Neurology (2014). PMID: 24510493 ↗
L2OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
[370]
Galovic M, Stauber AJ, Leisi N et al.. “Development and Validation of a Prognostic Model of Swallowing Recovery and Enteral Tube Feeding After Ischemic Stroke.” JAMA neurology (2019). PMID: 30742198 ↗
L2OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
[371]
Howard G, Schwamm LH, Donnelly JP et al.. “Participation in Get With The Guidelines-Stroke and Its Association With Quality of Care for Stroke.” JAMA neurology (2018). PMID: 30083763 ↗
L2OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
[372]
Chalos V, Venema E, Mulder MJHL et al.. “Development and Validation of a Postprocedural Model to Predict Outcome After Endovascular Treatment for Ischemic Stroke.” JAMA neurology (2023). PMID: 37523199 ↗
L2OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
[373]
Song S, Liang L, Fonarow GC et al.. “Comparison of Clinical Care and In-Hospital Outcomes of Asian American and White Patients With Acute Ischemic Stroke.” JAMA neurology (2019). PMID: 30667466 ↗
L3OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
[374]
Flint AC, Conell C, Rao VA et al.. “Effect of statin use during hospitalization for intracerebral hemorrhage on mortality and discharge disposition.” JAMA neurology (2014). PMID: 25244578 ↗
L3OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
[375]
Prabhakaran S, Gonzalez NR, Zachrison KS et al.. “2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association.” Stroke (2026). PMID: 41582814 ↗
L1REVIEW_NARRATIVECited in: Neurorehabilitation, Symptomatic & Supportive Care, Complications, Special Populations & Pregnancy, Prevention, Screening & Surveillance
[376]
Gu R, Ge M, Wang Z et al.. “Association of intensive blood pressure lowering with health-related quality of life after endovascular thrombectomy: a post-hoc analysis of the ENCHANTED2/MT trial.” Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation (2026). PMID: 42250116 ↗
L2RCTCited in: Neurorehabilitation, Symptomatic & Supportive Care
[377]
Yu X, Zhao N, Liu Y et al.. “Neuroplastic Mechanisms of Acupuncture in Post-Stroke Motor Recovery: A Randomized Multimodal MRI Trial.” CNS neuroscience & therapeutics (2026). PMID: 42231817 ↗
L1RCTCited in: Neurorehabilitation, Symptomatic & Supportive Care
[378]
Lisabeth LD, Brown DL, Dong L et al.. “Outcomes in the Year After First-Ever Ischemic Stroke in a Bi-Ethnic Population.” Annals of neurology (2022). PMID: 36134521 ↗
L2OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care, Prevention, Screening & Surveillance
[379]
Buetefisch CM, Wei L, Gu X et al.. “Neuroprotection of Low-Frequency Repetitive Transcranial Magnetic Stimulation after Ischemic Stroke in Rats.” Annals of neurology (2022). PMID: 36097798 ↗
L5OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
[380]
Hosp JA, Dressing A, Engesser A et al.. “The Role of Ascending Ventral-Tegmental Fibers for Recovery after Stroke.” Annals of neurology (2023). PMID: 36585896 ↗
L2OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
[381]
Oliveira Gonçalves AS, Rohmann JL, Piccininni M et al.. “Economic Evaluation of a Mobile Stroke Unit Service in Germany.” Annals of neurology (2023). PMID: 36637359 ↗
L2OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
[382]
Wang J, Hao D, Lu Y. “Early Bobath-based neurorehabilitation after mechanical thrombectomy for moderate-to-severe hemiparesis: preliminary findings from a propensity score-matched cohort study.” The International journal of neuroscience (2026). PMID: 42230331 ↗
L3COHORTCited in: Neurorehabilitation, Symptomatic & Supportive Care
[383]
Yesiloglu I, Pinto MV, Keser Z. “Clinical Vignette: Delayed Loss of Hand Dexterity in a Young Woman With Stroke.” American journal of physical medicine & rehabilitation (2026). PMID: 42348427 ↗
L4CASE_REPORTCited in: Neurorehabilitation, Symptomatic & Supportive Care
[384]
Berkhemer OA, Fransen PS, Beumer D et al.. “A randomized trial of intraarterial treatment for acute ischemic stroke.” The New England journal of medicine (2014). PMID: 25517348 ↗
L1RCTCited in: Complications
[385]
Jia B, Zhang X, Ma N et al.. “Comparison of Drug-Eluting Stent With Bare-Metal Stent in Patients With Symptomatic High-grade Intracranial Atherosclerotic Stenosis: A Randomized Clinical Trial.” JAMA neurology (2022). PMID: 34982098 ↗
L1RCTCited in: Complications
[386]
Hanley DF, Ziai WC, Vahidy FS et al.. “Intracerebral Hemorrhage: Keep It Simple.” Stroke (2024). PMID: 39474689 ↗
L5REVIEW_NARRATIVECited in: Complications
[387]
Sutter R, Marsch S, Fuhr P et al.. “Mortality and recovery from refractory status epilepticus in the intensive care unit: a 7-year observational study.” Epilepsia (2013). PMID: 23294049 ↗
L4OTHERCited in: Complications
[388]
de Havenon A, Abbasi M, Yaghi S et al.. “Effect of Alteplase on Ischemic Stroke Mortality Is Dependent on Stroke Severity.” Annals of neurology (2023). PMID: 36852919 ↗
L2OTHERCited in: Complications
[389]
Marcolongo F, Guariglia C, Tessari G et al.. “Topography and functional connectivity analysis of heart surgery-associated brain lesions: a literature review.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 42399477 ↗
L4SR_OBSCited in: Complications
[390]
Wu B, Li JJ, Jing J et al.. “Predictive Value of Composite Inflammatory Markers for Stroke Prognosis: A Prospective Cohort Study.” Annals of clinical and translational neurology (2026). PMID: 42433165 ↗
L2COHORTCited in: Complications, Prognosis & Natural History
[391]
Chiv R, Beradid S, Suissa S et al.. “Effectiveness and Safety of Edoxaban Compared With Apixaban in Elderly Patients With Nonvalvular Atrial Fibrillation: A Real-World Population-Based Cohort Study.” Stroke (2024). PMID: 38511316 ↗
L2COHORTCited in: Prognosis & Natural History, Special Populations & Pregnancy
[392]
Li S, Wang L, Liu B et al.. “Clinical and Prognostic Characteristics of Acute BAD-Related Stroke: A Multicenter MRI-Based Prospective Study.” Stroke (2024). PMID: 39315825 ↗
L2COHORTCited in: Prognosis & Natural History
[393]
Nie X, Leng X, Miao Z et al.. “Clinically Ineffective Reperfusion After Endovascular Therapy in Acute Ischemic Stroke.” Stroke (2022). PMID: 36475464 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History
[394]
Baek JH, Mark Park YM, Nam GE et al.. “Cardiovascular risk associated with intellectual disability among adults with type 2 diabetes: a nationwide cohort study in South Korea.” EClinicalMedicine (2026). PMID: 42433277 ↗
L2COHORTCited in: Prognosis & Natural History, Prevention, Screening & Surveillance
[395]
Sundelin H, Söderling J, Bang P et al.. “Risk of Autism After Pediatric Ischemic Stroke: A Nationwide Cohort Study.” Neurology (2022). PMID: 35314504 ↗
L2COHORTCited in: Special Populations & Pregnancy
[396]
Kunutsor SK, Khan H, Zaccardi F et al.. “Sauna bathing reduces the risk of stroke in Finnish men and women: A prospective cohort study.” Neurology (2018). PMID: 29720543 ↗
L2COHORTCited in: Special Populations & Pregnancy
[397]
Sporns PB, Bhatia KD, Muthusami P et al.. “Thrombectomy versus Medical Management for Pediatric Acute Ischemic Stroke Due to Isolated M2 Occlusion: A Multicenter Cohort Study.” Annals of neurology (2025). PMID: 41316719 ↗
L2COHORTCited in: Special Populations & Pregnancy
[398]
Lambers M, Goldenberg NA, Kenet G et al.. “Role of reduced ADAMTS13 in arterial ischemic stroke: a pediatric cohort study.” Annals of neurology (2012). PMID: 23225307 ↗
L3COHORTCited in: Special Populations & Pregnancy
[399]
Verburgt E, Hilkens NA, Verhoeven JI et al.. “History of Pregnancy Complications and the Risk of Ischemic Stroke in Young Women.” Neurology (2025). PMID: 40768689 ↗
L3OTHERCited in: Special Populations & Pregnancy
[400]
Sattin JA, Chiong W, Bonnie RJ et al.. “Consent Issues in the Management of Acute Ischemic Stroke: AAN Position Statement.” Neurology (2022). PMID: 35312627 ↗
L5OTHERCited in: Special Populations & Pregnancy
[401]
Poisson SN, Hills NK, Sidney S et al.. “Prevalence of Atherosclerotic Risk Factors Among Children and Young Adults With Arterial Ischemic Stroke.” JAMA neurology (2022). PMID: 35913708 ↗
L3OTHERCited in: Special Populations & Pregnancy
[402]
Bhatia KD, Briest R, Goetti R et al.. “Incidence and Natural History of Pediatric Large Vessel Occlusion Stroke: A Population Study.” JAMA neurology (2022). PMID: 35344005 ↗
L2OTHERCited in: Special Populations & Pregnancy
[403]
Sporns PB, Sträter R, Minnerup J et al.. “Feasibility, Safety, and Outcome of Endovascular Recanalization in Childhood Stroke: The Save ChildS Study.” JAMA neurology (2020). PMID: 31609380 ↗
L2OTHERCited in: Special Populations & Pregnancy
[404]
Saber H, Saver JL. “Distributional Validity and Prognostic Power of the National Institutes of Health Stroke Scale in US Administrative Claims Data.” JAMA neurology (2020). PMID: 32065612 ↗
L2OTHERCited in: Special Populations & Pregnancy
[405]
Grelli KN, Gindville MC, Walker CH et al.. “Association of Blood Pressure, Blood Glucose, and Temperature With Neurological Outcome After Childhood Stroke.” JAMA neurology (2016). PMID: 27214847 ↗
L3OTHERCited in: Special Populations & Pregnancy
[406]
Kernan WN, Ovbiagele B, Black HR et al.. “Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.” Stroke (2014). PMID: 24788967 ↗
L1OTHERCited in: Special Populations & Pregnancy
[407]
Demaerschalk BM, Kleindorfer DO, Adeoye OM et al.. “Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.” Stroke (2015). PMID: 26696642 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
[408]
Yu C, Hussain SM, Fransquet PD et al.. “Polygenic Risk Identifies Older Adults Who May Benefit From Aspirin for the Primary Prevention of Ischemic Stroke.” Stroke (2026). PMID: 42100829 ↗
L2RCTCited in: Special Populations & Pregnancy
[409]
Bigi S, Fischer U, Wehrli E et al.. “Acute ischemic stroke in children versus young adults.” Annals of neurology (2011). PMID: 21823153 ↗
L2OTHERCited in: Special Populations & Pregnancy
[410]
Beslow LA, Linds AB, Fox CK et al.. “Pediatric Ischemic Stroke: An Infrequent Complication of SARS-CoV-2.” Annals of neurology (2021). PMID: 33332607 ↗
L4OTHERCited in: Special Populations & Pregnancy
[411]
Felling RJ, Rafay MF, Bernard TJ et al.. “Predicting Recovery and Outcome after Pediatric Stroke: Results from the International Pediatric Stroke Study.” Annals of neurology (2020). PMID: 32215969 ↗
L2OTHERCited in: Special Populations & Pregnancy
[412]
Yang W, Song TJ, Koh SH et al.. “SVO70 (Optimal Target Low-Density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke): Rationale and Study Design.” Journal of the American Heart Association (2026). PMID: 42047198 ↗
L5TRIAL_NONRANDOMCited in: Special Populations & Pregnancy
[413]
O'Riordan S, Daly FP, Bowe A et al.. “Preterm Delivery and Long-Term Risk of Maternal Stroke: Systematic Review and Meta-Analysis.” Stroke (2026). PMID: 42044225 ↗
L2SR_OBSCited in: Special Populations & Pregnancy
[414]
Ngo TKT, Tran TC, Nguyen TH. “Safety and Clinical Outcomes of Endovascular Thrombectomy in Very Elderly Patients (≥80 Years) with Acute Ischemic Stroke: A Prospective Multicenter Cohort Study in Vietnam.” Clinical interventions in aging (2026). PMID: 42293353 ↗
L2COHORTCited in: Special Populations & Pregnancy
[415]
Elkaim LM, Chen JS, Abecassis IJ et al.. “Surgical revascularization versus nonsurgical management in children with symptomatic moyamoya arteriopathy: a North American multicenter cohort study.” Journal of neurosurgery. Pediatrics (2026). PMID: 42139725 ↗
L2COHORTCited in: Special Populations & Pregnancy
[416]
Tang Y, Zhang Y, Chen X et al.. “Association of lipoprotein(a) and composite inflammatory indices with functional outcomes in acute ischemic stroke: a prospective cohort study.” Lipids in health and disease (2026). PMID: 42116143 ↗
L2COHORTCited in: Special Populations & Pregnancy
[417]
Serinken M, Eken C, Güngör F et al.. “Clinical Predictors of Intracranial Pathology in Emergency Department Patients with Non-traumatic Headache and No Neurological Deficits: Prospective Study.” The western journal of emergency medicine (2026). PMID: 42054129 ↗
L4COHORTCited in: Special Populations & Pregnancy
[418]
Johnston SC, Amarenco P, Denison H et al.. “Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.” The New England journal of medicine (2020). PMID: 32668111 ↗
L1RCTCited in: Prevention, Screening & Surveillance
[419]
Yang P, Zhang Y, Zhang L et al.. “Endovascular Thrombectomy with or without Intravenous Alteplase in Acute Stroke.” The New England journal of medicine (2020). PMID: 32374959 ↗
L1RCTCited in: Prevention, Screening & Surveillance
[420]
Wang Y, Meng X, Wang A et al.. “Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA.” The New England journal of medicine (2021). PMID: 34708996 ↗
L1RCTCited in: Prevention, Screening & Surveillance
[421]
Hart RG, Sharma M, Mundl H et al.. “Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.” The New England journal of medicine (2018). PMID: 29766772 ↗
L2RCTCited in: Prevention, Screening & Surveillance
[422]
Søndergaard L, Kasner SE, Rhodes JF et al.. “Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke.” The New England journal of medicine (2017). PMID: 28902580 ↗
L1RCTCited in: Prevention, Screening & Surveillance
[423]
Pan Y, Meng X, Jin A et al.. “Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial.” JAMA neurology (2022). PMID: 35727586 ↗
L2RCTCited in: Prevention, Screening & Surveillance
[424]
Xiong Y, Meng X, Jin A et al.. “Prourokinase vs Standard Care for Patients With Mild Ischemic Stroke: The PUMICE Randomized Clinical Trial.” JAMA neurology (2025). PMID: 39836393 ↗
L1RCTCited in: Prevention, Screening & Surveillance
[425]
Wang JZ, Vyas MV, Saposnik G et al.. “Incidence and management of seizures after ischemic stroke: Systematic review and meta-analysis.” Neurology (2017). PMID: 28835405 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance
[426]
Stefanou MI, Palaiodimou L, Aguiar de Sousa D et al.. “Acute Arterial Ischemic Stroke Following COVID-19 Vaccination: A Systematic Review and Meta-analysis.” Neurology (2022). PMID: 36002319 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance
[427]
Psaltopoulou T, Sergentanis TN, Panagiotakos DB et al.. “Mediterranean diet, stroke, cognitive impairment, and depression: A meta-analysis.” Annals of neurology (2013). PMID: 23720230 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance
[428]
Ip YMB, Lau KK, Ko H et al.. “Association of Alternative Anticoagulation Strategies and Outcomes in Patients With Ischemic Stroke While Taking a Direct Oral Anticoagulant.” Neurology (2023). PMID: 37225430 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[429]
Triantafyllou S, Katsanos AH, Dilaveris P et al.. “Implantable Cardiac Monitoring in the Secondary Prevention of Cryptogenic Stroke.” Annals of neurology (2020). PMID: 32827232 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[430]
Monjazeb S, Chang HV, Lyden PD. “Before, during, and after: An Argument for Safety and Improved Outcome of Thrombolysis in Acute Ischemic Stroke with Direct Oral Anticoagulant Treatment.” Annals of neurology (2024). PMID: 39258443 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[431]
Suzuki H, Yoshimoto T, Hayakawa M et al.. “Stroke Scales for Large Vessel Occlusion in the Prehospital Emergency Setting: A Systematic Review and Meta-Analysis.” Journal of the American Heart Association (2026). PMID: 42333681 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance
[432]
Sotos-Prieto M, Maroto-Rodriguez J, Pangalangan J et al.. “The Lifestyle Medicine Health Behavior Scale and Cardiovascular Disease: A Prospective Cohort Study From the UK Biobank.” American journal of preventive medicine (2026). PMID: 42329207 ↗
L2COHORTCited in: Prevention, Screening & Surveillance
[433]
Wu JY, Lee KW, Huang SC et al.. “Association Between Angiotensin Receptor Blocker Use and Cardiovascular Outcomes Compared With Angiotensin-Converting Enzyme Inhibitors in Patients With Atherosclerotic Cardiovascular Disease: A Real-World Cohort Study.” Mayo Clinic proceedings (2026). PMID: 42320690 ↗
L2COHORTCited in: Prevention, Screening & Surveillance
[434]
Zhang Y, Feng W, Wang L et al.. “Association between red meat consumption and risk of stroke: a meta-analysis of prospective cohort studies.” Frontiers in nutrition (2026). PMID: 42404157 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance

Quick Reference

Overview and Recommendations

Background

Evaluation

Management

Board Review — High Yield

Deep Dive — Evidence Details

Definition, Classification & Nomenclature

Also Called / Synonyms

Key Clinical Definitions

Etiologic Classification Systems

Clinical Significance

Pathophysiology & Mechanism (Neuroanatomic Localization)

The Ischemic Cascade

Core, Penumbra, and Oligemia: A Dynamic Continuum

Neuroanatomic Localization of Clinical Deficits

Immunothrombosis and Inflammation

Molecular Pathways and Emerging Targets

Epidemiology, Etiology & Risk Factors

Etiologic Classification

Risk Factors

Special Populations and Temporal Trends

Clinical Presentation

Presenting Symptoms

Neurological Examination Findings

Phenotypic Variants

Red Flags

Atypical Presentations

Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)

Neuroimaging: Modality Selection

Gold-Standard Test

Laboratory Studies

EEG

Lumbar Puncture and NCS/EMG

Diagnostic Algorithm

Differential Diagnosis of Stroke Mimics

Controversies and Guideline Disagreement

Severity, Staging & Risk Stratification

Imaging-Based Infarct Staging

Functional Outcome and Prognostic Models

Risk Stratification for Recurrent Events

Controversies and Guideline Disagreement

Acute Management: Neurologic Emergencies & Attack Abortion

Step 1: Triage and Imaging-Based Selection

Step 2: Intravenous Thrombolysis

Step 3: Endovascular Thrombectomy

Step 4: Post-Thrombolysis Antiplatelet Therapy

Dosing Table

Step 5: Periprocedural and Hemodynamic Management

Controversies and Guideline Disagreement

Long-term & Definitive Management (Evidence Ladder)

Step 1: Etiology-Based Antithrombotic Selection

Step 2: Revascularization

Step 3: Intensive Risk-Factor Modification

Step 4: Adherence and Polypill Strategy

Emerging and Adjunctive Neuroprotection

What NOT to Do

Controversies and Guideline Disagreement

History and Evolution of Treatment

The Endovascular Revolution

Evolution of Antiplatelet and Anticoagulant Strategy

Neuroprotection: A History of Failed Promise

Secondary Prevention: Beyond Antiplatelets

Abandoned Approaches

Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation

Step 1: Identify Candidates for Disease-Modifying Therapy

Step 2: Pharmacogenomic Screening Before and During Therapy

Step 3: De-Escalation of Antiplatelet and Anticoagulant Regimens

Step 4: Emerging Immunotherapies for Disease Modification

Step 5: Safety Monitoring for Disease-Modifying Agents

Neurorehabilitation, Symptomatic & Supportive Care

Early Mobilization and Rehabilitation

Dysphagia and Respiratory Care

Cardiovascular and Autonomic Complications

DVT Prophylaxis and Pain Management

Hospital-Acquired Complications

Complication Table

Complications: Anticipating and Intercepting Deterioration

Respiratory Monitoring

DVT Prophylaxis and Pain

Pain